Fiche personne
Territoire
Lorraine
Statut
Hospitalo-Universitaire
Affiliation
Centre hospitalier régional universitaire de Nancy (CHRU Nancy)
Inserm U1256 "Nutrition, génétique et exposition aux risques environnementaux" (Inserm U1256 NGERE)
Équipes/plateformes
Projets
Rôles de TREM-1 et du microbiote intestinal dans la régulation de l'inflammation muqueuse et la prévention des cancers colorectaux associés aux maladies inflammatoires chroniques intestinales
2015 - Porteur du projet : Pr PEYRIN-BIROULET Laurent
Publications
Imaging endpoints in inflammatory bowel disease: current evidence and future directions for ultrasound and MRI.
Faggiani I, Danese S, Biroulet LP, Jairath V, Rubin DT, Allocca M
BMC Med. 2026 05 29;:
Patient-reported Outcomes in Clinical Trials of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Hanzel J, Yuan Y, Goodwin SW, Nardone OM, Roseira J, Solitano V, Vuyyuru SK, Leong RW, Sands BE, Turner D, Moum B, Long MD, Louis E, Reinisch W, Rubin DT, Danese S, Dignass A, Siegel CA, Panaccione R, Dubinsky MC, Peyrin-Biroulet L, Halfvarson J, Magro F, Hart A, Jairath V,
Clin Gastroenterol Hepatol. 2026 05 28;:
Acute severe ulcerative colitis: efficacy and safety of JAK inhibitors.
Bruno A, Bencardino S, D'Amico F, Peyrin-Biroulet L, Danese S
Expert Opin Pharmacother. 2026 05 20;:1-12
Precision nutrition for the prevention and management of inflammatory bowel disease.
Chen J, Dan L, Wellens J, Jairath V, Yanai H, Khalili H, Danese S, Peyrin-Biroulet L, Wang X, Li X, Magro F
Nat Rev Gastroenterol Hepatol. 2026 05 19;:
Breaking the therapeutic ceiling in inflammatory bowel disease: myth or reality?
Solitano V, Jairath V, Magro F, Armuzzi A, Peyrin-Biroulet L, Danese S
Lancet Gastroenterol Hepatol. 2026 05 14;:
Clinical characteristics and treatment pathways of ulcerative colitis patients with isolated proctitis in Europe and the United States.
Armuzzi A, Danese S, Barreiro-de Acosta M, Hur P, Bartolome L, Wosik K, Knight H, Palace V, Peyrin-Biroulet L
Ther Adv Gastroenterol. 2026 05 8;19:17562848261448080
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.
Wils P, Jairath V, Sands BE, Dignass A, Magro F, Rubin DT, Dotan I, Reinisch W, Dulai P, Gearry R, Ma C, Long M, Armuzzi A, Kobayashi T, Turner D, Vieujean S, Verstockt B, Hart A, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2026 05 8;20(5):
Vedolizumab clinical decision support tool predicts clinically relevant targets in patients with Crohn's disease.
Dulai PS, Bamias G, Jairath V, Buisson A, Meyer M, Lindner D, Agboton C, Peyrin-Biroulet L
Ther Adv Gastroenterol. 2026 05 4;19:17562848261436120
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 92 of the QUASAR Long-Term Extension Study.
Lichtenstein GR, Allegretti JR, Rubin DT, Magro F, Bressler B, Panés J, Afif W, Samaan MA, Ye BD, Yarandi S, Germinaro M, Shipitofsky N, Miao Y, Zhang H, Dignass A, Sands BE, Hisamatsu T, Peyrin-Biroulet L
Am J Gastroenterol. 2026 05 1;:
Partial responders to intravenous corticosteroids at day 3 benefit from continued therapy in acute severe ulcerative colitis.
Singh A, Bhardwaj A, Sharma R, Singh D, Jain D, Bansal N, Sebastian S, Peyrin-Biroulet L, Midha V, Sood A
Sci Rep. 2026 04 30;:
Digital twins in IBD-bridging data, biology and trial innovation.
Colwill M, Honap S, Young AM, Magro F, Jairath V, Danese S, Peyrin-Biroulet L
Gut. 2026 04 29;:
Inflammatory bowel disease and Primary sclerosing cholangitis: immunological links and clinical outlook.
Massironi S, Fanizzi F, Invernizzi F, Furfaro F, Ciocca L, Arcari I, Allocca M, Peyrin-Biroulet L, Danese S
Expert Rev Clin Immunol. 2026 04 22;:
The Role of Microbiota and Fecal Transplantation in Inflammatory Bowel Disease.
Lagos I, Pérez de Arce E, Faggiani I, D'Amico F, Zilli A, Furfaro F, Massironi S, Cicerone C, Solitano V, Parigi TL, Peyrin-Biroulet L, Danese S, Allocca M
Pathogens. 2026 04 21;15(4):
Beyond class effects: moving towards drug-level precision in inflammatory bowel disease therapy.
Honap S, Jairath V, Magro F, Danese S, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2026 04 8;:
Efficacy and Safety of Ravagalimab in Patients with Moderate-to-Severe Ulcerative Colitis: Data from a Phase 2a Trial.
Peyrin-Biroulet L, Seenan JP, Armuzzi A, Lazar A, Eldred A, Doan T, Polakow SB, Al Mahi N, Liu M, Nader A, Bhatnagar S, Schreiber S
Adv Ther. 2026 04 1;:
Development and external validation of a predictive model for postoperative recurrence of Crohn's disease in the biologic era.
Allez M, Bak MTJ, Brand S, Diebakate-Scordamaglia L, Capelle E, Seksik P, Nancey S, Gornet JM, Buisson A, Carbonnel F, Peyrin-Biroulet L, Louis E, Hébuterne X, Serrero M, Bourreille A, Treton X, Wils P, Fumery M, Blanc P, Uzzan M, Sokol H, Barnich N, Kirchgesner J, Colombel JF, Maggiori L, Bezault M, Silverberg MS, De Vries AC, Lambert J, Hammoudi N
Clin Gastroenterol Hepatol. 2026 03 27;:
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's disease.
Moreira PL, Dignass A, Estevinho MM, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Dotan I, Jairath V, Magro F,
J Crohns Colitis. 2026 03 10;20(3):
Position Paper: IOlBD Evidence-based Consensus on the Use of Artificial Intelligence for Assessment of Endoscopic and Histologic Endpoints in Clinical Trials of Inflammatory Bowel Disease.
Dignass A, Narula N, Pratap K, Danese S, Dotan I, Iacucci M, Jairath V, Loftus EV, Magro F, Mantzaris G, Peyrin-Biroulet L, Rubin DT, Sands BE, Turner D, Reinisch W,
J Crohns Colitis. 2026 03 9;:
Semi-Automatic Assessment of Crohn's Disease Activity by Combined Analysis of Bowel Lesions and Creeping Fat.
Kneib A, Lemore A, Hossu G, Peyrin-Biroulet L, Laurent V, Odille F
Magn Reson Med. 2026 03 7;:
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.
Sands BE, Clemow DB, D'Haens G, Irving PM, Kobayashi T, Peyrin-Biroulet L, Samaan K, Gaur A, Arora R, Todd K, Moses R, Dignass A
Inflamm Bowel Dis. 2026 03 2;:
Long-term Safety of Upadacitinib in Patients with Inflammatory Bowel Disease: Integrated Analysis of Phase 2/3 Studies.
Panaccione R, Panés J, Peyrin-Biroulet L, Colombel JF, Lindsay JO, Baert F, Atreya R, Vermeire S, Fujii T, Dubcenco E, Klaff J, Duncan B, Suravaram S, Fish I, Lacerda AP, Vladea R, Ford S, Shah S, Anyanwu SI, Rubin DT
Clin Gastroenterol Hepatol. 2026 02 26;:
Seeing the invisible: muscle failure and malnutrition in inflammatory bowel disease.
Massironi S, Zilli A, Peyrin-Biroulet L, Danese S
Pol Arch Intern Med. 2026 02 26;136(2):
Uncovering the dynamics of mucosa-associated microbiota in post-operative recurrence of Crohn's disease.
Dubois L, Chaussard A, Seksik P, Nancey S, Nachury M, Treton X, Buisson A, Carbonnel F, Fumery M, Peyrin-Biroulet L, Boureille A, Hebuterne X, Serrero M, Louis E, Blanc P, Brot L, Rolhion N, Vermeire S, Manichanh C, Fossmark R, Bezault M, Uzzan M, ,Allez M, Sokol H
Gastroenterology. 2026 02 24;:
Building a Robust Investigator-Initiated Platform: The I-CARE Experience.
Kirchgesner J, Beaugerie L, Baumann C, Baert F, Rahier JF, Bergemalm D, Cañete F, Caron B, Cossignani M, Dias S, Farkas K, Girod P, Goren I, Holvoet T, Krasz S, Kumar A, Rimmer P, Sheridan J, Thut J, Uzzan M, Viazis N, Weimers P, Zagórowicz E, Buisson A, Avedano L, Rousseau H, Peyrin-Biroulet L, Sebastian S,
Clin Pharmacol Ther. 2026 02 15;:
Tools and Advanced Imaging Technologies for Assessing Intestinal Epithelial Barrier Integrity: A Systematic Review.
Vieujean S, Atreya R, Buda A, Caradec J, Citi S, Danese S, Dewit O, Friedrich M, Ghosh S, Iacucci M, Jairath V, Kaser A, Leong RW, Neurath MF, Pierre N, Pohin M, Rath T, Rivière P, Travis S, Westcott J, Zeissig S, Peyrin-Biroulet L
Am J Physiol Gastrointest Liver Physiol. 2026 02 12;:
Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders.
Solitano V, Peyrin-Biroulet L, Vermeire S, Dubinsky MC, Siegmund B, Mosig R, Cataldi F, Derluyn L, Danese S, Verstockt B
Inflamm Bowel Dis. 2026 02 10;:
Clinical remission in ulcerative colitis: restoring precision in trial terminology.
Honap S, Jairath V, Magro F, Danese S, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2026 02;11(2):96-97
A Descriptive Comparison of Phase 3 Results and Head-to-Head Trials in Inflammatory Bowel Diseases.
Chkolnaia Z, Peyrin-Biroulet L, Uzzan M
J Crohns Colitis. 2026 01 29;:
Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib.
Magro F, Rogler G, Feagan BG, Peyrin-Biroulet L, Oortwijn A, Cougnaud L, Faes M, Bauer Y, Randall M, Rudolph C, Reinisch W
J Crohns Colitis. 2026 01 22;:
Perianal Crohn's Disease in Inflammatory Bowel Disease: Diagnosis, Assessment and Treatment.
Faggiani I, Villaseca IL, D'Amico F, Furfaro F, Zilli A, Massironi S, Parigi TL, Solitano V, Cicerone C, Peyrin-Biroulet L, Danese S, Allocca M
Life (Basel). 2026 01 22;16(1):
Microbiota modulation by a human Paneth cell α-defensin fragment protects against DSS-induced colitis.
Bonazzi E, Hao F, Patterson AD, Peyrin-Biroulet L, Jensen BAH, Chassaing B
iScience. 2026 01 16;29(1):114310
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial.
Long M, Allegretti JR, Danese S, Germinaro M, Baker T, Alvarez Y, Kavalam M, Han C, Jörgens S, Jiang L, Zhang H, Hisamatsu T, Rubin DT, Peyrin-Biroulet L,
Lancet Gastroenterol Hepatol. 2026 01 13;:
Clinical Trial Endpoints for Perianal Fistulizing Crohn's Disease.
Reinisch W, Atreya R, Rieder F, Jairath V, Rimola J, Peyrin-Biroulet L, Tozer P, Buskens CJ, Hart A
Am J Gastroenterol. 2026 01 8;:
Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial.
Reinisch W, Peyrin-Biroulet L, D'Haens G, Sturm A, Anderson JK, Messina I, Arikan D, Zimmerman-Bennett A, Parmentier J, Feng T, D'Cunha R, Lazar A, Louis E
Crohns Colitis 360. 2026 01;8(2):otag014
Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study.
Jairath V, Hunter Gibble T, Peyrin-Biroulet L, Sands BE, Hirai F, Hibi T, Loftus EV, Cross RK, Protic M, Chan LS, Morris N, Traxler K, Rubin DT
Crohns Colitis 360. 2026 01;8(1):otag018
Bowel Urgency Improvement Correlates With Clinical, Biochemical, and Intestinal Ultrasound Improvements in Inflammatory Bowel Disease: A Cross Sectional Multicenter Study.
D'Amico F, Nardone OM, Bruno A, Allocca M, Zilli A, Furfaro F, Parigi TL, Solitano V, Ungaro F, Faggiani I, La Mantia A, Calabrese G, Fiorino G, Jairath V, Peyrin-Biroulet L, Massimino L, Castiglione F, Danese S
United European Gastroenterol J. 2025 12 17;:
Building a healthcare data warehouse: considerations, opportunities, and challenges.
Knezevic Ivanovski T, Honap S, Matic R, Markovic S, Peyrin-Biroulet L
Front Digit Health. 2025 12 16;7:1691142
TL1A blockade in inflammatory bowel diseases: Clinical trials to watch.
D'Amico F, Peyrin-Biroulet L, Jairath V, Danese S
Med. 2025 12 12;6(12):100931
Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study.
Peyrin-Biroulet L, Atreya R, Danese S, Lindsay JO, Chapman JC, Anschutz T, Huang X, Zambrano J, van Haaren S, Joshi N, Duan WR, Cross RK
J Crohns Colitis. 2025 12 4;:
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.
Danese S, Sands BE, Feagan BG, Jairath V, Panaccione R, Peyrin-Biroulet L, Irving PM, Schreiber S, Dotan I, Ferrante M, D'Haens GR, Jones S, Freire M, Lindner D, Adsul S, Oberai P, Colombel JF
Contemp Clin Trials Commun. 2025 12;48:101574
Inflammatory Bowel Disease therapies and Demyelinating Diseases: A Practical Guide to Therapeutic Benefit and Risk.
Honap S, Debouverie M, Filippi M, Selchen D, Jairath V, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2025 11 29;:
Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease.
Shebab M, Al-Hindawi A, Goodwin SW, Yuan Y, Bessissow T, Peyrin-Biroulet L, Jairath V
Lancet Gastroenterol Hepatol. 2025 11 25;:
From Resection to Preservation: Redefining the Surgical Paradigm in Crohn's Disease.
Migliorisi G, Delaplace R, Honap S, Germain A, Mouillot T, Peyrin-Biroulet L, Kotze PG
J Crohns Colitis. 2025 11 24;:
Benefit-Risk Profile of Upadacitinib: Exploratory Post Hoc Analysis of Phase 2b/3 Studies in Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.
Vermeire S, Colombel JF, Danese S, Panaccione R, Peyrin-Biroulet L, Beck K, Chaparro M, Gisbert JP, Dubcenco E, Klaff J, Naling G, Ford S, Remple V, Joshi N, Suravaram S, Duncan B, Wang Y, Wick-Urban B, Loftus EV
J Crohns Colitis. 2025 11 20;:
Recommendations to Standardize the Conduct of Clinical Trials Evaluating Novel Therapies for Perianal Fistulizing Crohn's Disease.
Vuyyuru SK, Hanzel J, Brar MS, Danese S, D'Haens G, Faubion WA, Feagan BG, Hart A, Kotze PG, Lee MJ, Panaccione R, Panes J, Peyrin-Biroulet L, Rimola J, Sands BE, Santillan CS, Segal JP, Stoker J, Taylor SA, Archer S, Kiarasi S, Shackelton LM, Jairath V, Ma C
Clin Gastroenterol Hepatol. 2025 11 18;:
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.
Jairath V, Danese S, D'Haens GR, Feagan BG, Peyrin-Biroulet L, Sands BE, Gaemers I, Westfall M, Terry AQ, Roberts KJ, Barbat S, Wedel P, Benson JM, Sattler C
Lancet Gastroenterol Hepatol. 2025 11 13;:
Placebo rates in randomised clinical trials of ulcerative colitis: An individual patient data meta-analysis.
Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Vuyyuru S, Macdonald JK, Zou G, Yuan Y, Sands BE, Panaccione R, Feagan BG, Hanzel J, Sedano R, Dulai P, Narula N, Ma C, Jairath V
J Crohns Colitis. 2025 11 9;:
Establishing a Multiple Outcome Set for Crohn's Disease in Real-World Evidence Studies: Results from a Delphi e-Survey.
Moreira PL, Dignass A, Estevinho MM, Santiago M, Reinisch W, Sands BE, D'Haens G, Mantzaris GJ, Danese S, Peyrin-Biroulet L, Dotan I, Jairath V, Magro F,
J Crohns Colitis. 2025 11 8;:
Management of Patients with Ulcerative Proctitis: A Global Survey.
Caron B, Sequier L, Dignass A, Ghosh S, Hart A, Jairath V, Kobayashi T, Kotze PG, Lakatos PL, Louis E, Magro F, Sebastian S, Solitano V, Sidhu S, Danese S, Peyrin-Biroulet L
Dig Dis Sci. 2025 11 8;:
Expert opinion on hot topics in the field of IBD.
Vuitton L, Hupé M, Grados L, Amiot A, Peyrin-Biroulet L, Fumery M
Clin Res Hepatol Gastroenterol. 2025 11 7;:102724
An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease.
Solitano V, Hanžel J, Ma C, Battat R, Raine T, Siegmund B, Peyrin-Biroulet L, Verstockt B, Torres J, Mehandru S, D'Haens G, Hogan M, Ungaro F, Atreya R, Panés J, Panaccione R, Parker CE, Sands BE, Feagan BG, Danese S, Jairath V
EClinicalMedicine. 2025 11;89:103582
Pharmacological management of upper gastrointestinal crohn's disease: A systematic review.
Chatto M, Alaskar D, Ma C, Yuan Y, Vuyyuru SK, Bessissow T, Narula N, Danese S, Peyrin-Biroulet L, Singh S, Jairath V, Sedano R
J Crohns Colitis. 2025 10 28;:
Long-term safety of ustekinumab in Crohn's disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data.
Peyrin-Biroulet L, Nazar M, Sheahan A, Geldhof A, Azzabi A, Baert F, Mailhat C, Rousseau H, Rahier JF, Beaugerie L
Dig Liver Dis. 2025 10 25;:
The impact of E-Cigarettes and Heat-Not-Burn Tobacco on Postoperative Recurrence of Crohn's Disease: A Multicenter International Study.
Parigi TL, Nardone OM, Lisa M, Massimino L, Gabbiadini R, Innocenti T, Bertani L, Del Gaudio A, Florez P, Bertin L, Barberio B, Hupé M, Lopetuso L, Allocca M, D'Amico F, Furfaro F, Zilli A, Fiorino G, Ungaro F, Castiglione F, Savarino E, Dragoni G, Scaldaferri F, Armuzzi A, Peyrin-Biroulet L, Jairath V, Pizarro TT, Danese S
Am J Gastroenterol. 2025 10 24;:
Long-term safety of vedolizumab in patients with ulcerative colitis/Crohn's disease: A prospective observational study.
Louis E, Sebastian S, Siegmund B, Bossuyt P, Danese S, de Boer N, Loftus EV, Moum B, Peyrin-Biroulet L, Schreiber S, Zhou J, Angellotti E, Adsul S, Jones S, Siegel CA
Clin Gastroenterol Hepatol. 2025 10 13;:
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis.
Ferrante M, Peyrin-Biroulet L, Arkkila P, Armuzzi A, Colombel JF, Danese S, Faggiani R, Guardiola J, Hanauer SB, Jahnsen J, Reinisch W, Roblin X, Smith PJ, Sang Kwon T, Kim S, Nam K, Atreya R
Therap Adv Gastroenterol. 2025 10 8;18:17562848251383767
Optimising Monoclonal Antibody Drug Development for Inflammatory Bowel Disease.
Colwill M, Honap S, Danese S, Peyrin-Biroulet L
Clin Exp Gastroenterol. 2025 09 30;18:233-249
Targeting the unmet needs in IBD: Emerging therapies beyond biologics and small molecules.
Fanizzi F, Peyrin-Biroulet L, Danese S, D'Amico F
Curr Opin Pharmacol. 2025 09 29;85:102577
Systematic Review: Ultrasound Goes Echo-Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound.
Massironi S, Zilli A, Furfaro F, Allocca M, Peyrin-Biroulet L, Jairath V, Danese S
Aliment Pharmacol Ther. 2025 09 23;:
International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials.
Allocca M, Jairath V, Sands BE, Rubin DT, Caron B, Laurent V, Novak K, Panaccione R, Bossuyt P, Bruining DH, Dignass A, Dotan I, Fletcher J, Fumery M, Furfaro F, Halfvarson J, Hart A, Kobayashi T, Krugliak Cleveland N, Kucharzik T, Laghi A, Lakatos PL, Leong RW, Loftus EV, Louis E, Magro F, Olivera PA, Sebastian S, Siegmund B, Vavricka SR, Wilson SR, Stoker J, Rimola J, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2025 09 18;:
Skin Cancer Risk in Patients with Non-dermatologic Immune-mediated Inflammatory Diseases.
Letarouilly JG, Wils P, Staumont-Sallé D, Jullien D, Mortier L, Peyrin-Biroulet L, Richez C, Boileau M, Flipo RM
Joint Bone Spine. 2025 09 16;:105972
Comparative Efficacy of Mesalazine and Ozanimod following Induction Treatment in Mesalazine-Exposed Advanced Therapy-Naïve Adult Ulcerative Colitis Patients.
D'Haens G, Safroneeva E, Peyrin-Biroulet L, Danese S, Jairath V, Thorne H, Laoun R
Inflamm Intest Dis. 2025 09 15;10(1):337-346
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.
Wils P, Altwegg R, Buisson A, Vuitton L, Nancey S, Richard N, Fumery M, Bouguen G, Guillo L, Caron B, Duveau N, Stefanescu C, Pelletier AL, Reenaers C, Gilletta C, Uzzan M, Arab N, Laharie D, Vidon M, Amiot A, Le Berre C, Kirchgesner J, Dewit O, Simon M, Goutorbe F, Vicaut E, Peyrin-Biroulet L
J Crohns Colitis. 2025 09 10;:
Blood proteomic signatures associated with disease activity in Inflammatory Bowel Diseases.
Veyssière M, Hammoudi N, Le Bourhis L, Hassid D, Bonnet J, Tran Minh ML, Baudry C, Gornet JM, Chardiny V, Seksik P, Nancey S, Carbonnel F, Treton X, Wils P, Buisson A, Boureille A, Hébuterne X, Serrero M, Fumery M, Louis E, Blanc P, Peyrin-Biroulet L, Bezault M, Soumelis V, Allez M
J Crohns Colitis. 2025 09 8;:
Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity-Matched Cohort Study.
D'Amico F, Allocca M, Lusetti F, Parigi TL, Rusconi F, Hernandez G, Segovia-Hilara A, Solitano V, Zilli A, Furfaro F, Fiorino G, Invernizzi P, Peyrin-Biroulet L, Jairath V, Danese S
United European Gastroenterol J. 2025 09 8;:
Catching fibrosis in motion: time-dependent diffusion MRI-derived cell diameter reveals the transitional state of intestinal scarring in Crohn's disease.
Faggiani I, Bencardino S, Peyrin-Biroulet L
J Crohns Colitis. 2025 09 7;19(8):
Reliability and Responsiveness of Endoscopic Indices for Assessing Crohn's Disease Postoperative Recurrence in the PREVENT trial.
Hanzel J, Vuyyuru SK, Bressler B, Samaan MA, Hogan M, Zou G, Shackelton LM, Remillard J, De Cruz P, Regueiro M, Singh S, Stidham RW, Duijvestein M, D'Haens GR, Peyrin-Biroulet L, Danese S, Sands BE, Panaccione R, Feagan BG, Jairath V, Ma C
Clin Gastroenterol Hepatol. 2025 09 2;:
Sub-cutaneous infliximab for perianal Crohn's disease: the BioLap-Rem multicentre study from the GETAID.
André M, Kirchgesner J, Laharie D, Guillo L, Seksik P, Abramowitz L, Fumery M, Wils P, Amil M, Nancey S, Le Berre C, Buisson A, Fathallah N, Giletta C, Uzzan M, Moussata D, Duveau N, Peyrin-Biroulet L, Nahon S, Richard N, Charkaoui M, Vicaut E, Vuitton L,
Am J Gastroenterol. 2025 08 28;:
International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical Practice.
Caron B, Jairath V, Sands BE, Rubin DT, Allocca M, Laurent V, Novak K, Panaccione R, Bossuyt P, Bruining DH, Dignass A, Dotan I, Fletcher J, Fumery M, Furfaro F, Halfvarson J, Hart A, Kobayashi T, Cleveland NK, Kucharzik T, Laghi A, Lakatos PL, Leong RW, Loftus EV, Louis E, Magro F, Olivera PA, Shaji S, Siegmund B, Vavricka SR, Danese S, Stoker J, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2025 08 27;:
Impact of Type 2 Diabetes on Clinical Outcomes and Advanced Therapy Use in Patients with Crohn's Disease: a Real-World Propensity Score-Matched Analysis.
Massironi S, Solitano V, Furfaro F, D'Amico F, Zilli A, Allocca M, Peyrin-Biroulet L, Jairath V, Danese S
J Crohns Colitis. 2025 08 21;:
Bayesian Statistics: A Narrative Review on Application in Inflammatory Bowel Diseases.
Camara H, Vicaut E, Caron B, Honap S, Baumann C, Peyrin-Biroulet L
Inflamm Bowel Dis. 2025 08 12;:
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on Infliximab.
Magro F, Domingues B, Estevinho MM, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Fernandes S, Dias CC, Dias S, Peyrin-Biroulet L, Danese S, Santiago M,
J Crohns Colitis. 2025 08 11;:
A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis.
Sands BE, Schreiber S, Danese S, Kierkus J, Abhyankar B, Choi MY, Soo C, Wu Y, Sun F, Lee D, Cui D, Mangada M, Singhal P, Hussain A, Rogers BN, Peyrin-Biroulet L, Feagan BG
Clin Gastroenterol Hepatol. 2025 08 4;:
Biobetters and biosimilars in inflammatory bowel disease.
Fanizza J, Faggiani I, Allocca M, Furfaro F, Zilli A, Parigi TL, Cicerone C, Fiorino G, Peyrin-Biroulet L, Danese S, Olivera PA, D'Amico F
Best Pract Res Clin Gastroenterol. 2025 08;77:101992
Treatment sequencing in inflammatory bowel disease: Towards clinical precision medicine.
Sequier L, Caron B, Honap S, Caillo L, Altwegg R, Netter P, Fumery M, Buisson A, Peyrin-Biroulet L
Best Pract Res Clin Gastroenterol. 2025 08;77:101994
Treatment targets in IBD: is it time for new strategies?
Fanizzi F, D'Amico F, Peyrin-Biroulet L, Danese S, Dignass A
Best Pract Res Clin Gastroenterol. 2025 08;77:101990
Is Transmural Healing an Achievable Goal in Inflammatory Bowel Disease?
Faggiani I, Solitano V, D'Amico F, Parigi TL, Zilli A, Furfaro F, Peyrin-Biroulet L, Danese S, Allocca M
Pharmaceuticals (Basel). 2025 07 27;18(8):
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis.
Honap S, St-Pierre J, Colwill M, Patel K, Le Berre C, Caron B, Nogami A, Kobayashi T, Altwegg R, Laharie D, Hebuterne X, Nachury M, Roblin X, Uzzan M, Kotze PG, Lukáš M, Vieujean S, D'Amico F, Albshesh A, Guillo L, Fumery M, Nancey S, Ye BD, Bergemalm D, Halfvarson J, Buisson A, Karmiris K, Rubin D, Vicaut E, Peyrin-Biroulet L,
Clin Gastroenterol Hepatol. 2025 07 26;:
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial.
Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkuś J, Leong RW, Yarur AJ, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, McBride JM, Bojic D, Lasch K, Schiffman C, Feagan BG
Lancet Gastroenterol Hepatol. 2025 07 21;:
Spatiotemporal analysis of Crohn's disease reveals PECAM2 signaling at the basis of inflammation-to-fibrosis transition.
Massimino L, Parigi TL, Riva M, Nicolò S, Errico C, Spanò S, Mino S, Bugatti M, Frontali A, Scarfò F, Vignali A, Municchi A, Villanacci V, Albarello L, Ponzoni M, Solitano V, Malesci A, Jairath V, Peyrin-Biroulet L, Sileri P, Danese S, Ungaro F
J Crohns Colitis. 2025 07 18;:
Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.
Danese S, Leong RW, Sands BE, Ma T, Marano C, Peyrin-Biroulet L
Aliment Pharmacol Ther. 2025 07 16;:
Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial.
Jairath V, D'Haens G, Sands BE, Travis S, Chaparro M, Peyrin-Biroulet L, Chen MH, Dubinsky M, Ferrante M, Schreiber S, McGinnis K, Vadhariya A, Appelmans S, Lin Z, Yu G, Protic M, Moses R, Ghosh S
Clin Gastroenterol Hepatol. 2025 07 14;:
Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study.
Roblin X, Vieujean S, Nancey S, Hebuterne X, Arab-Hocine N, Savoye G, Viennot S, Bouguen G, Fumery M, Duru G, Botelho-Nevers E, Berger AE, Tardy B, Mathieu N, Barrau M, Peyrin-Biroulet L, Paul S
J Crohns Colitis. 2025 07 3;19(7):
Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.
Vieujean S, Sands BE, Panaccione R, Rubin DT, Jairath V, Danese S, Peyrin-Biroulet L, Schreiber S, Vermeire S, D'Haens G, Dignass A, Dulai PS, Narula N, Reinisch W
J Crohns Colitis. 2025 07 3;19(7):
Long-term efficacy of JAK inhibitors in ulcerative colitis: tipping toward safe success.
Solitano V, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2025 07 3;19(7):
The Role of Vitamin D in Inflammatory Bowel Diseases: From Deficiency to Targeted Therapeutics and Precise Nutrition Strategies.
Dell'Anna G, Fanizzi F, Zilli A, Furfaro F, Solitano V, Parigi TL, Ciliberto A, Fanizza J, Mandarino FV, Fuccio L, Facciorusso A, Donatelli G, Allocca M, Massironi S, Annese V, Peyrin-Biroulet L, Danese S, D'Amico F
Nutrients. 2025 06 29;17(13):
The preclinical discovery and development of upadacitinib for the treatment of Crohn's disease.
Vieujean S, Danese S, Peyrin-Biroulet L
Expert Opin Drug Discov. 2025 06 27;:1-21
Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Sands BE, Peyrin-Biroulet L, Schreiber S, Danese S, Armuzzi A, Buisson A, Fumery M, Dignass A, Powell N, Kennedy NA, Zeissig S, Kwon T, Kim S, Nam K, Hanauer SB
J Clin Med. 2025 06 21;14(13):
Janus kinase (JAK) inhibitor-induced acne in inflammatory bowel disease - an international, multicenter, retrospective cohort study.
Honap S, Temido MJ, Shakweh E, Badrulhisham F, Shields N, Mehta S, McBride J, Uzzan M, Lukáš M, Fumery M, Nogami A, Kobayashi T, Nancey S, Neves JC, Mendes JM, Wegener BA, Bergereau E, Fernandes R, Kuriakose Kuzhiyanjal AJ, Vieujean S, Spencer A, Baillie S, Estevinho MM, Simão I, O'Neill C, Gututui M, Thompson E, Jama A, Chai N, Pavlidis P, D'Amico F, Limdi J, Magro F, Sebastian S, Digby-Bell J, Parkes GC, Din S, Hart A, Peyrin-Biroulet L,
Clin Gastroenterol Hepatol. 2025 06 10;:
Development and validation of a novel Endoscopic ulcer Activity Score for Evaluation of Crohn's Disease (EASE-CD) using data from two randomised controlled trials.
Ma C, Khanna R, Maguire BR, Zou G, Bressler B, Hindryckx P, Mosli M, Sparrow MP, Hart AL, Leong RW, Rubin DT, Rémillard J, Shackelton LM, D'Haens GR, Danese S, Peyrin-Biroulet L, Sands BE, Panaccione R, Feagan BG, Jairath V
Lancet Gastroenterol Hepatol. 2025 06 9;:
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease.
D'Amico F, Bencardino S, Magro F, Dignass A, Gutiérrez Casbas A, Verstockt B, Hart A, Armuzzi A, Peyrin-Biroulet L, Danese S
Biologics. 2025 05 31;19:351-363
An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease.
Hanžel J, Solitano V, Vuyyuru SK, Panaccione R, Sands BE, Peyrin-Biroulet L, Danese S, D'Haens GR, Atreya R, Allez M, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen BL, Colombel JF, D'Amico F, Dignass A, Dubinsky M, Fleshner P, Gearry RB, Hanauer SB, Hart AL, Kayal M, Kucharzik T, Lakatos PL, Louis E, Magro F, Narula N, Leong RW, Panés J, Raine T, Ran Z, Regueiro MD, Reinisch W, Singh S, Steinhart AH, Travis S, Ungaro RC, Janneke van der Woude C, Yamamoto T, Ahuja V, Rubin DT, Dulai PS, Cornfield LJ, Hogan M, Sandborn WJ, Feagan BG, Jairath V, Ma C
Gastroenterology. 2025 05 28;:
JAK Inhibitors and Risk of Cancer in IBD Patients.
Bernardi F, Faggiani I, Parigi TL, Zilli A, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S, D'Amico F
Cancers (Basel). 2025 05 28;17(11):
Obefazimod in Patients with Moderate-to-Severely Active Ulcerative Colitis: Efficacy and Safety Analysis from the 96-week Open-label Maintenance Phase 2b study.
Vermeire S, Nitcheu J, Gineste P, Flatres A, Santo J, Scherrer D, Peyrin-Biroulet L, Dulai PS, Danese S, Dubinsky M, Tilg H, Siegmund B, Hisamatsu T, Shan K, Rabbat C, Sands BE
J Crohns Colitis. 2025 05 26;:
Advanced Combination Therapy in Inflammatory Bowel Disease.
Morizot C, Sequier L, Jouzeau JY, Moulin D, Netter P, Caron B, Honap S, Lœuille D, Peyrin-Biroulet L
Joint Bone Spine. 2025 05 23;:105922
Advanced Therapies for Inflammatory Bowel Disease and Risk of Skin Cancer: What's New?
Bencardino S, Bernardi F, Allocca M, Zilli A, Furfaro F, Peyrin-Biroulet L, Danese S, D'Amico F
Cancers (Basel). 2025 05 20;17(10):
PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission.
Mathieu N, Hupé M, Heluwaert F, Rivière P, Hébuterne X, Chupin A, Abitbol V, Bouguen G, Vuitton L, Gornet JM, Montuclard C, Nancey S, Cadiot G, Wils P, Gilletta C, de Maissin A, Altwegg R, Chanteloup E, Plastaras L, Ah Soune P, Bourreille A, Stefanescu C, Seksik P, Simon M, Uzzan M, Andrau P, Rouillon C, Arondel Y, Buisson A, Peyrin-Biroulet L, Mboup B, Vicaut E, Laharie D
Clin Gastroenterol Hepatol. 2025 05 19;:
Factors associated with response to filgotinib and the prognostic power of faecal calprotectin for ulcerative colitis in the phase 2b/3 SELECTION trial.
Louis E, Schreiber S, Hisamatsu T, Hibi T, Jamoul C, Muller K, Taliadouros V, Oortwijn A, Peyrin-Biroulet L, Feagan BG
Dig Liver Dis. 2025 05 15;:
Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis.
D'Haens G, Danese S, Panaccione R, Rubin DT, Peyrin-Biroulet L, Matsuoka K, Loftus EV, Kobayashi T, Elsharkawi W, Miceli R, Ahmed S, Luo Y, Napoli A, Vaile J, Dornic Q, Patel A, Schreiber S
J Crohns Colitis. 2025 05 13;:
Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions.
Gordon M, Shaban N, Sinopoulou V, Vuyyuru S, Radford S, Magro F, Armuzzi A, Peyrin-Biroulet L, Jairath V, Moran G
Inflamm Bowel Dis. 2025 05 13;:
Concomitant medications and advanced therapies in ulcerative colitis: patient-centric approach for optimal disease control.
D'Amico F, Peyrin-Biroulet L, Danese S
Clin Gastroenterol Hepatol. 2025 05 8;:
Medical Therapy for Acute Severe Ulcerative Colitis: A Systematic Review with Meta-analysis.
Vuyyuru SK, Shaban N, Yuan Y, Honap S, Alphonsus L, De Silva TA, Alajmi A, MacDonald JK, Ma C, Dulai PS, Biroulet LP, Jairath V
Clin Gastroenterol Hepatol. 2025 05 6;:
Endoscopic submucosal dissection for visible dysplasia in IBD: A nationwide multicenter cohort from the GETAID and the SFED.
Geyl S, Jacques J, Anneraud A, Chaussade S, Abitbol V, Chevaux JB, Peyrin-Biroulet L, Yzet C, Pioche M, Berger A, Laharie D, Koch S, Leblanc S, Serrero M, Barthet M, Gonzalez JM, Wallenhorst T, Bouguen G, Camus M, Degand T, Charkaoui M, Rahmi G, Perrod G, Simon M, Gerard R, Stefanescu C, Benezech A, Vanbiervliet G, Baleur YL, Brieau B, Seksik P, Vuitton L, Schaefer M
J Crohns Colitis. 2025 04 25;:
Shaping the future of inflammatory bowel disease: a global research agenda for better management and public health response.
Solitano V, Bernstein CN, Dotan I, Dignass A, Domilici R, Dubinsky MC, Gearry RB, Hart A, Kaplan GG, Ma C, Magro F, Mak JWY, Ng SC, Panaccione R, Raja S, Rubin DT, Siegel CA, Jairath V, Peyrin-Biroulet L, Danese S
Nat Rev Gastroenterol Hepatol. 2025 04 22;:
Triple Biologic Therapy for Refractory Crohn's Disease.
Vieujean S, Peyrin-Biroulet L
J Crohns Colitis. 2025 04 19;:
Disease Clearance in Ulcerative Colitis: A Narrative Review.
Danese S, Peyrin-Biroulet L, Jairath V, D'Amico F, Adsul S, Agboton C, Magro F
United European Gastroenterol J. 2025 04 16;:
Artificial Intelligence for Clinical Trial Facilitation, Lessons for Inflammatory Bowel Disease: A Scoping Review.
Le Berre C, Jairath V, Panaccione R, Bourreille A, Magro F, Danese S, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2025 04 10;:
Plasma Concentration of Calprotectin, but Not Serum Concentration, Is a Predictive Biomarker for Clinical Remission in Ulcerative Colitis.
Honap S, Aimone-Gastin I, Salignac S, Flayac J, Paoli J, Peyrin-Biroulet L, Oussalah A
Inflamm Intest Dis. 2025 04 8;10(1):104-114
Prevention and interception trials in inflammatory bowel disease: an international taskforce assessment on clinical trial design.
Honap S, Agrinier N, Torres J, Croitoru K, Lee SH, Turpin W, Ungaro RC, Agrawal M, Peter I, Turner D, Dotan I, Hart AL, Netter P, D'Haens G, Rubin DT, Ng SC, Gearry R, Jairath V, Ananthakrishnan AN, Danese S, Colombel JF, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2025 04 2;:
What Is Moderate to Severe Inflammatory Bowel Disease?
Peyrin-Biroulet L
Gastroenterol Hepatol (N Y). 2025 04;21(4):247-249
Management of Patients with IBD and History of Cancer.
Faggiani I, Bencardino S, Allocca M, Furfaro F, Zilli A, Parigi TL, Cicerone C, Solitano V, Peyrin-Biroulet L, Danese S, D'Amico F
Cancers (Basel). 2025 03 21;17(7):
IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials.
Dziegielewski C, Yuan Y, Ma C, Boland BS, Chang JT, Syal G, Vuyyuru SK, Peyrin-Biroulet L, Jairath V, Singh S
Am J Gastroenterol. 2025 03 12;:
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study.
Richard N, Amiot A, Seksik P, Altwegg R, Laharie D, Vuitton L, Nachury M, Bouguen G, Nancey S, Gilletta C, Rouilon C, Coffin B, Allez M, Buisson A, Le Berre C, Uzzan M, Caillo L, Pelletier AL, Peyrin-Biroulet L, Fumery M,
Aliment Pharmacol Ther. 2025 03 4;:
Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes.
Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A
RMD Open. 2025 03 4;11(1):
Unlocking hope: The future of ustekinumab biosimilars in Crohn's disease treatment.
D'Amico F, Bencardino S, Gonçalves A, Allocca M, Furfaro F, Zilli A, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S
United European Gastroenterol J. 2025 02 18;:
Disease-Modifying Anti-Inflammatory Drugs: Shaping the Future of Inflammatory Bowel Disease Care.
Honap S, Peyrin-Biroulet L
J Crohns Colitis. 2025 02 8;:
Assessment of activity and severity of inflammatory bowel disease in cross-sectional imaging techniques: a systematic review.
Dal Buono A, Faita F, Armuzzi A, Jairath V, Peyrin-Biroulet L, Danese S, Allocca M
J Crohns Colitis. 2025 02 4;:
Overcoming the challenges of overtreating and undertreating inflammatory bowel disease.
Temido MJ, Honap S, Jairath V, Vermeire S, Danese S, Portela F, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2025 02 4;:
Dual Therapy in Inflammatory Bowel Disease.
Altieri G, Zilli A, Parigi TL, Allocca M, Furfaro F, Fiorino G, Cicerone C, Peyrin-Biroulet L, Danese S, D'Amico F
Biomolecules. 2025 02 3;15(2):
Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis-A Safety Analysis.
Afzali A, Regueiro M, Yarur AJ, Zabana Y, Ng SC, Menon S, McDonnell A, Lazin K, Keating M, Bhattacharjee A, Branquinho D, Bananis E, Peyrin-Biroulet L
United European Gastroenterol J. 2025 02 1;:
Understanding the therapeutic toolkit for inflammatory bowel disease.
Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, Danese S
Nat Rev Gastroenterol Hepatol. 2025 01 31;:
Comparative Improvement in Health-Related Quality of Life with Advanced Therapies for Moderate-to-Severe Crohn's Disease: A Network Meta-Analysis.
Olivera PA, Parks ML, Zubiaurre I, Peyrin-Biroulet L, Lasa JS, Targownik LE
Am J Gastroenterol. 2025 01 29;:
In vitro microbiota model recapitulates and predicts individualised sensitivity to dietary emulsifier.
Rytter H, Naimi S, Wu G, Lewis J, Duquesnoy M, Vigué L, Tenaillon O, Belda E, Vazquez-Gomez M, Touly N, Arnone D, Hao F, Ley RE, Clément K, Peyrin-Biroulet L, Patterson AD, Gewirtz AT, Chassaing B
Gut. 2025 01 27;:
Anti-tumor Necrosis Factor Drug Concentration Is Not Associated with Disease Outcomes in Pouchitis: A Retrospective, International Study.
Honap S, Caron B, Ollech JE, Fischman M, Papamichael K, De Jong D, Gecse KB, Centritto A, Samaan MA, Irving PM, Sparrow MP, Karmiris K, Chateau T, Dotan I, Peyrin-Biroulet L,
Dig Dis Sci. 2025 01 27;:
Systematic Review on definitions of Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease.
Allocca M, D'Amico F, Fiorino G, Jairath V, Kucharzik T, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2025 01 18;:
Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies.
Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M
J Crohns Colitis. 2025 01 13;:
Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.
Centanni L, Cicerone C, Fanizzi F, D'Amico F, Furfaro F, Zilli A, Parigi TL, Peyrin-Biroulet L, Danese S, Allocca M
Pharmaceuticals (Basel). 2025 01 10;18(1):
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis.
Vermeire S, Rubin DT, Peyrin-Biroulet L, Dubinsky MC, Regueiro M, Irving PM, Goetsch M, Lazin K, Gu G, Wu J, Modesto I, McDonnell A, Guo X, Green J, Dalam AB, Yarur AJ
BMJ Open Gastroenterol. 2025 01 8;12(1):
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
Sands BE, Panaccione R, D'Haens G, Schreiber S, Jairath V, DuVall A, Kierkus J, Walczak M, Naik S, Gilder K, Lindstrom B, Ogilvie K, Sandborn WJ, Vermeire S, Rubin DT, Peyrin-Biroulet L, Danese S
Lancet Gastroenterol Hepatol. 2025 01 7;:
Acute severe ulcerative colitis: defining the precise moment for colectomy.
Kotze PG, Honap S, Savio MC, Araújo RMM, Quaresma AB, Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol. 2025 01 3;:1-10
Advancing Colorectal Cancer Prevention in Inflammatory Bowel Disease (IBD): Challenges and Innovations in Endoscopic Surveillance.
Fasulo E, D'Amico F, Zilli A, Furfaro F, Cicerone C, Parigi TL, Peyrin-Biroulet L, Danese S, Allocca M
Cancers (Basel). 2024 12 28;17(1):
Role of Probiotics in the Management of Patients with Ulcerative Colitis and Pouchitis.
Bernardi F, Fanizzi F, Parigi TL, Zilli A, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S, D'Amico F
Microorganisms. 2024 12 25;13(1):
Effect of Risankizumab Induction and Maintenance Therapy on the Rate of Hospitalization in Patients with Crohn's Disease.
Feagan BG, Panaccione R, Schreiber S, Loftus EV, Peyrin-Biroulet L, Arai T, Lee WJ, Griffith J, Kalabic J, Kligys K, Xuan S, Liao X, Ferrante M
Gastro Hep Adv. 2024 12 24;4(4):100603
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A,
Lancet. 2024 12 17;:
A randomized phase 2 study of efmarodocokin alfa, an IL-22 agonist, versus vedolizumab in patients with ulcerative colitis.
Danese S, Rothenberg ME, Lim JJ, Ding HT, McBride JM, Chen Y, Dash A, Mar JS, Keir M, Peyrin-Biroulet L, Panes J, Colombel JF, Feagan B, Valentine JF, Schreiber S
Clin Gastroenterol Hepatol. 2024 12 16;:
Acute Severe Ulcerative Colitis: An International Delphi Consensus on Clinical Trial Design and Endpoints.
Honap S, Jairath V, Sands BE, Dulai PS, Higgins PD, De Cruz P, Gutiérrez A, Kotze PG, Ye BD, Kobayashi T, Gearry RB, Olivera PA, Amiot A, Mosli MH, Al Awadhi S, Halfvarson J, Patel KV, Sebastian S, Danese S, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2024 12 14;:
Exclusion diet and fasting practices in patients with inflammatory bowel disease: impact on nutritional status.
Quilliot D, Bonsack O, Mahmutovic M, Peyrin-Biroulet L, Caron B
Clin Nutr ESPEN. 2024 12 9;:
Serum Neutrophil Biomarkers to Predict Crohn's Disease Progression and Infliximab Treatment Outcomes.
Magalhaes D, Santiago M, Patita M, Arroja B, Lago P, Rosa I, Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Eugenia C, Sousa P, Portela F, Correia L, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC, Magro F,
United European Gastroenterol J. 2024 12 8;:
IgG4 in the gut: Gastrointestinal IgG4-related disease or a new subtype of inflammatory bowel disease.
Bencardino S, Matichecchia CS, Fanizza J, Peyrin-Biroulet L, Della-Torre E, Danese S, D'Amico F
Autoimmun Rev. 2024 12 7;:103720
Top-down infliximab plus azathioprine versus azathioprine alone in patients with acute severe ulcerative colitis responsive to intravenous steroids: a parallel, open-label randomised controlled trial, the ACTIVE trial.
Amiot A, Seksik P, Meyer A, Stefanescu C, Wils P, Altwegg R, Vuitton L, Plastaras L, Nicolau A, Pereira B, Duveau N, Laharie D, Mboup B, Boualit M, Allez M, Rajca S, Chanteloup E, Bouguen G, Bazin T, Goutorbe F, Richard N, Moussata D, Vicaut E, Peyrin-Biroulet L
Gut. 2024 11 25;:
Raising the bar in ulcerative colitis management.
Fanizzi F, Allocca M, Fiorino G, Zilli A, Furfaro F, Parigi TL, Peyrin-Biroulet L, Danese S, D'Amico F
Therap Adv Gastroenterol. 2024 11 24;17:17562848241273066
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial.
D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D
Lancet Gastroenterol Hepatol. 2024 11 18;:
Efficacy and safety of Advanced Combination Treatment in immune-mediated inflammatory disease: A systematic review and meta-analysis of randomized controlled trials.
Solitano V, Yuan Y, Singh S, Ma C, Nardone OM, Fiorino G, Acosta Felquer ML, Barra L, D'Agostino MA, Pope J, Peyrin-Biroulet L, Danese S, Jairath V
J Autoimmun. 2024 11 6;149:103331
Review article: Measuring disease severity in inflammatory bowel disease - Beyond treat to target.
Swaminathan A, Day AS, Sparrow MP, Peyrin-Biroulet L, Siegel CA, Gearry RB
Aliment Pharmacol Ther. 2024 11;60(9):1176-1199
Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies.
Caron B, Honap S, Peyrin-Biroulet L
J Crohns Colitis. 2024 10 30;18(Supplement_2):ii3-ii15
Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study.
Schreiber S, Feagan BG, Louis E, Hisamatsu T, Hibi T, Dron L, Jamoul C, Patel H, Harris K, Taliadouros V, Oortwijn A, Peyrin-Biroulet L
United European Gastroenterol J. 2024 10 25;:
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Gibble TH, Abreu MT, Lee SD, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Panaccione R, Dignass A
Inflamm Bowel Dis. 2024 10 25;:
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.
Dulai PS, Bonner LB, Sadler C, Raffals LE, Kochhar G, Lindholm P, Buckey JC, Toups GN, Rosas L, Narula N, Jairath V, Honap S, Peyrin-Biroulet L, Sands BE, Hanauer SB, Scholtens DM, Siegel CA,
Aliment Pharmacol Ther. 2024 10 15;:
Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis.
Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Zou G, Yuan Y, Sands BE, Feagan BG, Dulai PS, Narula N, Ma C, Jairath V
Gastroenterology. 2024 10 14;:
Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist.
Temido MJ, Honap S, Bursztejn AC, Portela F, Jairath V, Danese S, Spencer A, Peyrin-Biroulet L
Am J Gastroenterol. 2024 10 9;:
Interpreting modern randomized controlled trials of medical therapy in inflammatory bowel disease.
Ma C, Jairath V, Feagan BG, Peyrin-Biroulet L, Danese S, Sands BE, Panaccione R
Nat Rev Gastroenterol Hepatol. 2024 10 8;:
Defining mucosal healing in randomized controlled trials of inflammatory bowel disease: A systematic review and future perspective.
Parigi TL, Solitano V, Armuzzi A, Barreiro de Acosta M, Begun J, Ben-Horin S, Biedermann L, Colombel JF, Dignass A, Fumery M, Ghosh S, Kobayashi T, Louis E, Magro F, Panaccione R, Rausch A, Reinisch W, Selinger C, Jairath V, Danese S, Peyrin-Biroulet L
United European Gastroenterol J. 2024 10 5;:
Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis.
Estevinho MM, Sousa-Pinto B, Moreira PL, Solitano V, Mesquita P, Costa C, Peyrin-Biroulet L, Danese S, Jairath V, Magro F
Aliment Pharmacol Ther. 2024 10 5;:
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Sands BE, Feagan BG, Peyrin-Biroulet L, Danese S, Rubin DT, Laurent O, Luo A, Nguyen DD, Lu J, Yen M, Leszczyszyn J, Kempiński R, McGovern DPB, Ma C, Ritter TE, Targan S,
N Engl J Med. 2024 09 26;391(12):1119-1129
Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis.
Solitano V, Panaccione R, Sands BE, Wang Z, Hogan M, Zou G, Peyrin-Biroulet L, Danese S, Cornfield LJ, Feagan BG, Singh S, Jairath V, Ma C
Med. 2024 09 26;:
Screen Failures and Causes in Inflammatory Bowel Disease Randomized Controlled Trials: A Study of 16 913 Screened Patients.
Uzzan M, Georgiev G, Peyrin-Biroulet L, Bouhnik Y, Narula N, Jairath V, Ungaro R, Burisch J, Kirchgesner J, Verstock B, Hussain F, Reinisch W
Inflamm Bowel Dis. 2024 09 26;:
Dysregulated myeloid differentiation in colitis is induced by inflammatory osteoclasts in a TNFα-dependent manner.
Madel MB, Ibáñez L, Ciucci T, Halper J, Boutin A, Beldi G, Lavanant AC, Garchon HJ, Rouleau M, Mueller CG, Peyrin-Biroulet L, Moulin D, Blin-Wakkach C, Wakkach A
Mucosal Immunol. 2024 09 25;:
Disease prevention trials in IBD: feasibility to future outlook.
Honap S, Agrinier N, Danese S, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2024 09 20;:
Personalized (N-of-1) Clinical Trials for Inflammatory Bowel Disease: Opportunities and Challenges.
Honap S, Zou G, Danese S, Peyrin-Biroulet L, Jairath V
Clin Gastroenterol Hepatol. 2024 09 18;:
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis.
Rubin DT, Kubassova O, Weber CR, Adsul S, Freire M, Biedermann L, Koelzer VH, Bressler B, Xiong W, Niess JH, Matter MS, Kopylov U, Barshack I, Mayer C, Magro F, Carneiro F, Maharshak N, Greenberg A, Hart S, Dehmeshki J, Peyrin-Biroulet L
Inflamm Bowel Dis. 2024 09 16;:
Clinical experience of using biosimilars in Crohn's disease and their effectiveness.
Sequier L, Caron B, Danese S, Peyrin-Biroulet L
Expert Opin Biol Ther. 2024 09 13;:1-25
Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory bowel disease.
Parigi TL, Massimino L, Carini A, Gabbiadini R, Bertoli P, Allocca M, Bezzio C, Dal Buono A, D'Amico F, Furfaro F, Loy L, Zilli A, Ungaro F, Jairath V, Peyrin-Biroulet L, Armuzzi A, Danese S
J Crohns Colitis. 2024 09 12;:
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis.
Vieujean S, Peyrin-Biroulet L
Expert Opin Drug Metab Toxicol. 2024 09 9;:
Fecal urgency and incontinence in inflammatory bowel disease perceived by physician and patient: Results from the Swiss fecal urgency survey.
Wespi N, Vavricka S, Brand S, Aepli P, Burri E, Misselwitz B, Seibold F, Hruz P, Peyrin-Biroulet L, Schoepfer A, Biedermann L, Sokollik C, Rogler G, Greuter T
United European Gastroenterol J. 2024 09 8;:
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus.
D'Amico F, Magro F, Dignass A, Al Awadhi S, Gutierrez Casbas A, Queiroz NSF, Rydzewska G, Duk Ye B, Ran Z, Hart A, Jairath V, Fiorino G, Peyrin-Biroulet L, Danese S
Expert Rev Gastroenterol Hepatol. 2024 09 3;:1-10
Clinical Trial: A Pragmatic Randomised Controlled Study to Assess the Effectiveness of Two Patient Management Strategies in Mild to Moderate Ulcerative Colitis-The OPTIMISE Study.
Danese S, Fiorino G, Vicaut E, Paridaens K, Ugur A, Clark B, Vanasek T, Stepek D, D'Amico F, West R, Gilissen LPL, Wisniewska Jarosinka M, Drobinski P, Fronik G, Fic M, Walczak M, Kowalski M, Korczowski B, Wiatr M, Peyrin-Biroulet L
J Clin Med. 2024 08 30;13(17):
Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?
Temido MJ, Honap S, Danese S, Jairath V, Magro F, Portela F, Peyrin-Biroulet L
J Crohns Colitis. 2024 08 29;:
The GETAID: 40 years of a family story in IBD.
Laharie D, Vuitton L, Bourreille A, Bouhnik Y, Colombel JF, Louis E, Fumery M, Mailhat C, Mary JY, Peyrin-Biroulet L
J Crohns Colitis. 2024 08 29;:
Inflammatory Bowel Disease and Colorectal Cancer.
Fanizza J, Bencardino S, Allocca M, Furfaro F, Zilli A, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S, D'Amico F
Cancers (Basel). 2024 08 23;16(17):
The Role of Fecal Microbiota Transplantation in IBD.
Fanizzi F, D'Amico F, Zanotelli Bombassaro I, Zilli A, Furfaro F, Parigi TL, Cicerone C, Fiorino G, Peyrin-Biroulet L, Danese S, Allocca M
Microorganisms. 2024 08 23;12(9):
Small Bowel Cancer in Crohn's Disease.
Faggiani I, D'Amico F, Furfaro F, Zilli A, Parigi TL, Cicerone C, Fiorino G, Peyrin-Biroulet L, Danese S, Allocca M
Cancers (Basel). 2024 08 21;16(16):
Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID.
Caron B, Seksik P, Buisson A, Wils P, Savoye G, Stefanescu C, Laharie D, Guillo L, Abitbol V, Bonnet J, Altwegg R, Vuitton L, Moussata D, Bourreille A, Biron A, Gilletta C, Fumery M, Nahon S, Nancey S, Camara H, Peyrin-Biroulet L
Therap Adv Gastroenterol. 2024 08 7;17:17562848241265776
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
Feagan BG, Matsuoka K, Rogler G, Laharie D, Vermeire S, Danese S, Loftus EV, Beales I, Schreiber S, Kim HJ, Faes M, de Haas A, Masior T, Rudolph C, Peyrin-Biroulet L
Aliment Pharmacol Ther. 2024 07 31;:
Endoscopic, Histologic, and Composite Endpoints in Patients with Ulcerative Colitis Treated with Etrasimod [106/120 characters, including spaces].
Magro F, Peyrin-Biroulet L, Sands BE, Danese S, Jairath V, Goetsch M, Bhattacharjee A, Wu J, Branquinho D, Modesto I, Feagan BG
Clin Gastroenterol Hepatol. 2024 07 30;:
Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease.
Sequier L, Caron B, Loeuille D, Honap S, Jairath V, Netter P, Danese S, Sibilia J, Peyrin-Biroulet L
Aliment Pharmacol Ther. 2024 07 30;:
Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials.
Louis E, Schreiber S, Panaccione R, Bossuyt P, Biedermann L, Colombel JF, Parkes G, Peyrin-Biroulet L, D'Haens G, Hisamatsu T, Siegmund B, Wu K, Boland BS, Melmed GY, Armuzzi A, Levine P, Kalabic J, Chen S, Cheng L, Shu L, Duan WR, Pivorunas V, Sanchez Gonzalez Y, D'Cunha R, Neimark E, Wallace K, Atreya R, Ferrante M, Loftus EV,
JAMA. 2024 07 22;:
ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS?
Teixeira FV, Peyrin-Biroulet L, Danese S
Arq Gastroenterol. 2024 07 19;61:e24046
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M,
N Engl J Med. 2024 07 18;391(3):213-223
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study.
D'Amico F, Massimino L, Palmieri G, Buono AD, Gabbiadini R, Caron B, Moreira P, Silva I, Bosca-Watts M, Innocenti T, Dragoni G, Bezzio C, Zilli A, Furfaro F, Saibeni S, Chaparro M, García MJ, Michalopoulos G, Viazis N, Mantzaris GJ, Ellul P, Gisbert JP, Magro F, Peyrin-Biroulet L, Armuzzi A, Ungaro F, Danese S, Fiorino G, Allocca M
Eur J Clin Invest. 2024 07 9;:e14283
Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study.
Bendaoud S, Nahon S, Beaugerie L, Gornet JM, Wils P, Amiot A, Peyrin-Biroulet L, Abitbol V, Hébuterne X, Altwegg R, Rosa I, Amil M, Heluwaert F, Plastaras L, Stefanescu C, Quentin V, Antoni M, Bideau K, Boualit M, Cuillerier E, Locher C, Skinazi F, Boureille A, Buisson A, Simon M
Dig Liver Dis. 2024 07 8;:
Implications of von Willebrand Factor in Inflammatory Bowel Diseases: Beyond Bleeding and Thrombosis.
Lagrange J, Ahmed MU, Arnone D, Lacolley P, Regnault V, Peyrin-Biroulet L, Denis CV
Inflamm Bowel Dis. 2024 07 3;:
Development and investigation of a non-invasive disease severity index for inflammatory bowel disease.
Swaminathan A, Borichevsky GM, Frampton C, Kettle AJ, Peyrin-Biroulet L, Siegel CA, Day AS, Gearry RB
J Crohns Colitis. 2024 07 2;:
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Vermeire S, Sands BE, Peyrin-Biroulet L, D'Haens GR, Panés J, Yarur AJ, Wolf DC, Ritter T, Schreiber S, Woolcott JC, Modesto I, Keating M, Shan K, Wu J, Chiorean MV, Baert F, Dubinsky MC, Goetsch M, Danese S, Feagan BG
J Crohns Colitis. 2024 06 15;:
Target Trial Emulation: Improving the Quality of Observational Studies in Inflammatory Bowel Disease Using the Principles of Randomized Trials.
Honap S, Danese S, Peyrin-Biroulet L
Inflamm Bowel Dis. 2024 06 11;:
Acute severe ulcerative colitis trials: the past, the present and the future.
Honap S, Jairath V, Sands BE, Dulai PS, Danese S, Peyrin-Biroulet L
Gut. 2024 06 4;:
Differential efficacy of medical therapies for ulcerative colitis according to disease extent: patient-level analysis from multiple randomized controlled trials.
Vuyyuru SK, Ma C, Nguyen TM, Zou G, Peyrin-Biroulet L, Danese S, Dulai P, Narula N, Singh S, Jairath V
EClinicalMedicine. 2024 06;72:102621
Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey.
D'Amico F, Peyrin-Biroulet L, Danese S
J Clin Med. 2024 05 24;13(11):
Navigating the complexities of drug development for inflammatory bowel disease.
Honap S, Jairath V, Danese S, Peyrin-Biroulet L
Nat Rev Drug Discov. 2024 05 22;:
Long-Term Neoplastic Risk Associated With Colorectal Strictures in Crohn's Disease: A Multicenter Study.
Hunaut T, Peyrin-Biroulet L, Le Bozec A, Germain A, Gower-Rousseau C, Sabbagh C, Cadiot G, Fumery M
Gastro Hep Adv. 2024 05 16;3(6):731-737
Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
Fumery M, Caron B, Hébuterne X, Altwegg R, Roblin X, Stefanescu C, Meyer A, Nachury M, Laharie D, Le Berre C, Guillo L, Biron A, Caillo L, Buisson A, Nancey S, Uzzan M, Vuitton L, Gilletta C, Geyl S, Blain A, Kirchgesner J, Ah-Soune P, Duveau N, Vidon M, Abitbol V, Paupard T, Tran-Minh ML, Defrance A, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2024 05 8;:
Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate to severe Crohn's disease.
Faggiani I, D'Amico F, Bernardi F, Bencardino S, Allocca M, Furfaro F, Parigi TL, Zilli A, Fiorno G, Peyrin-Biroulet L, Danese S
Expert Opin Drug Metab Toxicol. 2024 05 7;:
MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations.
D'Amico F, Lusetti F, Peyrin-Biroulet L, Danese S
Dig Liver Dis. 2024 05 4;:
Ultrasound remission after biologic induction and long-term endoscopic remission in Crohn's disease: a prospective cohort study.
Allocca M, Dell'Avalle C, Zilli A, Furfaro F, D'Amico F, Jairath V, Rubin DT, Peyrin-Biroulet L, Fiorino G, Danese S
EClinicalMedicine. 2024 05;71:102559
Basket, Umbrella, and Platform Trials: The Potential for Master Protocol -Based Trials in Inflammatory Bowel Disease.
Honap S, Sands BE, Jairath V, Danese S, Vicaut E, Peyrin-Biroulet L
Gastroenterology. 2024 04 25;:
Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey.
D'Amico F, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S
J Clin Med. 2024 04 24;13(9):
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease.
Lusetti F, D'Amico F, Allocca M, Furfaro F, Zilli A, Fiorino G, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S
Immunotherapy. 2024 04 17;:
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L, Dubinsky MC, Sands BE, Panés J, Schreiber S, Reinisch W, Feagan BG, Danese S, Yarur AJ, D'Haens GR, Goetsch M, Wosik K, Keating M, Lazin K, Wu J, Modesto I, McDonnell A, Bartolome L, Vermeire S
J Crohns Colitis. 2024 04 13;:
Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.
Caron B, Habert A, Bonsack O, Camara H, Jeanbert E, Parigi TL, Netter P, Danese S, Peyrin-Biroulet L
United European Gastroenterol J. 2024 04 9;:
An artificial intelligence-driven scoring system to measure histological disease activity in ulcerative colitis.
Peyrin-Biroulet L, Adsul S, Stancati A, Dehmeshki J, Kubassova O
United European Gastroenterol J. 2024 04 8;:
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus.
Olivera PA, Dignass A, Dubinsky MC, Peretto G, Kotze PG, Dotan I, Kobayashi T, Ghosh S, Magro F, Faria-Neto JR, Siegmund B, Danese S, Peyrin-Biroulet L
Dig Liver Dis. 2024 04 6;:
Differences Between the 2016 and 2022 Food and Drug Administration Guidance-Implications for Design and Interpretation of Clinical Trials in Ulcerative Colitis.
Hanzel J, Ma C, Peyrin-Biroulet L, Danese S, Sands BE, Jairath V
Crohns Colitis 360. 2024 04;6(2):otae038
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trials.
Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Ferrante M, Jordi Guardiola,Jahnsen J, Louis E, Lukáš M, Reinisch W, Roblin X, Smith PJ, Kwon T, Kim J, Yoon S, Kim DH, Atreya R
BMC Gastroenterol. 2024 03 27;24(1):121
TL1A inhibition for inflammatory bowel disease treatment: From inflammation to fibrosis.
Solitano V, Jairath V, Ungaro F, Peyrin-Biroulet L, Danese S
Med. 2024 03 26;:
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
Peyrin-Biroulet L, Bossuyt P, Bettenworth D, Loftus EV, Anjie SI, D'Haens G, Saruta M, Arkkila P, Park H, Choi D, Kim DH, Reinisch W
Dig Dis Sci. 2024 03 18;:
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Peyrin-Biroulet L, Panaccione R, Louis E, Atreya R, Rubin DT, Lindsay JO, Siffledeen J, Lukin DJ, Wright J, Watanabe K, Ford S, Remple VP, Lacerda AP, Dubcenco E, Garrison A, Zhou Q, Berg S, Anyanwu SI, Schreiber S
Clin Gastroenterol Hepatol. 2024 03 14;:
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Sands BE, D'Haens G, Clemow DB, Irving PM, Johns JT, Hunter Gibble T, Abreu MT, Lee S, Hisamatsu T, Kobayashi T, Dubinsky MC, Vermeire S, Siegel CA, Peyrin-Biroulet L, Moses RE, Milata J, Arora V, Panaccione R, Dignass A
Inflamm Bowel Dis. 2024 03 9;:
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies.
Peyrin-Biroulet L, Colombel JF, Louis E, Ferrante M, Motoya S, Panaccione R, Torres J, Ungaro RC, Kligys K, Kalabic J, Zambrano J, Zhang Y, D'Haens G
Gastro Hep Adv. 2024 03 7;3(4):539-550
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.
Allocca M, Catalano G, Savarino EV, Chaparro M, Levartovsky A, Michalopoulos G, Viazis N, Fousekis FS, Psistakis A, Noviello D, Nascimento CND, Caron B, Kitsou V, Bamias G, García MJ, Zacharopoulou E, Foteinogiannopoulou K, D'Amico F, Koutroubakis I, Ellul P, Tzouvala M, Peyrin-Biroulet L, Torres J, Caprioli F, Karmiris K, Theodoropoulou A, Katsanos KH, Christodoulou DK, Mantzaris GJ, Kopylov U, Gisbert JP, Danese S, Magro F, Carla F, Fiorino G
United European Gastroenterol J. 2024 02 28;:
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial.
Jairath V, Zou G, Wang Z, Adsul S, Colombel JF, D'Haens GR, Freire M, Moran GW, Peyrin-Biroulet L, Sandborn WJ, Sebastian S, Travis S, Vermeire S, Radulescu G, Sigler J, Hanžel J, Ma C, Sedano R, McFarlane SC, Arya N, Beaton M, Bossuyt P, Danese S, Green D, Harlan W, Horynski M, Klopocka M, Petroniene R, Silverberg MS, Wolanski L, Feagan BG
BMJ Open Gastroenterol. 2024 02 8;11(1):
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials.
D'Haens G, Higgins PDR, Peyrin-Biroulet L, Sands BE, Lee S, Moses RE, Redondo I, Escobar R, Gibble TH, Keohane A, Morris N, Zhang X, Arora V, Kobayashi T
Inflamm Bowel Dis. 2024 01 25;:
Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.
Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L
J Crohns Colitis. 2024 01 20;:
The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients.
Magro F, Fernandes S, Patita M, Arroja B, Lago P, Rosa I, de Sousa HT, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Moreira P, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Vucicevic KM, Santiago M
J Crohns Colitis. 2024 01 19;:
Are all the IL-23 blockers the same in inflammatory bowel disease?
Danese S, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2024 01 5;:
Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Vuyyuru SK, Nguyen TM, Murad MH, Narula N, Bessissow T, Zou G, McCurdy JD, Peyrin-Biroulet L, Danese S, Ma C, Singh S, Jairath V
Clin Gastroenterol Hepatol. 2024 01 5;:
The Role of IL-23 Inhibitors in Crohn's Disease.
Fanizza J, D'Amico F, Lusetti F, Fasulo E, Allocca M, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S, Fiorino G
J Clin Med. 2023 12 30;13(1):
The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease.
Swaminathan A, Fulforth JM, Frampton CM, Borichevsky GM, Mules TC, Kilpatrick K, Choukour M, Fields P, Ramkissoon R, Helms E, Hanauer SB, Leong RW, Peyrin-Biroulet L, Siegel CA, Gearry RB
Inflamm Bowel Dis. 2023 12 22;:
Implementation of regulatory guidance for JAK inhibitors use in patients with immune-mediated inflammatory diseases: An international appropriateness study.
Solitano V, Facheris P, Petersen M, D'Amico F, Ortoncelli M, Aletaha D, Olivera PA, Bieber T, Ramiro S, Ghosh S, D'Agostino MA, Siegmund B, Chary-Valckenaere I, Hart A, Dagna L, Magro F, Felten R, Kotze PG, Jairath V, Costanzo A, Kristensen LE, Biroulet LP, Danese S
Autoimmun Rev. 2023 12 19;:103504
Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-term Maintenance Study.
Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, Zhang H, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Peyrin-Biroulet L, Sands BE, Marano C
Am J Gastroenterol. 2023 12 14;:
Leaving behind the Mucosa: Advances and Future Directions of Intestinal Ultrasound in Ulcerative Colitis.
Barchi A, Dal Buono A, D'Amico F, Furfaro F, Zilli A, Fiorino G, Parigi TL, Peyrin-Biroulet L, Danese S, Allocca M
J Clin Med. 2023 12 8;12(24):
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.
Vieujean S, Laharie D, Buisson A, Roblin X, Fumery M, Nancey S, Wils P, Altwegg R, Seidel L, Caron B, Peyrin-Biroulet L
Dig Liver Dis. 2023 12 7;:
Management and treatment optimization of patients with mild to moderate ulcerative colitis.
D'Amico F, Fasulo E, Jairath V, Paridaens K, Peyrin-Biroulet L, Danese S
Expert Rev Clin Immunol. 2023 12 7;:
Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn's Disease Activity.
Solitano V, Schaeffer DF, Hogan M, Casteele NV, Pai RK, Zou G, Pai RK, Parker CE, Rémillard J, Christensen B, Danese S, Peyrin-Biroulet L, Panaccione R, Sands BE, D'Haens G, Feagan BG, Ma C, Jairath V
Clin Gastroenterol Hepatol. 2023 12 4;:
The Impact of the COVID-19 Pandemic on Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey.
Peyrin-Biroulet L, Ylänne K, Sipes A, Segovia M, Gardiner S, Cappelleri JC, Mulvey A, Panaccione R
Adv Ther. 2023 12 4;:
Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?
Honap S, Danese S, Peyrin-Biroulet L
Gastroenterol Hepatol (N Y). 2023 12;19(12):727-738
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Peyrin-Biroulet L, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravatà I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Danese S
Aliment Pharmacol Ther. 2023 11 30;:
Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post hoc Analysis of the Phase 2b/3 SELECTION Study.
Watanabe K, Peyrin-Biroulet L, Danese S, Fujitani Y, Faes M, Oortwijn A, Lindsay JO, Rogler G, Hibi T
J Crohns Colitis. 2023 11 29;:
The role of filgotinib in ulcerative colitis and Crohn's disease.
Fanizza J, D'Amico F, Lauri G, Martinez-Dominguez SJ, Allocca M, Furfaro F, Zilli A, Fiorino G, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S
Immunotherapy. 2023 11 27;:
The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease.
Schellenberg C, Lagrange J, Ahmed MU, Arnone D, Campoli P, Louis H, Touly N, Caron B, Plénat F, Perrin J, Lenting PJ, Regnault V, Lacolley P, Denis CV, Peyrin-Biroulet L
J Crohns Colitis. 2023 11 27;:
Efficacy, Safety, and Concerns on Microbiota Modulation, Antibiotics, Probiotics, and Fecal Microbial Transplant for Inflammatory Bowel Disease and Other Gastrointestinal Conditions: Results from an International Survey.
Parigi TL, Vieujean S, Paridaens K, Dalgaard K, Peyrin-Biroulet L, Danese S
Microorganisms. 2023 11 19;11(11):
Recent advances in the use of ultrasound in Crohn's disease.
Barchi A, D'Amico F, Zilli A, Furfaro F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S, Dal Buono A, Allocca M
Expert Rev Med Devices. 2023 11 14;:
The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.
Verstockt B, Vermeire S, Peyrin-Biroulet L, Mosig R, Feagan BG, Colombel JF, Siegmund B, Rieder F, Schreiber S, Yarur A, Panaccione R, Dubinsky M, Lichtiger S, Cataldi F, Danese S
J Crohns Colitis. 2023 11 11;:
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases (IBD): Real World Results from the International Organization for the study of IBD.
Vieujean S, Lindsay JO, D'Amico F, Ahuja V, Silverberg MS, Sood A, Yamamoto-Furusho JK, Nagahori M, Watanabe M, Koutroubakis IE, Foteinogiannopoulou K, Avni Biron I, Walsh A, Outtier A, Nordestgaard RLM, Abreu MT, Dubinsky M, Siegel C, Louis E, Dotan I, Reinisch W, Danese S, Rubin DT, Peyrin-Biroulet L
J Crohns Colitis. 2023 10 21;:
Lymphoma In Patients With Inflammatory Bowel Disease: A Multicenter Collaborative Study Between Getaid And Lysa.
Muller M, Broséus J, Guilloteau A, Wasse S, Thiéblemont C, Nancey S, Cadiot G, Amiot A, Laharie D, Vieujean S, Bouhnik Y, Martineau C, Michiels C, Hebuterne X, Savoye G, Franchimont D, Seksik P, Beaugerie L, Maynadié M, Feugier P, Peyrin-Biroulet L
J Crohns Colitis. 2023 10 18;:
Disease Clearance is not Synonymous with Cure.
D'Amico F, Peyrin-Biroulet L, Danese S
Inflamm Bowel Dis. 2023 10 5;:
Tofacitinib for patients with anti-TNF refractory ulcerative proctitis: a multicenter cohort study from the GETAID.
Uzzan M, Nachury M, Nuzzo A, Amiot A, Caron B, Benezech A, Buisson A, Bouguen G, Le Berre C, Reenaers C, Le Cosquer G, Savoye G, Charkaoui M, Vidon M, Guillo L, Fumery M, Peyrin-Biroulet L, Kirchgesner J, Bouhnik Y,
J Crohns Colitis. 2023 10 5;:
Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus.
D'Amico F, Solitano V, Magro F, Olivera PA, Halfvarson J, Rubin D, Dignass A, Al Awadhi S, Kobayashi T, Queiroz NSF, Calvo M, Kotze PG, Ghosh S, Peyrin-Biroulet L, Danese S
J Clin Med. 2023 10 3;12(19):
Washout periods in inflammatory bowel disease trials: A systematic literature review and proposed solutions.
Wils P, Jairath V, Sands BE, Reinisch W, Danese S, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2023 09 22;:
Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease.
Wils P, Jairath V, Sands BE, Magro F, Reinisch W, Rubin D, Danese S, Baumann C, Peyrin-Biroulet L
United European Gastroenterol J. 2023 09 5;:
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A, ,Abrahamovych O, Afanasieva H, Aitova L, Altintas E, Altwegg R, Andreev P, Aomatsu K, Augustyn M, Balestrieri P, Begun J, Brunatto L, Bulgheroni D, Bunkova E, Cabello M, Cao Q, Caprioli F, Cerqueira R, Chen B, Chen CC, Chen CP, Chiu CT, Choi CH, Cicala M, Datsenko O, Dewint P, Domenech E, Dutré J, Duvall G, Fernandez J, Filip R, Fogel R, Fowler S, Fujii T, Fukata M, Furumoto Y, Gasbarrini A, Gawdis-Wojnarska B, Gilletta C, Gionchetti P, Goldin E, Golovchenko O, Gonciarz M, Gonen C, Segura GG, Gridnyev O, Gyokeres T, Hébuterne X, Hedin C, Hellström P, Hilmi IN, Horný I, Horvat G, Hoshi N, Hrdlicka L, Ishihara S, Ivanishyn O, Jang BI, Junior O, Kagaya T, Kanmura S, Karakina M, Katsuhiko N, Kierkus J, Kim HJ, Kim TO, Kim YH, Kiss GG, Klaus J, Kleczkowski D, Klopocka M, Kobayashi T, Kobielusz-Gembala I, Koo JS, Kopon A, Kravchenko T, Kudo M, Kwon KA, Lago P, Laharie D, Lawrance I, Leszczyszyn J, Li Y, Lukas M, Maaser C, Maemoto A, Marusawa H, McBride M, Mendu S, Miheller P, Miyabayashi H, Mohl W, Moore G, Motoya S, Murali N, Naem M, Nakajima K, Nakamoto Y, Nancey S, Neto J, Onizawa M, Ono Y, Ono Y, Osada T, Osipenko M, Owczarek D, Patel B, Patel K, Petrova E, Poroshina E, Portela F, Prystupa L, Rivero M, Roblin X, Romatowski J, Rydzewska G, Saibeni S, Sakuraba H, Samaan M, Schultz M, Schulze J, Sedghi S, Seidler U, Shin SJ, Stanislavchuk M, Stokesberry D, Suzuki T, Taguchi H, Tankova L, Thin L, Tkachev A, Torrealba L, Tsarynna N, Tulassay Z, Ueo T, Valuyskikh E, Vasilevskaya O, Viamonte M, Wei SC, Weisshof R, Wojcik K, Ye BD, Yen HH, Yoon H, Yoshida K, Yurkiv A, Zaha O, Zhan Q
Gastroenterology. 2023 08 31;:
The risk of COVID-19 in IBD patients is increased by urban living and is not influenced by disease activity or intravenous biologics.
Lelong M, Josien R, Coste-Burel M, Rimbert M, Bressollette-Bodin C, Nancey S, Bouguen G, Allez M, Serrero M, Caillo L, Rouillon C, Blanc P, Laharie D, Olivier R, Peyrin-Biroulet L, Dib N, De Maissin A, Montuclard C, Trang-Poisson C, Vavasseur F, Gallot G, Berthome M, Braudeau C, Chevreuil J, Bourreille A, Le Berre C
Front Immunol. 2023 08 28;14:1243898
An update on the safety of long-term vedolizumab use in inflammatory bowel disease.
Honap S, Netter P, Danese S, Peyrin-Biroulet L
Expert Opin Drug Saf. 2023 08 23;:1-10
Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?
Honap S, Peyrin-Biroulet L
Aliment Pharmacol Ther. 2023 08 21;:
Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations.
Schreiber S, Danese S, Dignass A, Domènech E, Fantini MC, Ferrante M, Halfvarson J, Hart A, Magro F, Lees CW, Leone S, Pierik MJ, Peters M, Field P, Fishpool H, Peyrin-Biroulet L
J Crohns Colitis. 2023 08 16;:
A comparison of treatment effect sizes in matched phase 2 and phase 3 trials of advanced therapeutics in inflammatory bowel disease: systematic review and meta-analysis.
Hanzel J, Solitano V, Zou L, Zou GY, Peyrin-Biroulet L, Danese S, Singh S, Ma C, Wils P, Jairath V
Clin Transl Gastroenterol. 2023 08 14;:
RISK OF CANCER RECURRENCE IN PATIENTS WITH IMMUNE-MEDIATED DISEASES WITH USE OF IMMUNOSUPPRESSIVE THERAPIES: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS.
Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN
Clin Gastroenterol Hepatol. 2023 08 12;:
Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus.
D'Amico F, Magro F, Siegmund B, Kobayashi T, Kotze PG, Solitano V, Caron B, Al Awadhi S, Hart A, Jairath V, Dignass A, Peyrin-Biroulet L, Danese S
Inflamm Bowel Dis. 2023 08 7;:
Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.
Vermeire S, Feagan BG, Peyrin-Biroulet L, Oortwijn A, Faes M, de Haas A, Rogler G
J Crohns Colitis. 2023 08 4;:
Prevalence of and factors associated with extraintestinal manifestations and their remission in inflammatory bowel disease: the EXTRA prospective study from the GETAID.
Guillo L, Savoye G, Amiot A, Gilletta C, Nachury M, Dib N, Bourreille A, Roblin X, Caillo L, Allez M, Picon L, Hébuterne X, Seksik P, Chupin A, Buisson A, Brixi H, Altwegg R, Simon M, Amil M, Laharie D, Bouguen G, Serrero M, Elgharabawy Y, Peyrin-Biroulet L
Clin Transl Gastroenterol. 2023 08 1;:
Defining magnetic resonance imaging treatment response and remission in Crohn's disease: a systematic review.
Caron B, Jairath V, Laurent V, Stoker J, Laghi A, D'Haens GR, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2023 07 31;:
Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.
Bencardino S, D'Amico F, Faggiani I, Bernardi F, Allocca M, Furfaro F, Parigi TL, Zilli A, Fiorino G, Peyrin-Biroulet L, Danese S
J Clin Med. 2023 07 30;12(15):
Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
Parkes G, Ungaro RC, Danese S, Abreu MT, Arenson E, Zhou W, Ilo D, Laroux FS, Deng H, Sanchez Gonzalez Y, Peyrin-Biroulet L
J Gastroenterol. 2023 07 25;:
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 patients from 12 studies.
Huinink STB, Thomassen D, Steyerberg EW, Pauwels RWM, Casanova MJ, Bouguen G, Mak JWY, Molnár T, Lobo AJ, Seidelin JB, Amiot A, D'Haens G, Rivière P, Guidi L, Bor R, Lin WC, Peyrin-Biroulet L, Gisbert JP, van der Woude CJ, de Vries AC
J Crohns Colitis. 2023 07 12;:
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting.
Parigi TL, D'Amico F, Abreu MT, Dignass A, Dotan I, Magro F, Griffiths AM, Jairath V, Iacucci M, Mantzaris GJ, O'Morain C, Reinisch W, Sachar DB, Turner D, Yamamoto T, Rubin DT, Peyrin-Biroulet L, Ghosh S, Danese S
Lancet Gastroenterol Hepatol. 2023 07 6;:
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
Schreiber S, Rubin DT, Ng SC, Peyrin-Biroulet L, Danese S, Modesto I, Guo X, Su C, Kwok KK, Jo H, Chen Y, Yndestad A, Reinisch W, Dubinsky MC
J Crohns Colitis. 2023 07 4;:
Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
D'Amico F, Peyrin-Biroulet L, Danese S
United European Gastroenterol J. 2023 07 3;:
Stemming the tide with ileocaecal Crohn's disease: when is pharmacotherapy enough?
Vieujean S, Kotze PG, Netter P, Germain A, Louis E, Danese S, Peyrin-Biroulet L
Expert Opin Pharmacother. 2023 07 3;:
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
D'Haens G, Peyrin-Biroulet L, Marks DJB, Lisi E, Liefaard L, Beaton A, Srinivasan N, Bouma G, Prasad N, Cameron R, Kayali Z, Tarzi R, Hanauer S, Sandborn WJ
Aliment Pharmacol Ther. 2023 06 16;:
Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: Systematic review and meta-analysis.
Solitano V, Vuyyuru SK, MacDonald JK, Zayadi A, Parker CE, Narula N, Peyrin-Biroulet L, Danese S, Feagan BG, Singh S, Ma C, Jairath V
J Crohns Colitis. 2023 06 15;:
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study.
Magro F, Estevinho MM, Catalano G, Patita M, Arroja B, Lago P, Rosa I, Tavares de Sousa H, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Moreira P, Santiago M, Dias S, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC,
United European Gastroenterol J. 2023 06 15;:
Real-world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey.
Nardone OM, Iacucci M, Villanacci V, Peyrin-Biroulet L, Ghosh S, Danese S, Parigi TL
United European Gastroenterol J. 2023 06 15;:
Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey.
Odufalu FD, Dubinsky MC, Peyrin-Biroulet L, Ylänne K, Sipes A, Cappelleri JC, Russo LJ, Segovia M, Gardiner S, Johnson EP, Mulvey A, Panaccione R
Inflamm Bowel Dis. 2023 06 10;:
Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study.
Khanna R, Ma C, Hogan M, Zou G, Bessissow T, Bressler B, Colombel JF, Danese S, Daperno M, East JE, Hookey L, Loftus EV, McDonald JWD, Panaccione R, Peyrin-Biroulet L, Rutter M, Sands BE, Vermeire S, Rémillard J, McFarlane SC, Sandborn WJ, D'Haens GR, Feagan BG, Jairath V
Clin Gastroenterol Hepatol. 2023 06 10;:
Promising phase II biologics for future Crohn's disease therapy.
Wils P, Danese S, Peyrin-Biroulet L
Expert Opin Investig Drugs. 2023 05 31;:1-13
Effectiveness and safety of tofacitinib in patients with chronic pouchitis multirefractory to biologics: A multicenter cohort study from the GETAID.
Uzzan M, Nachury M, Amiot A, Peyrin-Biroulet L, Kirchgesner J, Bouhnik Y,
Dig Liver Dis. 2023 05 27;:
Defining biological remission in Crohn's disease: interest, challenges and future directions.
Pierre N, Vieujean S, Peyrin-Biroulet L, Meuwis MA, Louis E
J Crohns Colitis. 2023 05 19;:
Ulcerative proctitis: Challenges for clinical management.
Caron B, Peyrin-Biroulet L
J Gastroenterol Hepatol. 2023 05 11;:
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.
Panés J, Vermeire S, D'Haens GR, Danese S, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravatà I, Gaya DR, Peyrin-Biroulet L, Dignass A,
United European Gastroenterol J. 2023 05 4;:
Risk-Benefit of IBD Drugs: A Physicians and Patients Survey.
D'Amico F, Vieujean S, Caron B, Peyrin-Biroulet L, Danese S
J Clin Med. 2023 04 24;12(9):
Early intestinal ultrasound predicts long-term endoscopic response to biologics in ulcerative colitis.
Allocca M, Dell'Avalle C, Furfaro F, Zilli A, D'Amico F, Peyrin-Biroulet L, Fiorino G, Danese S
J Crohns Colitis. 2023 04 21;:
Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic.
Bonsack O, Caron B, Baumann C, Heba AC, Vieujean S, Arnone D, Netter P, Danese S, Quilliot D, Peyrin-Biroulet L
United European Gastroenterol J. 2023 04 20;:
Can we change the natural course of inflammatory bowel disease?
Le Berre C, Danese S, Peyrin-Biroulet L
Therap Adv Gastroenterol. 2023 04 17;16:17562848231163118
Resolving Histologic Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programs.
Magro F, Pai RK, Kobayashi T, Jairath V, Rieder F, Redondo I, Lissoos T, Morris N, Shan M, Park M, Peyrin-Biroulet L
J Crohns Colitis. 2023 04 14;:
Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors.
Goetsch A, D'Amico F, Allocca M, Fiorino G, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S
Expert Opin Pharmacother. 2023 04 11;:1-13
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
Olivera PA, Lasa JS, Peretto G, Zuily S, Danese S, Peyrin-Biroulet L
Aliment Pharmacol Ther. 2023 04 10;:
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars.
Gibofsky A, Jacobson G, Franklin A, O'Hara-Levi S, Peyrin-Biroulet L, McGrath M, McCabe D
J Manag Care Spec Pharm. 2023 04;29(4):343-349
Editorial: risankizumab - ready to break ceilings? author's reply.
Fumery M, Peyrin-Biroulet L
Aliment Pharmacol Ther. 2023 04;57(8):911
Prevalence and determinants of fatigue in patients with IBD: a cross-sectional survey from the GETAID.
Amiot A, Chaibi S, Bouhnik Y, Serrero M, Filippi J, Roblin X, Bourrier A, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Mathieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Le Berre C, Dib N, Brixi H, Painchart C, Plastaras L, Altwegg R, Fumery M, Caillo L, Laharie D, Nachury M,
J Crohns Colitis. 2023 03 29;:
A critical review of ustekinumab for the treatment of active ulcerative colitis in adults.
Vieujean S, Louis E, Danese S, Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol. 2023 03 22;:
The case for the prevention of fistulas in patients with perianal Crohn's disease.
de Parades V, Fathallah N, Peyrin-Biroulet L
Clin Res Hepatol Gastroenterol. 2023 03 21;:102113
Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
Dotan I, Feagan BG, Taliadouros V, Oortwijn A, Rudolph C, de Haas A, Santermans E, Hsieh J, Peyrin-Biroulet L, Hibi T
J Crohns Colitis. 2023 03 16;:
Inflammation and malnutrition in inflammatory bowel disease.
Massironi S, Viganò C, Palermo A, Pirola L, Mulinacci G, Allocca M, Peyrin-Biroulet L, Danese S
Lancet Gastroenterol Hepatol. 2023 03 15;:
Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease.
Magalhaes D, Peyrin-Biroulet L, Estevinho MM, Danese S, Magro F
Therap Adv Gastroenterol. 2023 03 11;16:17562848231155987
Identifying, understanding and managing fecal urgency in inflammatory bowel diseases.
Caron B, Ghosh S, Danese S, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2023 03 9;:
Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis.
Magro F, Moreira PL, Catalano G, Alves C, Roseira J, Estevinho MM, Silva I, Dignass A, Peyrin-Biroulet L, Danese S, Jairath V, Dias CC, Santiago M
United European Gastroenterol J. 2023 03 6;:
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG
Lancet. 2023 03 2;:
Etrasimod for the treatment of ulcerative colitis.
Wils P, Peyrin-Biroulet L
Immunotherapy. 2023 02 15;:
Gut virome-colonising genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation .
Massimino L, Palmieri O, Facoetti A, Fuggetta D, Spanò S, Lamparelli LA, D'Alessio S, Cagliani S, Furfaro F, D'Amico F, Zilli A, Fiorino G, Parigi TL, Noviello D, Latiano A, Bossa F, Latiano T, Pirola A, Mologni L, Piazza RG, Abbati D, Perri F, Bonini C, Peyrin-Biroulet L, Malesci A, Jairath V, Danese S, Ungaro F
Gut. 2023 02 14;:
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from SELECTION.
Schreiber S, Feagan BG, Peyrin-Biroulet L, Vermeire S, Faes M, Harris K, Oortwijn A, Daniele P, Patel H, Danese S
J Crohns Colitis. 2023 02 9;:
Declining enrolment and other challenges in IBD clinical trials: Causes and potential solutions.
Uzzan M, Bouhnik Y, Abreu M, Ahmad HA, Adsul S, Carlier H, Dubinsky M, Germinaro M, Jairath V, Modesto I, Mortensen E, Narula N, Neimark E, Oortwijn A, Protic M, Rubin DT, Oh YS, Wichary J, Peyrin-Biroulet L, Reinisch W
J Crohns Colitis. 2023 02 4;:
Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis.
Lichtenstein GR, Cohen BL, Salese L, Modesto I, Wang W, Chan G, Ahmed HM, Su C, Peyrin-Biroulet L
Dig Dis Sci. 2023 02 4;:
iSTART-II: An Update on the i Support Therapy-Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis.
D'Amico F, Magro F, Caron B, Dignass A, Jairath V, Hart A, Kotze PG, Paridaens K, Awadhi SA, Kobayashi T, Siegmund B, Peyrin-Biroulet L, Danese S
J Clin Med. 2023 02 1;12(3):
Adalimumab in biologic-naïve patients with Crohn's disease after resolution of an intra-abdominal abscess: a prospective study from the GETAID.
Bouhnik Y, De Chambrun GP, Lambert J, Nachury M, Seksik P, Altwegg R, Vuitton L, Stefanescu C, Nancey S, Aubourg A, Serrero M, Filippi J, Desseaux K, Viennot S, Abitbol V, Boualit M, Bourreille A, Giletta C, Buisson A, Roblin X, Dib N, Malamut G, Amiot A, Fumery M, Louis E, Elgharabawy Y, Peyrin-Biroulet L,
Clin Gastroenterol Hepatol. 2023 01 30;:
A multi-omic analysis reveals the esophageal dysbiosis as the predominant trait of eosinophilic esophagitis.
Massimino L, Barchi A, Mandarino FV, Spanò S, Lamparelli LA, Vespa E, Passaretti S, Peyrin-Biroulet L, Savarino EV, Jairath V, Ungaro F, Danese S
J Transl Med. 2023 01 25;21(1):46
Inflammatory bowel disease meets fertility: A physician and patient survey.
Vieujean S, De Vos M, D'Amico F, Paridaens K, Daftary G, Dudkowiak R, Peyrin-Biroulet L, Danese S
Dig Liver Dis. 2023 01 23;:
International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients.
Caron B, Jairath V, D'Amico F, Al Awadhi S, Dignass A, Hart AL, Kobayashi T, Kotze PG, Magro F, Siegmund B, Paridaens K, Danese S, Peyrin-Biroulet L
Medicina (Kaunas). 2023 01 16;59(1):
Deep Dive Into MicroRNAs in Inflammatory Bowel Disease.
Alfaifi J, Germain A, Heba AC, Arnone D, Gailly L, Ndiaye NC, Viennois E, Caron B, Peyrin-Biroulet L, Dreumont N
Inflamm Bowel Dis. 2022 12 21;:
Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: A GETAID multicentre cohort study.
Fumery M, Defrance A, Roblin X, Altwegg R, Caron B, Hébuterne X, Stefanescu C, Meyer A, Nachury M, Laharie D, Nancey S, Le Berre C, Serrero M, Geyl S, Giletta C, Ah-Soune P, Duveau N, Uzzan M, Abitbol V, Biron A, Tran-Minh ML, Paupard T, Vuitton L, Elgharabawy Y, Peyrin-Biroulet L
Aliment Pharmacol Ther. 2022 12 19;:
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance.
Danese S, Solitano V, Jairath V, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2022 12 19;:
Non-invasive assessment of postoperative disease recurrence in Crohn's Disease: a multicenter, prospective cohort study on behalf of the IG-IBD.
Furfaro F, D'Amico F, Zilli A, Craviotto V, Aratari A, Bezzio C, Spinelli A, Gilardi D, Radice S, Saibeni S, Papi C, Peyrin-Biroulet L, Danese S, Fiorino G, Allocca M
Clin Gastroenterol Hepatol. 2022 12 12;:
Inflammatory Bowel Disease Patients' Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience.
Remy C, Caron B, Gouynou C, Haghnejad V, Jeanbert E, Netter P, Danese S, Peyrin-Biroulet L
J Clin Med. 2022 12 8;11(24):
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Rayer C, Nachury M, Bourreille A, Roblin X, Peyrin-Biroulet L, Viennot S, Flamant M, Laharie D, Caron B, Dewitte M, Siproudhis L, Fumery M, Bouguen G
BMC Gastroenterol. 2022 12 1;22(1):498
Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study.
Burgevin A, Caron B, Sasson A, Luc A, Netter P, Baumann C, Ananthakrishnan AN, Peyrin-Biroulet L
J Clin Med. 2022 11 25;11(23):
Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild-moderate ulcerative colitis.
Cortesi PA, Fiorino G, Peyrin-Biroulet L, Mantovani LG, Jairath V, Paridaens K, Andersson FL, Danese S
Aliment Pharmacol Ther. 2022 11 15;:
ImmUniverse Consortium: Multi-omics integrative approach in personalized medicine for immune-mediated inflammatory diseases.
Vetrano S, Bouma G, Benschop RJ, Birngruber T, Costanzo A, D'Haens GRAM, Frasca L, Hillenbrand R, Iversen L, Johansen C, Kaser A, Koenen HJPM, Noehammer C, Peyrin-Biroulet L, Raes J, Ricotti L, Rosenstiel P, Satagopam VP, Schreiber S, Vermeire S, Wollenberg A, Weidinger S, Ziemek D, Danese S,
Front Immunol. 2022 11 9;13:1002629
Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries.
Yoo HK, Byun HG, Caprioli F, Fumery M, Peyrin-Biroulet L, Sreedhar S, Potter J, Jang M
BMC Health Serv Res. 2022 11 4;22(1):1319
Fertility and assisted reproductive technologies outcomes of women with non-surgically managed inflammatory bowel diseases: a systematic review.
Vieujean S, De Vos M, Paridaens K, Daftary GS, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2022 11 2;:
Filgotinib for moderately to severely active ulcerative colitis.
Mannucci A, D'Amico F, El Saadi A, Peyrin-Biroulet L, Danese S
Expert Rev Gastroenterol Hepatol. 2022 10 24;:
Placebo response rates in randomized controlled trials for perianal Crohn's disease: A systematic review and meta-analysis.
Sharma T, Ma C, Sedano R, Hanzel J, McDonald C, Hogan M, Kochhar GS, Narula N, Peyrin-Biroulet L, Danese S, MacDonald JK, Jairath V
J Crohns Colitis. 2022 10 22;:
Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials.
Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, Wallace K, Berg S, Liao X, Panes J, Loftus EV, Louis E
Aliment Pharmacol Ther. 2022 10 20;:
Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysis.
Roseira J, Santiago M, Estevinho MM, Moreira P, Alves C, Danese S, Peyrin-Biroulet L, Dignass A, Feakins R, Magro F
Inflamm Bowel Dis. 2022 10 17;:
Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis.
Millet V, Gensollen T, Maltese M, Serrero M, Lesavre N, Bourges C, Pitaval C, Cadra S, Chasson L, Vu Man TP, Masse M, Martinez-Garcia JJ, Tranchida F, Shintu L, Mostert K, Strauss E, Lepage P, Chamaillard M, Broggi A, Peyrin-Biroulet L, Grimaud JC, Naquet P, Galland F
Gut. 2022 09 29;:
New magnetic resonance imaging sequences for fibrosis assessment in Crohn's disease: a pilot study.
Caron B, Laurent V, Odille F, Danese S, Hossu G, Peyrin-Biroulet L
Scand J Gastroenterol. 2022 09 29;:1-4
Is selectivity the JAKpot winner for IBD treatment?
D'Amico F, Peyrin-Biroulet L, Danese S
Gastroenterology. 2022 09 22;:
I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Sebastian S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L,
Clin Gastroenterol Hepatol. 2022 09 21;:
Identification of circulating biomarkers of Crohn's disease and spondyloarthritis using FTIR spectroscopy.
Prada P, Brunel B, Moulin D, Rouillon L, Netter P, Loeuille D, Slimano F, Bouche O, Peyrin-Biroulet L, Jouzeau JY, Piot O
J Biophotonics. 2022 09 16;:e202200200
Landscape of new drugs and targets in inflammatory bowel disease.
Vieujean S, D'Amico F, Netter P, Danese S, Peyrin-Biroulet L
United European Gastroenterol J. 2022 09 16;:
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study.
D'Amico F, Fiorino G, Solitano V, Massarini E, Guillo L, Allocca M, Furfaro F, Zilli A, Bonovas S, Magro F, Peyrin-Biroulet L, Danese S
United European Gastroenterol J. 2022 09 15;:
Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study.
Bessissow T, Nguyen GC, Tarabain O, Peyrin-Biroulet L, Foucault N, McHugh K, Ruel J
World J Gastroenterol. 2022 09 14;28(34):5058-5075
Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study.
Paupard T, Gonzalez F, Caron B, Siproudhis L, Peyrin-Biroulet L
Eur J Gastroenterol Hepatol. 2022 09 12;:
Opportunistic Infections in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Olivera PA, Lasa JS, Zubiaurre I, Jairath V, Abreu MT, Rubin DT, Reinisch W, Magro F, Rahier JF, Danese S, Rabaud C, Peyrin-Biroulet L
J Crohns Colitis. 2022 09 10;:
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review.
Caron B, Jairath V, D'Amico F, Paridaens K, Magro F, Danese S, Peyrin-Biroulet L
United European Gastroenterol J. 2022 08 27;:
Identification of the optimal medical and surgical management for patients with perianal fistulising Crohn's disease.
Laland M, François M, D'Amico F, Zallot C, Brochard C, Dewitte M, Siproudhis L, Peyrin-Biroulet L, Bouguen G
Colorectal Dis. 2022 08 25;:
Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial.
Danese S, Ferrante M, Feagan BG, Peyrin-Biroulet L, Hibi T, Sandborn WJ, Schreiber S, Ritter T, Loftus EV, Rogler G, Oortwijn A, Yun C, Le Brun FO, Dinoso J, Hsieh J, Vermeire S
Am J Gastroenterol. 2022 08 23;:
Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study.
Guillo L, Flachaire B, Avouac J, Dong C, Nachury M, Bouguen G, Buisson A, Caillo L, Fumery M, Gilletta C, Hébuterne X, Lafforgue P, Laharie D, Mahé E, Marotte H, Nancey S, Ottaviani S, Salmon JH, Savoye G, Serrero M, Uzzan M, Viguier M, Richez C, Peyrin-Biroulet L, Seksik P, Pham T,
Dig Liver Dis. 2022 08 16;:
Available methods for benefit-risk assessment: lessons for inflammatory bowel disease drugs.
Caron B, D'Amico F, Jairath V, Netter P, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2022 08 11;:
Placebo rates in randomized controlled trials of proctitis therapy: A systematic review and meta-analysis.
De Silva TA, Alphonsus L, Ma C, Hogan M, Sedano R, Narula N, Danese S, Peyrin-Biroulet L, MacDonald JK, Singh S, Jairath V
J Crohns Colitis. 2022 08 5;:
Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era.
Cuny A, Guillo L, Baumann C, Netter P, Danese S, Caron B, Peyrin-Biroulet L, Angioi K
J Clin Med. 2022 08 4;11(15):
Performance measures for colonoscopy in inflammatory bowel disease patients: European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative.
Dekker E, Nass KJ, Iacucci M, Murino A, Sabino J, Bugajski M, Carretero C, Cortas G, Despott EJ, East JE, Kaminski MF, Karstensen JG, Keuchel M, Löwenberg M, Monged A, Nardone OM, Neumann H, Omar MM, Pellisé M, Peyrin-Biroulet L, Rutter MD, Bisschops R
Endoscopy. 2022 07 29;:
Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD).
Furfaro F, Ragaini E, Peyrin-Biroulet L, Danese S
J Clin Med. 2022 07 28;11(15):
Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge.
Wils P, Caron B, D'Amico F, Danese S, Peyrin-Biroulet L
J Clin Med. 2022 07 22;11(15):
Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study.
Meyer A, Fumery M, Peyrin-Biroulet L, Filippi J, Altwegg R, Bouhnik Y, Serrero M, Laharie D, Roblin X, Nachury M, Abitbol V, Cadiot G, Nancey S, Allez M, Gilletta C, Vuitton L, Savoye G, Nahon S, Bourrier A, Buisson A, Bouguen G, Bourreille A, Viennot S, Carbonnel F, Amiot A
Scand J Gastroenterol. 2022 07 12;:1-9
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study.
Buisson A, Serrero M, Orsat L, Nancey S, Rivière P, Altwegg R, Peyrin-Biroulet L, Nachury M, Hébuterne X, Gilletta C, Flamant M, Viennot S, Bouguen G, Amiot A, Mathieu S, Vuitton L, Plastaras L, Bourreille A, Caillo L, Goutorbe F, Pineton De Chambrun G, Attar A, Roblin X, Pereira B, Fumery M
Inflamm Bowel Dis. 2022 07 11;:
Impact of the Exposome on the Epigenome in Inflammatory Bowel Disease Patients and Animal Models.
Vieujean S, Caron B, Haghnejad V, Jouzeau JY, Netter P, Heba AC, Ndiaye NC, Moulin D, Barreto G, Danese S, Peyrin-Biroulet L
Int J Mol Sci. 2022 07 9;23(14):
Biological therapy for budesonide-refractory, -dependent or -intolerant microscopic colitis: a multicentre cohort study from the GETAID.
Boivineau G, Zallot C, Zerbib F, Plastaras L, Amiot A, Boivineau L, Koch S, Peyrin-Biroulet L, Vuitton L
J Crohns Colitis. 2022 07 6;:
LIAISON Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study.
Fiorino G, Danese S, Peyrin-Biroulet L, Sans M, Bonelli F, Calleri M, Zierold C, Pollastro R, Moretti F, Malesci A
United European Gastroenterol J. 2022 07 4;:
Is Hartmann's Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
Renaud M, Ayav A, Caron B, Peyrin-Biroulet L, Germain A
J Clin Med. 2022 07 3;11(13):
CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease.
Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Gearry RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Casteele NV, Feagan BG, Jairath V,
Gastroenterology. 2022 07 1;:
The impact of COVID-19 on patients with IBD in a prospective European cohort study.
Amiot A, Rahier JF, Baert F, Nahon S, Hart A, Viazis N, Biancone L, Domenech E, Reenears C, Peyrin-Biroulet L, Beaugerie L, Burisch J,
J Crohns Colitis. 2022 06 29;:
Weight change after colectomy for ulcerative colitis.
Kouki M, Caron B, Malgras A, Ayav A, Peyrin-Biroulet L, Germain A
Scand J Gastroenterol. 2022 06 20;:1-3
Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.
Napolitano M, D'Amico F, Ragaini E, Peyrin-Biroulet L, Danese S
Drug Des Devel Ther. 2022 06 17;16:1897-1913
EFFICACY AND SAFETY OF INFLIXIMAB RETREATMENT: IN CROHN'S DISEASE:A MULTICENTRE, PROSPECTIVE, OBSERVATIONAL COHORT (REGAIN) STUDY.
Boschetti G, Nachury M, Laharie D, Roblin X, Gilletta C, Aubourg A, Bourreille A, Zallot C, Hebuterne X, Buisson A, Grimaud JC, Bouhnik Y, Allez M, Altwegg R, Viennot S, Vuitton L, Carbonnel F, Paul S, Desseaux K, Lambert J, Biroulet LP,
Am J Gastroenterol. 2022 06 2;:
SARS-CoV-2 seroprevalence in healthcare workers and risk factors.
Weber S, Didelot A, Agrinier N, Peyrin-Biroulet L, Schvoerer E, Rabaud C, Jeulin H
Infect Dis Health. 2022 05 17;:
Ustekinumab in Crohn's Disease: New Data for Positioning in Treatment Algorithm.
D'Amico F, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2022 05 11;16(Supplement_2):ii30-ii41
Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study.
Poullenot F, Amiot A, Nachury M, Viennot S, Altwegg R, Bouhnik Y, Abitbol V, Nancey S, Vuitton L, Peyrin-Biroulet L, Biron A, Fumery M, Picon L, Vidon M, Reenaers C, Serrero M, Savoye G, Beaugerie L, Rivière P, Laharie D,
J Crohns Colitis. 2022 May 5;:
Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.
Parigi TL, D'Amico F, Abreu MT, Rubin DT, Dignass A, Dotan I, Jairath V, Magro F, Peyrin-Biroulet L, Ghosh S, Danese S
Lancet Gastroenterol Hepatol. 2022 May;7(5):390-391
Is it time to include older adults in inflammatory bowel disease trials? A call for action.
Vieujean S, Caron B, Jairath V, Benetos A, Danese S, Louis E, Peyrin-Biroulet L
Lancet Healthy Longev. 2022 05;3(5):e356-e366
Iron deficiency screening is a key issue in chronic inflammatory diseases: A call for actions.
Cacoub P, Choukroun G, Cohen-Solal A, Luporsi E, Peyrin-Biroulet L, Peoc'h K, Andrieu V, Lasocki S, Puy H, Trochu JN
J Intern Med. 2022 Apr 24;:
Prevalence of and Factors Associated with Respiratory Symptoms Among Patients with Inflammatory Bowel Disease: A Prospective Study.
Valentin S, Renel B, Manneville F, Caron B, Choukour M, Guillaumot A, Chaouat A, Poussel M, Chateau T, Peyrin-Biroulet C, Achit H, Peyrin-Biroulet L, Chabot F
Inflamm Bowel Dis. 2022 Apr 8;:
Iron Deficiency in Patients with Inflammatory Bowel Diseases: A Prospective Multicenter Cross-Sectional Study.
Peyrin-Biroulet L, Bouguen G, Laharie D, Pellet G, Savoye G, Gilletta C, Michiels C, Buisson A, Fumery M, Trochu JN, Cacoub P,
Dig Dis Sci. 2022 Apr 6;:
Prevalence of Self-Reported Venous Thromboembolism and Cardiovascular Risk Factors in Patients with Ulcerative Colitis: The GETAID FOCUS Study.
Guillo L, Amiot A, Serrero M, Altwegg R, Roblin X, Atanasiu C, Buisson A, Le Berre C, Reenaers C, Gornet JM, Laharie D, Abitbol V, Biron A, Caron B, Nancey S, Chupin A, Blain A, Vuitton L, Caillo L, Kirchgesner J, Nachury M, Peyrin-Biroulet L,
Dig Dis Sci. 2022 Mar 4;:
Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, Tikhonov I, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Arasaradnam RP, Afif W, Peyrin-Biroulet L, Sands BE, Marano C
J Crohns Colitis. 2022 Mar 3;:
Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study.
Allocca M, Dell'Avalle C, Craviotto V, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S
United European Gastroenterol J. 2022 Mar 1;:
Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases.
Cacoub P, Choukroun G, Cohen-Solal A, Luporsi E, Peyrin-Biroulet L, Peoc'h K, Andrieu V, Lasocki S, Puy H, Trochu JN
Nutrients. 2022 Feb 28;14(5):
How to manage inflammatory bowel disease patients when they withdraw anti-TNF due to severe anti-TNF-induced skin lesions? A multicenter cohort study.
Cottron C, Treton X, Altwegg R, Reenaers C, Amiot A, Fumery M, Vuitton L, Peyrin-Biroulet L, Bouguen G, Dewit O, Nancey S, Caillo L, Roblin X, Beylot-Barry M, Rivière P, Laharie D
J Crohns Colitis. 2022 Feb 26;:
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Gonzalez YS, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ
Gastroenterology. 2022 Feb 25;:
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: the PROCTRIAL Consensus.
Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, Griffiths AM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A, Lewis JD, Magro F, Mantzaris GJ, O'Morain C, Ran Z, Reinisch W, Rogler G, Sachar DB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C, Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2022 Feb 18;:
Postoperative Crohn's disease recurrence: time to adapt endoscopic recurrence scores to the leading surgical techniques.
Rivière P, Bislenghi G, Vermeire S, Domènech E, Peyrin-Biroulet L, Laharie D, D'Hoore A, Ferrante M
Clin Gastroenterol Hepatol. 2022 Feb 17;:
The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.
Muller M, Haghnejad V, Schaefer M, Gauchotte G, Caron B, Peyrin-Biroulet L, Bronowicki JP, Neuzillet C, Lopez A
Cancers (Basel). 2022 Feb 16;14(4):
JAK inhibitors in crohn's disease: ready to go?
Dell'Avalle C, D'Amico F, Gabbiadini R, Dal Buono A, Pugliese N, Zilli A, Furfaro F, Fiorino G, Allocca M, Peyrin-Biroulet L, Danese S
Expert Opin Investig Drugs. 2022 Feb 14;:1-17
Faecal incontinence in inflammatory bowel disease: The Nancy experience.
Kurt S, Caron B, Gouynou C, Netter P, Vaizey CJ, Wexner SD, Danese S, Baumann C, Peyrin-Biroulet L
Dig Liver Dis. 2022 Feb 2;:
Higher vs Standard Adalimumab Induction Dosing Regimens and 2 Maintenance Strategies: Randomized SERENE CD Trial Results.
D'Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panés J, Baert F, Colombel JF, Ferrante M, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S
Gastroenterology. 2022 Feb 2;:
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L,
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):171-185
Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S, Vermeire S, D'Haens G, Panés J, Dignass A, Magro F, Nazar M, Le Bars M, Lahaye M, Ni L, Bravata I, Lavie F, Daperno M, Lukáš M, Armuzzi A, Löwenberg M, Gaya DR, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2022 Feb 1;:
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O'Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2022 Jan 17;:
Tofacitinib Inhibits Leukocyte Trafficking Across the Intestinal Endothelial Barrier in a Specific Cohort of Ulcerative Colitis Patients.
Massimino L, Spanò S, Lamparelli LA, Fuggetta D, Peyrin-Biroulet L, Sileri P, Danese S, D'Alessio S, Ungaro F
Inflamm Bowel Dis. 2022 Jan 15;:
ECCO Position on harmonization of Crohn's disease mucosal histopathology.
Magro F, Sabino J, Rosini F, Tripathi M, Borralho P, Baldin P, Danese S, Driessen A, Gordon IO, Iacucci M, Noor N, Svrcek M, Peyrin-Biroulet L, Feakins R
J Crohns Colitis. 2022 Jan 11;:
Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era.
Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W
Adv Ther. 2022 Jan 6;:
Real-World Treatment Patterns and Physician Preferences for Biologics in Moderate-to-Severe Inflammatory Bowel Disease: Retrospective Chart Review in Europe.
Huynh L, Hass S, Peyrin-Biroulet L, Duh MS, Sipsma H, Cheng M, Lax A, Nag A
Crohns Colitis 360. 2022 01;4(1):otac001
Do JAK inhibitors have a realistic future in treating Crohn's disease?
Parigi TL, Solitano V, Peyrin-Biroulet L, Danese S
Expert Rev Clin Immunol. 2021 Dec 31;:1-3
Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta-analysis.
Magro F, Alves C, Santiago M, Ministro P, Lago P, Correia L, Gonçalves R, Carvalho D, Portela F, Dias CC, Dignass A, Danese S, Peyrin-Biroulet L, Estevinho MM, Moreira P,
United European Gastroenterol J. 2021 Dec 14;:
Evolving short- and long-term goals of management of IBD: getting it right, making it last.
Le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D
Gastroenterology. 2021 Dec 13;:
Sugars and Gastrointestinal Health.
Arnone D, Chabot C, Heba AC, Kökten T, Caron B, Hansmannel F, Dreumont N, Ananthakrishnan AN, Quilliot D, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2021 Dec 10;:
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years.
Magro F, Magalhaes D, Patita M, Arroja B, Lago P, Rosa I, Tavares de Sousa H, Ministro P, Mocanu I, Vieira A, Castela J, Moleiro J, Roseira J, Cancela E, Sousa P, Portela F, Correia L, Santiago M, Dias S, Alves C, Afonso J, Danese S, Peyrin-Biroulet L, Dias CC,
Clin Gastroenterol Hepatol. 2021 Dec 9;:
Revisiting fibrosis in inflammatory bowel disease: the gut thickens.
D'Alessio S, Ungaro F, Noviello D, Lovisa S, Peyrin-Biroulet L, Danese S
Nat Rev Gastroenterol Hepatol. 2021 Dec 7;:
The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe.
Ruiz-Casas L, Evans J, Rose A, Pedra GG, Lobo A, Finnegan A, Hayee B, Peyrin-Biroulet L, Sturm A, Burisch J, Terry H, Avendano L, Tucknott S, Fiorino G, Limdi J
BMC Gastroenterol. 2021 Dec 4;21(1):456
French experience with telemedicine in inflammatory bowel disease: a patients and physicians survey.
Guillo L, Bonnaud G, Nahon S, Caron B, Olympie A, Laurain A, Serrero M, Buisson A, Peyrin-Biroulet L
Eur J Gastroenterol Hepatol. 2021 Dec 3;:
Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus.
Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, Nachury M, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP, Mariat C, Peyrin-Biroulet L
Dig Liver Dis. 2021 Dec 2;:
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2021 Nov 29;:
Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient.
Nones RB, Fleshner PR, Queiroz NSF, Cheifetz AS, Spinelli A, Danese S, Peyrin-Biroulet L, Papamichael K, Kotze PG
J Clin Med. 2021 Nov 29;10(23):
Steroid-Free Deep Remission At One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, van der Woude CJ, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2021 Nov 26;:
Magnetic Resonance Elastography for Assessing Fibrosis in Patients with Crohn's Disease: A Pilot Study.
Avila F, Caron B, Hossu G, Ambarki K, Kannengiesser S, Odille F, Felblinger J, Danese S, Choukour M, Laurent V, Peyrin-Biroulet L
Dig Dis Sci. 2021 Nov 21;:
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ,
Lancet Gastroenterol Hepatol. 2021 Nov 16;:
Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis.
D'Amico F, Magro F, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2021 Nov 16;:
Bowel ultrasound score is accurate in assessing response to therapy in patients with Crohn's disease.
Allocca M, Craviotto V, Dell'Avalle C, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S
Aliment Pharmacol Ther. 2021 Nov 15;:
Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease.
Hanzel J, Jairath V, De Cruz P, Guizzetti L, Shackelton LM, Bossuyt P, Duijvestein M, Dulai PS, Grossmann J, Hirten RP, Khanna R, Panes J, Peyrin-Biroulet L, Regueiro M, Rubin DT, Singh S, Stidham RW, Sandborn WJ, Feagan BG, D'Haens GR, Ma C
Inflamm Bowel Dis. 2021 Nov 13;:
Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients with Crohn's Disease.
Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ
Gastroenterology. 2021 Nov 5;:
New-Onset Inflammatory Bowel Diseases Among IL-17 inhibitors-Treated Patients: Results From The Case-Control MISSIL Study.
Letarouilly JG, Pham T, Pierache A, Acquacalda É, Banneville B, Barbarot S, Baudart P, Bauer É, Claudepierre P, Constantin A, Dernis E, Felten R, Gaudin P, Girard C, Gombert B, Goupille P, Guennoc X, Henry-Desailly I, Jullien D, Karimova E, Lanot S, Le Dantec L, Pascart T, Plastaras L, Sultan N, Truchet X, Varin S, Wendling D, Gaboriau L, Staumont-Sallé D, Peyrin-Biroulet L, Flipo RM
Rheumatology (Oxford). 2021 Nov 3;:
Faster and less invasive tools to identify patients with ileal colonization by adherent-invasive E. coli in Crohn's disease.
Buisson A, Vazeille E, Fumery M, Pariente B, Nancey S, Seksik P, Peyrin-Biroulet L, Allez M, Ballet N, Filippi J, Yzet C, Nachury M, Boschetti G, Billard E, Dubois A, Rodriguez S, Chevarin C, Goutte M, Bommelaer G, Pereira B, Hebuterne X, Barnich N,
United European Gastroenterol J. 2021 Nov;9(9):1007-1018
Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials.
Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH
Gastroenterology. 2021 Oct 29;:
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
Mysler E, Azevedo VF, Danese S, Alvarez D, Iikuni N, Ingram B, Mueller M, Peyrin-Biroulet L
Drugs. 2021 Oct 27;:
Endoscopic surveillance in IBD: The VIRTUE is in high definition.
Parigi TL, Peyrin-Biroulet L, Danese S
Gastroenterology. 2021 Oct 21;:
Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID.
Reenaers C, de Roover A, Kohnen L, Nachury M, Simon M, Pourcher G, Trang-Poisson C, Rajca S, Msika S, Viennot S, Alttwegg R, Serrero M, Seksik P, Peyrin-Biroulet L, Picon L, Bourbao Tournois C, Gontier R, Gilletta C, Stefanescu C, Laharie D, Roblin X, Nahon S, Bouguen G, Carbonnel F, Attar A, Louis E, Coffin B
Inflamm Bowel Dis. 2021 Oct 12;:
Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth exploring?
Caron B, Netter P, Danese S, Peyrin-Biroulet L
Expert Opin Biol Ther. 2021 Oct 6;:
Inflammatory Bowel Disease Patients' Perspectives of Clinical Trials: A Global Quantitative and Qualitative Analysis.
Rubin DT, Peyrin-Biroulet L, Reinisch W, Tole S, Sullivan L, Park KT, Regueiro M
Crohns Colitis 360. 2021 10;3(4):otab079
Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S
Clin Gastroenterol Hepatol. 2021 Sep 28;:
Web-based and machine learning approaches for identification of patient-reported outcomes in inflammatory bowel disease.
Ricci L, Toussaint Y, Becker J, Najjar H, Renier A, Choukour M, Buisson A, Devos C, Epstein J, Peyrin Biroulet L, Guillemin F
Dig Liver Dis. 2021 Sep 26;:
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.
Olivera PA, Zuily S, Kotze PG, Regnault V, Al Awadhi S, Bossuyt P, Gearry RB, Ghosh S, Kobayashi T, Lacolley P, Louis E, Magro F, Ng SC, Papa A, Raine T, Teixeira FV, Rubin DT, Danese S, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2021 Aug 27;:
Cluster Randomized Trials: Lessons for Inflammatory Bowel Disease Trials.
Caron B, D'Amico F, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2021 Aug 14;:
The Inflammatory Bowel Disease Transcriptome and Metatranscriptome Meta-Analysis (IBD TaMMA) framework.
Massimino L, Lamparelli LA, Houshyar Y, D'Alessio S, Peyrin-Biroulet L, Vetrano S, Danese S, Ungaro F
Nat Comput Sci. 2021 08;1(8):511-515
polymorphisms (P268S, IVS8, G908R, L1007fs, R702W) among Kuwaiti patients with Crohn's disease: A case-control study.
Abdelnaby H, Ndiaye NC, D'Amico F, Fouad AM, Hassan S, Elshafey A, Al Hashash W, Faisal M, Alshamali Y, Al-Taweel T, Peyrin-Biroulet L
Saudi J Gastroenterol. 2021 Jul 29;:
Gastroenterological safety of IL-17 inhibitors: a systematic literature review.
Caron B, Jouzeau JY, Miossec P, Petitpain N, Gillet P, Netter P, Peyrin-Biroulet L
Expert Opin Drug Saf. 2021 Jul 26;:
Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study.
Fumery M, Filippi J, Abitbol V, Biron A, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Nachury M, Amiot A
Aliment Pharmacol Ther. 2021 Jul 23;:
Viral infections in inflammatory bowel disease: Tips and tricks for correct management.
Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M
World J Gastroenterol. 2021 Jul 21;27(27):4276-4297
Patients' perception of surgery for inflammatory bowel disease.
Spinelli A, Carvello M, Adamina M, Panis Y, Warusavitarne J, Tulchinsky H, Bemelman WA, Kotze PG, D'Hoore A, Lastikova L, Danese S, Peyrin-Biroulet L, Avedano L, Pagnini F
Colorectal Dis. 2021 Jul 16;:
Telomeres: New players in immune-mediated inflammatory diseases?
Heba AC, Toupance S, Arnone D, Peyrin-Biroulet L, Benetos A, Ndiaye NC
J Autoimmun. 2021 Jul 13;123:102699
A MAGNETIC RESONANCE IMAGING INDEX TO PREDICT CROHN'S DISEASE POSTOPERATIVE RECURRENCE: THE MONITOR INDEX.
Schaefer M, Laurent V, Grandmougin A, Vuitton L, Bourreille A, Luc A, Clerc-Urmes I, Orry X, Frampas E, De Billy M, Pouillon L, Le Berre C, Gay C, Meyer J, Baumann C, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2021 Jun 30;:
Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease.
Sousa P, Ministro P, Armuzzi A, Dignass A, Høivik ML, Barreiro-de Acosta M, Vavricka S, Saad-Hossne R, Gustavo Kotze P, Peyrin-Biroulet L, Magro F
Dig Liver Dis. 2021 Jun 26;:
Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease.
Grandmougin A, D'Amico F, Remen T, Danese S, Bonneton M, Galloy MA, Peyrin-Biroulet L, Laurent V
Dig Dis Sci. 2021 Jun 22;:
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.
Uzzan M, Bresteau C, Laharie D, Stefanescu C, Bellanger C, Carbonnel F, Serrero M, Viennot S, Nachury M, Amiot A, Altwegg R, Picon L, Nahon S, Vuitton L, Ah Soune P, Kirchgesner J, Peyrin-Biroulet L, Bouhnik Y,
Aliment Pharmacol Ther. 2021 Jun 20;:
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY.
Peyrin-Biroulet L, Loftus EV, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA
Gastroenterology. 2021 Jun 15;:
IBD goes home: from telemedicine to self-administered advanced therapies.
Solitano V, Alfarone L, D'Amico F, Peyrin-Biroulet L, Danese S
Expert Opin Biol Ther. 2021 Jun 11;:
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempiński R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L
Lancet. 2021 Jun 3;:
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.
Geyl S, Guillo L, Laurent V, D'Amico F, Danese S, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2021 Jun 3;:
Lack of protective effect of CCR3 blockade during experimental colitis may be related to CCR3 expression by colonic Tregs.
Ferhat M, Hablot J, Taieb M, Salem F, Netter P, Peyrin-Biroulet L, Jouzeau JY, Moulin D
Clin Transl Med. 2021 Jun;11(6):e455
Defining difficult-to-treat inflammatory bowel disease: why and how.
Danese S, Parigi TL, Peyrin-Biroulet L, Ghosh S
Lancet Gastroenterol Hepatol. 2021 May 18;:
Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey.
Caron B, Neuville E, Peyrin-Biroulet L
Dig Dis Sci. 2021 May 12;:
Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus.
D'Amico F, Solitano V, Aletaha D, Hart A, Magro F, Selmi C, Ng SC, Al Awadhi S, Choy E, Schulze-Koops H, Bossuyt P, Olivera PA, Kotze PG, Ghosh S, Peyrin-Biroulet L, Danese S
Autoimmun Rev. 2021 May 8;:102849
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases.
D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, Olivera PA, Bossuyt P, Pouillon L, Louis E, Domènech E, Ghosh S, Danese S, Peyrin-Biroulet L
United European Gastroenterol J. 2021 May 7;:
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
Buisson A, Nancey S, Manlay L, Rubin DT, Hebuterne X, Pariente B, Fumery M, Laharie D, Roblin X, Bommelaer G, Pereira B, Peyrin-Biroulet L, Vuitton L,
United European Gastroenterol J. 2021 May 5;:
Predictive value of bowel ultrasound in Crohn's disease: a 12-month prospective study.
Allocca M, Craviotto V, Bonovas S, Furfaro F, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S
Clin Gastroenterol Hepatol. 2021 Apr 22;:
Determinants of IBD-related disability: a cross-sectional survey from the GETAID.
Tannoury J, Nachury M, Martins C, Serrero M, Filippi J, Roblin X, Bourrier A, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWitt O, Vuitton L, Mathieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Trang-Poisson C, Laharie D, Amiot A,
Aliment Pharmacol Ther. 2021 Apr 5;:
Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis.
D'Amico F, Guillo L, Baumann C, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2021 Apr 5;:
Drug development for ulcerative proctitis: current concepts.
Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L
Gut. 2021 Mar 31;:
Validation of the "Inflammatory Bowel Disease - Distribution, Chronicity, Activity (IBD-DCA) Score" for Ulcerative Colitis and Crohn´s disease.
Lang-Schwarz C, Angeloni M, Agaimy A, Atreya R, Becker C, Dregelies T, Danese S, Fléjou JF, Gaßler N, Grabsch HI, Hartmann A, Kamarádová K, Kühl AA, Lauwers GY, Lugli A, Nagtegaal I, Neurath MF, Oberhuber G, Peyrin-Biroulet L, Rath T, Riddell R, Rubio CA, Sheahan K, Siegmund B, Tilg H, Villanacci V, Westerhoff M, Ferrazzi F, Vieth M
J Crohns Colitis. 2021 Mar 27;:
The Evolution of Biologics Administration From Intravenous to Subcutaneous: Treatments for Inflammatory Bowel Disease Goes Home.
Solitano V, Vuitton L, Peyrin-Biroulet L, Danese S
Gastroenterology. 2021 Mar 24;:
Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
Peyrin-Biroulet L, Louis E, Loftus EV, Lacerda A, Zhou Q, Sanchez Gonzalez Y, Ghosh S
Adv Ther. 2021 Mar 23;:
Ethnic Differences in the Smoking-Related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Piovani D, Pansieri C, Kotha SRR, Piazza AC, Comberg CL, Peyrin-Biroulet L, Danese S, Bonovas S
J Crohns Colitis. 2021 Mar 15;:
Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI on quality of life and quality of care in patients with inflammatory bowel disease.
Bonnaud G, Haennig A, Altwegg R, Caron B, Boivineau L, Zallot C, Gilleta de Saint-Joseph C, Moreau J, Gonzalez F, Reynaud D, Faure P, Aygalenq P, Combis JM, Peyrin-Biroulet L
Scand J Gastroenterol. 2021 Mar 10;:1-7
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE
Clin Gastroenterol Hepatol. 2021 Mar 5;:
Safety of S1P Modulators in Patients with Immune-Mediated Diseases: A Systematic Review and Meta-Analysis.
Lasa JS, Olivera PA, Bonovas S, Danese S, Peyrin-Biroulet L
Drug Saf. 2021 Mar 5;:
Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?
Guillo L, Peyrin-Biroulet L, Louis E
J Crohns Colitis. 2021 Feb 23;:
Calorie Restriction as a New Treatment of Inflammatory Diseases.
Kökten T, Hansmannel F, Ndiaye NC, Heba AC, Quilliot D, Dreumont N, Arnone D, Peyrin-Biroulet L
Adv Nutr. 2021 Feb 8;:
Endpoints for perianal Crohn's disease trials: past, present, and future.
Caron B, D'Amico F, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2021 Feb 7;:
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know.
Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L
Dig Liver Dis. 2021 Feb 6;:
Physician-patient communication is key to improve IBD management during COVID-19 pandemic.
D'Amico F, Peyrin-Biroulet L, Danese S
Gastroenterology. 2021 Feb 3;:
Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients' and Physicians' View.
Dubinsky MC, Watanabe K, Molander P, Peyrin-Biroulet L, Rubin M, Melmed GY, Deuring JJ, Woolcott J, Cappelleri JC, Steinberg K, Connor S
Inflamm Bowel Dis. 2021 Feb 2;:
Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study.
Laurain PA, Guillo L, D'Amico F, Netter P, Danese S, Baumann C, Luc A, Clerc-Urmes I, Spyridon S, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2021 Jan 22;:
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ
J Crohns Colitis. 2021 Jan 21;:
SARS-CoV-2 vaccination in IBD: more pros than cons.
D'Amico F, Rabaud C, Peyrin-Biroulet L, Danese S
Nat Rev Gastroenterol Hepatol. 2021 Jan 20;:
The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases.
Peppas S, Pansieri C, Piovani D, Danese S, Peyrin-Biroulet L, Tsantes AG, Brunetta E, Tsantes AE, Bonovas S
J Clin Med. 2021 Jan 20;10(3):
An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials.
Almradi A, Ma C, D'Haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-Biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK
Aliment Pharmacol Ther. 2021 Jan 7;:
IL-17 inhibitors and inflammatory bowel diseases: a post-marketing study in Vigibase®.
Petitpain N, D'Amico F, Yelehe-Okouma M, Jouzeau JY, Netter P, Peyrin-Biroulet L, Gillet P
Clin Pharmacol Ther. 2021 Jan 7;:
Selecting Endpoints for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT consensus from the IOIBD.
Le Berre C, Peyrin-Biroulet L,
Gastroenterology. 2021 Jan 6;:
Clinical pharmacists and patients with inflammatory bowel diseases: are we ready for the multidisciplinary approach?
D'Amico F, Peyrin-Biroulet L, Danese S
Gastroenterology. 2021 Jan 5;:
'Treat to Target' in Mild to Moderate Ulcerative Colitis: Evidence to Support this Strategy.
Dal Buono A, Roda G, Argollo M, Paridaens K, Peyrin-Biroulet L, Danese S
Curr Drug Targets. 2021 ;22(1):117-125
Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients.
Garcia KS, Facas BP, Machado MB, Teixeira FV, Avedano L, Lönnfors S, Hossne RS, Peyrin-Biroulet L, Queiroz NSF
Therap Adv Gastroenterol. 2021 ;14:17562848211013249
Long-Term Overconsumption of Fat and Sugar Causes a Partially Reversible Pre-inflammatory Bowel Disease State.
Arnone D, Vallier M, Hergalant S, Chabot C, Ndiaye NC, Moulin D, Aignatoaei AM, Alberto JM, Louis H, Boulard O, Mayeur C, Dreumont N, Peuker K, Strigli A, Zeissig S, Hansmannel F, Chamaillard M, Kökten T, Peyrin-Biroulet L
Front Nutr. 2021 ;8:758518
Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?
Solitano V, D'Amico F, Allocca M, Fiorino G, Zilli A, Loy L, Gilardi D, Radice S, Correale C, Danese S, Peyrin-Biroulet L, Furfaro F
Therap Adv Gastroenterol. 2021 ;14:17562848211005692
The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases.
Solitano V, D'Amico F, Da Rio L, Peyrin-Biroulet L, Danese S
Crohns Colitis 360. 2021 01;3(1):otab012
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.
Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S
Therap Adv Gastroenterol. 2021 ;14:17562848211059954
Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study.
Guillo L, Uzzan M, Beaugerie L, Gornet JM, Amiot A, Pelletier AL, Altwegg R, Laharie D, Abitbol V, Filippi J, Goutorbe F, Nachury M, Nancey S, Viennot S, Reenaers C, Amil M, Caillo L, Buisson A, Collins M, Picon L, Vidon M, Benezech A, Rabaud C, Baumann C, Rousseau H, Dubourg G, Serrero M, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2020 Dec 24;:
Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.
Guillo L, D'Amico F, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2020 Dec 24;:
Milan Ultrasound Criteria are accurate in assessing disease activity in ulcerative colitis: External validation.
Allocca M, Filippi E, Costantino A, Bonovas S, Fiorino G, Furfaro F, Peyrin-Biroulet L, Fraquelli M, Caprioli F, Danese S
United European Gastroenterol J. 2020 Dec 21;:2050640620980203
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A,
Gastroenterology. 2020 Dec 21;:
Probe-based confocal laser endomicroscopy for in vivo assessment of histological healing in ulcerative colitis: development and validation of the ENHANCE index.
Rahmi G, Coron E, Perrod G, Levy M, Moreau J, Moussata D, Perez-Cuadrado-Robles E, Chupin A, Quénéhervé L, Bourreille A, Marchal A, Cellier C, Peyrin-Biroulet L
J Crohns Colitis. 2020 Dec 18;:
Defining and assessing the reproducibility of Crohn's disease endoscopic lesions: a Delphi-like method from the GETAID.
Buisson A, Filippi J, Amiot A, Cadiot G, Allez M, Marteau P, Bouhnik Y, Pineton de Chambrun G, Pelletier AL, Nancey S, Moussata D, Attar A, Blain A, Vuitton L, Vernier-Massouille G, Seksik P, Nachury M, Dupas JL, Laharie D, Peyrin-Biroulet L, Louis E, Mary JY
J Crohns Colitis. 2020 Dec 12;:
New Paradigms to Help Decisions in Treatment Choice: Head to Head Trial of Biological Therapies in Inflammatory Bowel Diseases.
Loy L, Fiorino G, Roda G, Allocca M, Furfaro F, Zilli A, Gilardi D, Radice S, Peyrin-Biroulet L, Danese S
Curr Drug Targets. 2020 Dec 11;:
Confounding and bias in observational studies in inflammatory bowel disease: a meta-epidemiological study.
Piovani D, Pansieri C, Peyrin-Biroulet L, Danese S, Bonovas S
Aliment Pharmacol Ther. 2020 Dec 9;:
Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
Weislinger L, Guillo L, D'Amico F, Danese S, Achit H, Ayav C, Guillemin F, Peyrin-Biroulet L, Frimat L
Eur J Gastroenterol Hepatol. 2020 Nov 30;:
New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?
D'Amico F, Peyrin-Biroulet L, Danese S, Fiorino G
Curr Opin Pharmacol. 2020 Nov 27;55:141-150
The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease.
Tadbiri S, Nachury M, Bouhnik Y, Serrero M, Hébuterne X, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Allez M, Viennot S, Trang-Poisson C, Dib N, Brixi H, Boualit M, Plastaras L, Boivineau L, Fumery M, Caillo L, Laharie D, Amiot A
J Crohns Colitis. 2020 Nov 27;:
Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
Broussard D, Rivière P, Bonnet J, Fotsing G, Amiot A, Peyrin-Biroulet L, Rajca S, Buisson A, Gilleta C, Pelletier AL, Serrero M, Bouguen G, Altwegg R, Hebuterne X, Nancey S, Fumery M, Cadiot G, Nahon S, Rahier JF, Gornet JM, Vendrely V, Laharie D,
Aliment Pharmacol Ther. 2020 Nov 26;:
Application of Ultrasound Elastography for Assessing Intestinal Fibrosis in Inflammatory Bowel Disease: Fiction or Reality?
Gabbiadini R, Zacharopoulou E, Furfaro F, Craviotto V, Zilli A, Gilardi D, Roda G, Loy L, Fiorino G, Peyrin-Biroulet L, Danese S, Allocca M
Curr Drug Targets. 2020 Nov 19;:
Endoscopic balloon dilation of colorectal strictures complicating Crohn's disease: a multicenter study.
Tilmant M, Serrero M, Poullenot F, Bouguen G, Pariente B, Altwegg R, Basile P, Filippi J, Vanelslander P, Buisson A, Desjeux A, Laharie D, Le Balch E, Nachury M, Boivineau L, Savoye G, Hebuterne X, Poincloux L, Vuitton L, Brazier F, Yzet C, Lamrani A, Peyrin-Biroulet L, Fumery M
Clin Res Hepatol Gastroenterol. 2020 Nov 16;:
Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases.
Solitano V, D'Amico F, Correale C, Peyrin-Biroulet L, Danese S
Br Med Bull. 2020 Nov 16;:
Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX.
Rivière P, DʼHaens G, Peyrin-Biroulet L, Baert F, Lambrecht G, Pariente B, Bossuyt P, Buisson A, Oldenburg B, Vermeire S, Laharie D
Am J Gastroenterol. 2020 Nov 10;:
Patients' real-world experience with inflammatory bowel disease: A cross-sectional survey in tertiary care centres from the GETAID group.
Nachury M, Bouhnik Y, Serrero M, Filippi J, Roblin X, Kirchgesner J, Bouguen G, Franchimont D, Savoye G, Buisson A, Louis E, Nancey S, Abitbol V, Reimund JM, DeWit O, Vuitton L, Matthieu N, Peyrin-Biroulet L, Gilletta C, Tadbiri S, Allez M, Viennot S, Bourreille A, Laharie D, Amiot A,
Dig Liver Dis. 2020 Nov 10;:
Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus.
Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H, Peyrin-Biroulet L,
Dig Liver Dis. 2020 Nov 4;:
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
Chapuis-Biron C, Kirchgesner J, Pariente B, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Pineton de Chambrun G, Abitbol V, Nancey S, Caillo L, Plastaras L, Savoye G, Chanteloup E, Simon M, Dib N, Rajca S, Amil M, Parmentier AL, Peyrin-Biroulet L, Vuitton L,
Am J Gastroenterol. 2020 Nov;115(11):1812-1820
Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study.
Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D'Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris GJ, Papaconstantinou I, Katsanos K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert JP, Danese S, Fiorino G
J Clin Med. 2020 Oct 31;9(11):
An Anti-Migration Self-Expandable and Removable Metal Stent for Crohn's Disease Strictures: A Nationwide Study From the Getaid and the Sfed.
Attar A, Branche J, Coron E, Privat J, Caillo L, Chevaux JB, Vuitton L, Amiot A, Belkhodja H, Dray X, Ponchon T, Bouhnik Y, Baumann C, Peyrin-Biroulet L
J Crohns Colitis. 2020 Oct 27;:
Providing Guidance During a Global Viral Pandemic for the Care of Patients With Inflammatory Bowel Disease.
Abreu MT, Peyrin-Biroulet L
J Crohns Colitis. 2020 Oct 21;14(Supplement_3):S767-S768
Herpes zoster and vaccination strategies in inflammatory bowel diseases: a practical guide.
Guillo L, Rabaud C, Choy EH, D'Amico F, Danese S, Ng SC, Peyrin-Biroulet L
Clin Gastroenterol Hepatol. 2020 Oct 17;:
Bowel Damage at Diagnosis Using the Lémann Index Score in Saudi Arabian Patients With Crohn's Disease.
Halawani H, Abduljabbar A, Wazzan M, Hashem DA, Baumann C, Luc A, Peyrin-Biroulet L, Saadah OI, Mosli M
Cureus. 2020 Oct 12;12(10):e10912
Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W,
Lancet Gastroenterol Hepatol. 2020 Oct 5;:
Treat to target: The role of histologic healing in inflammatory bowel diseases: A systematic review and meta-analysis.
Gupta A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN
. 2020 Sep 30;:
Validation of the Red Flags Index for Early Diagnosis of Crohn's Disease: A Prospective Observational IG-IBD Study Among General Practitioners.
Fiorino G, Bonovas S, Gilardi D, Di Sabatino A, Allocca M, Furfaro F, Roda G, Lenti MV, Aronico N, Mengoli C, Angeli E, Gaffuri N, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2020 Sep 28;:
Impact of an Education Program on Ibd Patient's Skills: Results of A Randomized Controlled Multicenter Study (Ecipe).
Moreau J, Hammoudi N, Marthey L, Trang-Poisson C, Nachury M, Altwegg R, Grimaud JC, Orempuller S, Hébuterne X, Aubourg A, Baudry C, Seksik P, Roblin X, Nahon S, Savoye G, Mesnard B, Stefanescu C, Simon M, Coffin B, Fumery M, Carbonnel F, Peyrin-Biroulet L, Desseaux K, Allez M,
J Crohns Colitis. 2020 Sep 24;:
Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S
Expert Rev Clin Immunol. 2020 Sep 21;:
Characteristics Of Lymphoma In Patients With Inflammatory Bowel Disease: A Systematic Review.
Muller M, Broséus J, Feugier P, Thieblemont C, Laurent B, Danese S, Arnone D, Ndiaye NC, Kokten T, Houlgatte R, Peyrin-Biroulet L
J Crohns Colitis. 2020 Sep 19;:
Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study.
Lambin T, Amiot A, Stefanescu C, Gornet JM, Seksik P, Laharie D, Reenaers C, Bourreille A, Cadiot G, Carbonnel F, Dib N, Fumery M, Gilletta de St Joseph C, Filippi J, Viennot S, Plastaras L, Coffin B, Serrero M, Nahon S, Pineton de Chambrun G, Rahier JF, Roblin X, Boualit M, Bouguen G, Peyrin-Biroulet L, Pariente B,
Dig Liver Dis. 2020 Sep 19;:
Predictors for short bowel syndrome in Crohn's disease.
Vaillant S, Guillo L, Michot N, D'Amico F, Germain A, Danese S, Baumann C, Rousseau H, Quilliot D, Peyrin-Biroulet L
Dig Liver Dis. 2020 Sep 14;:
TNF inhibitors and risk of malignancy in patients with inflammatory bowel diseases: a systematic review.
Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2020 Sep 11;:
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy.
Magro F, Alves C, Lopes J, Lopes S, Tavares de Sousa H, Cotter J, Macedo da Silva V, Lago P, Vieira A, Brito M, Duarte MA, Portela F, Silva JP, Ministro P, Arroja B, Carvalho L, Torres J, Santiago M, Estevinho M, Danese S, Peyrin-Biroulet L, Dias CC, Borralho P, Feakins RM, Carneiro F
Clin. Gastroenterol. Hepatol.. 2020 Sep 10;:
Ulcerative colitis.
Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T
Nat Rev Dis Primers. 2020 Sep 10;6(1):74
Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis.
Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2020 Sep 8;:
Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn's Disease: A Multicenter Study.
Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, Gilletta C, Veyrard P, Bouguen G, Viennot S, Poullenot F, Filippi J, Buisson A, Bozon A, Brazier F, Pouillon L, Flourie B, Boivineau L, Siproudhis L, Laharie D, Roblin X, Diouf M, Treton X
J Crohns Colitis. 2020 Sep 8;:
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis.
Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S
J Clin Med. 2020 Sep 8;9(9):
Thrombosis in IBD in the era of JAK inhibition.
Solitano V, Fiorino G, D'Amico F, Peyrin-Biroulet L, Danese S
Curr Drug Targets. 2020 Sep 2;:
Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?
D'Amico F, Solitano V, Peyrin-Biroulet L, Danese S
Expert Opin Biol Ther. 2020 Aug 28;:
Emerging treatment options for extraintestinal manifestations in IBD.
Greuter T, Rieder F, Kucharzik T, Peyrin-Biroulet L, Schoepfer AM, Rubin DT, Vavricka SR
Gut. 2020 Aug 26;:
Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G
Gastroenterology. 2020 Aug 24;:
Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience.
D'Amico F, Netter P, Baumann C, Veltin M, Zallot C, Aimone-Gastin I, Danese S, Peyrin-Biroulet L
J Clin Med. 2020 Aug 20;9(9):
Ustekinumab for Perianal Crohn's Disease: The BioLAP Multicenter Study From the GETAID.
Chapuis-Biron C, Kirchgesner J, Pariente B, Bouhnik Y, Amiot A, Viennot S, Serrero M, Fumery M, Allez M, Siproudhis L, Buisson A, Pineton de Chambrun G, Abitbol V, Nancey S, Caillo L, Plastaras L, Savoye G, Chanteloup E, Simon M, Dib N, Rajca S, Amil M, Parmentier AL, Peyrin-Biroulet L, Vuitton L,
Am. J. Gastroenterol.. 2020 Aug 19;:
Crohn's Disease Only Visible on Small Bowel Capsule Endoscopy: A New Entity.
Chateau T, Damico F, Zallot C, Mathieu N, Peyrin-Biroulet L
Dig. Dis. Sci.. 2020 Aug 18;:
Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13.
Parigi TL, D'Amico F, Peyrin-Biroulet L, Danese S
Expert Opin Biol Ther. 2020 Aug 17;:
Early Intervention in Ulcerative Colitis: Ready for Prime Time?
Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S
J Clin Med. 2020 Aug 14;9(8):
Assessment of extraintestinal manifestations in inflammatory bowel diseases: A systematic review and a proposed guide for clinical trials.
Guillo L, D'Amico F, Serrero M, Angioi K, Loeuille D, Costanzo A, Danese S, Peyrin-Biroulet L
United European Gastroenterol J. 2020 Aug 10;:2050640620950093
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic.
Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV
J Crohns Colitis. 2020 Aug 7;:
Evolution of endoscopic lesions in steroid-refractory acute severe ulcerative colitis responding to infliximab or cyclosporine.
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-Sanroman A, Fumery M, Carbonnel F, Buisson A, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Peyrin-Biroulet L, Mary JY
Clin. Gastroenterol. Hepatol.. 2020 Aug 7;:
Systematic review on IBD patients with COVID-19: it is time to take stock.
D'Amico F, Danese S, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2020 Aug 7;:
Treat to target or "treat to clear" in inflammatory bowel diseases: one step further?
Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S
Expert Rev Gastroenterol Hepatol. 2020 Aug 7;:
Low Back Pain and Sacroiliitis on Cross-Sectional Abdominal Imaging for Axial Spondyloarthritis Diagnosis in Inflammatory Bowel Diseases.
Fauny M, Cohen N, Morizot C, Leclerc-Jacob S, Wendling D, Lux G, Laurent V, Blum A, Netter P, Baumann C, Chary-Valckenaere I, Peyrin-Biroulet L, Loeuille D
. 2020 Aug;5(3):124-131
A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool.
Ghosh S, Sensky T, Casellas F, Rioux LC, Ahmad T, Márquez JR, Vanasek T, Gubonina I, Sezgin O, Ardizzone S, Kligys K, Petersson J, Suzuki Y, Peyrin-Biroulet L
J Crohns Colitis. 2020 Jul 29;:
Inflammatory bowel disease management during the COVID-19 outbreak: The 10 do's and don'ts from the ECCO-COVID Taskforce.
Magro F, Rahier JF, Abeu C, MacMahon E, Hart A, van der Woude CJ, Gordon H, Adamina M, Viget N, Vavricka S, Kucharzik T, Leone S, Siegmund B, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2020 Jul 29;:
Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials.
D'Amico F, Danese S, Peyrin-Biroulet L
J Clin Med. 2020 Jul 23;9(8):
Early Intervention With Vedolizumab on Longer Term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programs.
Dulai PS, Peyrin-Biroulet L, Demuth D, Lasch K, Hahn KA, Lindner D, Patel H, Jairath V
J Crohns Colitis. 2020 Jul 21;:
Paradoxical gastrointestinal effects of interleukin-17 blockers.
Fauny M, Moulin D, D'Amico F, Netter P, Petitpain N, Arnone D, Jouzeau JY, Loeuille D, Peyrin-Biroulet L
Ann. Rheum. Dis.. 2020 Jul 21;:
Point-of-care ultrasound in Inflammatory Bowel Disease.
Allocca M, Furfaro F, Fiorino G, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2020 Jul 17;:
Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review.
D'Amico F, Wexner SD, Vaizey CJ, Gouynou C, Danese S, Peyrin-Biroulet L
United European Gastroenterol J. 2020 Jul 17;:2050640620943699
Thiopurines' Metabolites and Drug Toxicity: A Meta-Analysis.
Sousa P, Estevinho MM, Dias CC, Ministro P, Kopylov U, Danese S, Peyrin-Biroulet L, Magro F
J Clin Med. 2020 Jul 13;9(7):
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Hu A, Kotze PG, Burgevin A, Tan W, Jess A, Li PS, Kroeker K, Halloran B, Panaccione R, Peyrin-Biroulet L, Ma C, Ananthakrishnan AN
Clin. Gastroenterol. Hepatol.. 2020 Jul 12;:
More on Covid-19 in Immune-Mediated Inflammatory Diseases.
Peyrin-Biroulet L, Danese S
N. Engl. J. Med.. 2020 Jul 10;383:
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease.
Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S
Inflamm. Bowel Dis.. 2020 Jul 7;:
Flare-IBD: development and validation of a questionnaire based on patients' messages on an internet forum for early detection of flare in inflammatory bowel disease: study protocol.
Ricci L, Epstein J, Buisson A, Devos C, Toussaint Y, Peyrin-Biroulet L, Guillemin F
BMJ Open. 2020 Jul 1;10(7):e037211
JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis.
D'Amico F, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2020 Jun 24;:
Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going.
D'Amico F, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2020 Jun 24;:
PK, PD and interactions: the new scenario with JAK inhibitors and S1P Receptor Modulators, two classes of small molecule drugs, in IBD.
Gilardi D, Gabbiadini R, Allocca M, Correale C, Fiorino G, Furfaro F, Zilli A, Peyrin-Biroulet L, Danese S
Expert Rev Gastroenterol Hepatol. 2020 Jun 22;:
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience.
Furfaro F, Vuitton L, Fiorino G, Koch S, Allocca M, Gilardi D, Zilli A, D'Amico F, Radice S, Chevaux JB, Schaefer M, Chaussade S, Danese S, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2020 Jun 11;:
Clinical trials for inflammatory bowel disease: a global guidance during COVID-19 pandemic.
Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV
J Crohns Colitis. 2020 Jun 10;:
Safety of drugs during previous and current coronavirus pandemics: Lessons for IBD.
Sebastian S, Gonzalez HA, Peyrin-Biroulet L
J Crohns Colitis. 2020 Jun 10;:
Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study.
D'Amico F, Peyrin-Biroulet L, Vandromme L, Bouhnik Y, Faure P, Nahon S, Hagege H, Hebuterne X, Benkhalifa S, Nachury M
Dig Liver Dis. 2020 Jun 9;:
Targeting the gut layers in Crohn's disease: mucosal or transmural healing?
Zacharopoulou E, Craviotto V, Fiorino G, Furfaro F, Zilli A, Gilardi D, Peyrin-Biroulet L, Danese S, Allocca M
Expert Rev Gastroenterol Hepatol. 2020 Jun 9;:
ECCO Position Paper: Harmonisation of the approach to Ulcerative Colitis Histopathology.
Magro F, Doherty G, Peyrin-Biroulet L, Svrcek M, Borralho P, Walsh A, Carneiro F, Rosini F, de Hertogh G, Biedermann L, Pouillon L, Scharl M, Tripathi M, Danese S, Villanacci V, Feakins R
J Crohns Colitis. 2020 Jun 6;:
Which MRI Score and Technique Should Be Used for Assessing Crohn's Disease Activity?
D'Amico F, Chateau T, Laurent V, Danese S, Peyrin-Biroulet L
J Clin Med. 2020 Jun 2;9(6):
The day after COVID-19 in IBD: how to go back to 'normal'.
Danese S, Sands B, Ng SC, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2020 Jun 1;:
Long-term safety of approved biologics for ulcerative colitis.
D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S
Expert Opin Drug Saf. 2020 May 22;:
Risk of Late Post-Operative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers.
Pouillon L, Remen T, Amicone C, Louis E, Maes S, Reenaers C, Germain A, Baumann C, Bossuyt P, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2020 May 20;:
Variation of faecal calprotectin level within the first three months after bowel resection is predictive of endoscopic postoperative recurrence in Crohn's disease.
Boube M, Laharie D, Nancey S, Hebuterne X, Fumery M, Pariente B, Roblin X, Peyrin-Biroulet L, Minet-Quinard R, Pereira B, Bommelaer G, Buisson A,
Dig Liver Dis. 2020 May 20;:
Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic.
D'Amico F, Peyrin-Biroulet L, Danese S
J Clin Med. 2020 May 19;9(5):
Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach.
D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, Danese S
Expert Rev Gastroenterol Hepatol. 2020 May 19;:
Protecting patients with IBD during the COVID-19 pandemic.
Fiorino G, Peyrin-Biroulet L, Danese S
Lancet Gastroenterol Hepatol. 2020 May 19;:
Balancing risks and benefits in inflammatory bowel disease patients during the COVID-19 pandemic.
Kotze PG, Peyrin-Biroulet L, Danese S
Gastroenterology. 2020 May 15;:
Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey.
D'Amico F, Rahier JF, Leone S, Peyrin-Biroulet L, Danese S
Lancet Gastroenterol Hepatol. 2020 May 13;:
A practical guide for faecal calprotectin measurement: myths and realities.
D'Amico F, Nancey S, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2020 May 11;:
Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice.
Bonnaud G, Bouhnik Y, Hagege H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L
Dig Liver Dis. 2020 May 5;:
Efficacy of anti-TNFα drugs in patients with stricturing Crohn's disease.
D'Amico F, Pugliese N, Peyrin-Biroulet L, Danese S
Expert Rev Gastroenterol Hepatol. 2020 Apr 30;:
Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts.
Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, Danese S, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2020 Apr 30;:
Inflammatory bowel disease management during the COVID-19 outbreak: a survey from the European Crohn's and Colitis Organization (ECCO).
D'Amico F, Danese S, Peyrin-Biroulet L,
Gastroenterology. 2020 Apr 30;:
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R, Laurent V, Zappa M, Savoye-Collet C, Pariente B, Filippi J, Baert F, D'haens G, Laharie D, Peyrin-Biroulet L, Vermeire S,
Clin. Gastroenterol. Hepatol.. 2020 Apr 28;:
Surgery for Crohn's disease during pregnancy: A nationwide survey.
Germain A, Chateau T, Beyer-Berjot L, Zerbib P, Lakkis Z, Amiot A, Buisson A, Laharie D, Lefèvre JH, Nancey S, Stefanescu C, Bresler L, Peyrin-Biroulet L,
United European Gastroenterol J. 2020 Apr 23;:2050640620921060
Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease.
Daude S, Remen T, Chateau T, Danese S, Gastin I, Baumann C, Gueant JL, Peyrin-Biroulet L
Aliment. Pharmacol. Ther.. 2020 Apr 22;:
Will COVID-19 infection be less severe in ulcerative colitis than in Crohn's patients due to a lower rate of smokers?
Peyrin-Biroulet C, D'Amico F, Peyrin-Biroulet L
J Crohns Colitis. 2020 Apr 18;:
Head-to-head trials in inflammatory bowel disease: past, present and future.
Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2020 Apr 17;:
Inflammatory bowel diseases and COVID-19: the invisible enemy.
D'Amico F, Peyrin-Biroulet L, Danese S
Gastroenterology. 2020 Apr 16;:
Clinical Research and Trials-A "Nonessential" Victim of the COVID-19 Pandemic?
Peyrin-Biroulet L, Ananthakrishnan AN
Am. J. Gastroenterol.. 2020 Apr 14;:
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
Amiot A, Filippi J, Abitbol V, Cadiot G, Laharie D, Serrero M, Altwegg R, Bouhnik Y, Peyrin-Biroulet L, Gilletta C, Roblin X, Pineton de Chambrun G, Vuitton L, Bourrier A, Nancey S, Gornet JM, Nahon S, Bouguen G, Viennot S, Pariente B, Fumery M,
Aliment. Pharmacol. Ther.. 2020 Apr 14;:
Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention and management.
D'Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2020 Apr 8;:
Genomic and molecular alterations in human inflammatory bowel disease-associated colorectal cancer.
Muller M, Hansmannel F, Arnone D, Choukour M, Ndiaye NC, Kokten T, Houlgatte R, Peyrin-Biroulet L
United European Gastroenterol J. 2020 Apr 8;:2050640620919254
Crohn's disease.
Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S
Nat Rev Dis Primers. 2020 Apr 2;6(1):22
Mucosal Healing in Crohn's Disease and Ulcerative Colitis.
Peyrin-Biroulet L
Gastroenterol Hepatol (N Y). 2020 Apr;16(4):206-208
Will the quality of research remain the same during the COVID-19 pandemic?
Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2020 Mar 30;:
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF
Gastroenterology. 2020 Mar 25;:
Compared efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
Hupé M, Rivière P, Nancey S, Roblin X, Altwegg R, Filippi J, Fumery M, Bouguen G, Peyrin-Biroulet L, Bourreille A, Caillo L, Simon M, Goutorbe F, Laharie D
Aliment. Pharmacol. Ther.. 2020 Mar 22;:
Looking for innovative digital solutions to optimize patient recruitment in IBD trials.
Bouhnik Y, Louis E, Peyrin-Biroulet L
Gastroenterology. 2020 Mar 19;:
Challenges and opportunities for IBD drug development: from early stage to regulatory approval.
Danese S, Schabel E, Ainsworth MA, Peyrin-Biroulet L
Gut. 2020 Mar 16;:
Systematic review with meta-analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease.
Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Bonovas S
Aliment. Pharmacol. Ther.. 2020 Mar 13;:
Treatment Algorithms for Crohn's Disease.
Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F,
Digestion. 2020 Mar 13;:1-15
Emerging therapies for the treatment of ulcerative colitis.
Pugliese N, Roda G, Peyrin-Biroulet L, Danese S
Expert Opin Emerg Drugs. 2020 Mar 9;:1-9
Statins and inflammatory bowel disease: Where do we stand?
Peppas S, Piovani D, Peyrin-Biroulet L, Danese S, Bonovas S
Eur. J. Intern. Med.. 2020 Mar 6;:
Evolving therapeutic goals in Crohn's disease management.
Chateau T, Peyrin-Biroulet L
United European Gastroenterol J. 2020 Mar;8(2):133-139
Modulation of sphingosine-1-phosphate in ulcerative colitis.
Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L, Danese S
Expert Opin Biol Ther. 2020 Feb 25;:1-8
Vedolizumab for perianal Crohn's disease: a multicentre cohort study in 151 patients.
Chapuis-Biron C, Bourrier A, Nachury M, Nancey S, Bouhnik Y, Serrero M, Armengol-Debeir L, Buisson A, Tran-Minh ML, Zallot C, Fumery M, Bouguen G, Abitbol V, Viennot S, Chanteloup E, Rajca S, Dib N, Parmentier AL, Peyrin-Biroulet L, Vuitton L,
Aliment. Pharmacol. Ther.. 2020 Feb 20;:
Pharmacological Prevention of Postoperative Recurrence in Crohn's Disease.
Vuitton L, Peyrin-Biroulet L
Drugs. 2020 Feb 13;:
Review article: faecal calprotectin and histologic remission in ulcerative colitis.
D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L
Aliment. Pharmacol. Ther.. 2020 Feb 12;:
INTRODUCTION TO THE SPECIAL ISSUE: The Present and Future of IBD Care.
Singh S, Peyrin-Biroulet L, Ananthakrishnan A
Clin. Gastroenterol. Hepatol.. 2020 Feb 10;:
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J
Gastroenterology. 2020 Feb 7;:
Histologically confirmed upper gastrointestinal Crohn's disease: is it rare or are we just not searching hard enough?
Saadah OI, Fallatah KB, Baumann C, Elbaradie AA, Howladar FT, Daiwali MT, Alshuaibi OH, Alsahafi MA, Bokhary RY, Qari YA, Peyrin-Biroulet L, Mosli MH
Intest Res. 2020 Feb 7;:
Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
Fiorino G, Allocca M, Correale C, Roda G, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Danese S
Expert Opin Biol Ther. 2020 Feb 6;:
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases.
Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH
Drugs. 2020 Jan 30;:
Transmural Histological Scoring Systems in Crohn's Disease: A Systematic Review With Assessment of Methodological Quality and Operating Properties.
Tavares De Sousa H, Estevinho MM, Peyrin-Biroulet L, Danese S, Dias CC, Carneiro F, Magro F
J Crohns Colitis. 2020 Jan 27;:
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Roblin X, Williet N, Boschetti G, Phelip JM, Del Tedesco E, Berger AE, Vedrines P, Duru G, Peyrin-Biroulet L, Nancey S, Flourie B, Paul S
Gut. 2020 Jan 24;:
Positioning therapies in ulcerative colitis.
Danese S, Fiorino G, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2020 Jan 23;:
Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases.
Lagrange J, Lacolley P, Wahl D, Peyrin-Biroulet L, Regnault V
Clin. Gastroenterol. Hepatol.. 2020 Jan 20;:
Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F, Danese S, Peyrin-Biroulet L
Expert Opin Biol Ther. 2020 Jan 17;:
Maintenance of remission among patients with inflammatory bowel disease after vedolizumab discontinuation: a multicentre cohort study.
Martin A, Nachury M, Peyrin-Biroulet L, Bouhnik Y, Nancey S, Bourrier A, Serrero M, Fumery M, Buisson A, Laharie D, Gilletta C, Filippi J, Allez M, Bouguen G, Roblin X, Altwegg R, Dib N, Pineton de Chambrun G, Savoye G, Carbonnel F, Viennot S, Amiot A
J Crohns Colitis. 2020 Jan 13;:
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis.
Olivera P, Lasa J, Bonovas S, Danese S, Peyrin-Biroulet L
Gastroenterology. 2020 Jan 8;:
Phase 1, 2 and 3 trials in inflammatory bowel diseases: a practical guide for the non-specialist.
D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2020 Jan 4;:
A snapshot of the ongoing clinical research on COVID-19.
Piovani D, Pansieri C, Peyrin-Biroulet L, Danese S, Bonovas S
F1000Res. 2020 ;9:373
Treatment Adherence in Inflammatory Bowel Disease Patients from Argentina: A Multicenter Study.
Lasa J, Correa G, Fuxman C, Garbi L, Linares ME, Lubrano P, Rausch A, Toro M, Yantorno M, Zubiaurre I, Peyrin-Biroulet L, Olivera P
Gastroenterol Res Pract. 2020 ;2020:4060648
A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease.
Dulai PS, Amiot A, Peyrin-Biroulet L, Jairaith V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F,
Aliment. Pharmacol. Ther.. 2019 Dec 22;:
Fecal calprotectin for the diagnosis of bowel inflammation in patients with rheumatological diseases: a systematic review.
Fauny M, D'Amico F, Bonovas S, Netter P, Danese S, Loeuille D, Peyrin-Biroulet L
J Crohns Colitis. 2019 Dec 20;:
Histological healing: should it be considered as a new outcome for ulcerative colitis?
Dal Buono A, Roda G, Argollo M, Peyrin-Biroulet L, Danese S
Expert Opin Biol Ther. 2019 Dec 17;:
Environmental exposures and the risk of inflammatory bowel disease: a case-control study from Saudi Arabia.
Algethmi W, Baumann C, Alnajjar W, Sroji A, Alsahafi M, Jawa H, Qari Y, Peyrin-Biroulet L, Saadah OI, Mosli M
Eur J Gastroenterol Hepatol. 2019 Dec 16;:
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, DʼHaens G
Am. J. Gastroenterol.. 2019 Dec 16;:
Evolving primary and secondary endpoints in randomized controlled trials leading to approval of biologics and small molecules in IBD: an historical perspective.
Allen PB, Bonovas S, Danese S, Peyrin-Biroulet L
Expert Opin Biol Ther. 2019 Dec 9;:
Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.
Chateau T, Feakins R, Marchal-Bressenot A, Magro F, Danese S, Peyrin-Biroulet L
Am. J. Gastroenterol.. 2019 Dec 5;:
Use of Cross-sectional Imaging for Tight Monitoring of Inflammatory Bowel Diseases.
Allocca M, Danese S, Laurent V, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2019 Dec 5;:
Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group.
D'Amico F, Pouillon L, Argollo M, Hart A, Fiorino G, Vegni E, Radice S, Gilardi D, Fazio M, Leone S, Bonovas S, Magro F, Danese S, Peyrin-Biroulet L
Dig Liver Dis. 2019 Dec 4;:
Changes in inflammatory bowel disease patients' perspectives on biosimilars: A follow-up survey.
Peyrin-Biroulet L, Lönnfors S, Avedano L, Danese S
United European Gastroenterol J. 2019 Dec;7(10):1345-1352
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK
United European Gastroenterol J. 2019 Dec;7(10):1285-1303
Time to include patients with ulcerative proctitis in clinical trials.
de Chambrun GP, Danese S, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):900-902
Two Cases of Inflammatory Bowel Disease Patients Treated With Ustekinumab 90 mg Every 3 Weeks.
Chateau T, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2019 Nov 26;:
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis.
Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ
Aliment. Pharmacol. Ther.. 2019 Nov 22;:
Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease.
Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M
Clin. Gastroenterol. Hepatol.. 2019 Nov 16;:
The management of emergency hospital visits for inflammatory bowel diseases: A French national expert consensus report.
Hébuterne X, Peyrin-Biroulet L, Hausfater P
Dig Liver Dis. 2019 Nov 13;:
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L, Stefanescu C, Vaysse T, Laharie D, Roblin X, Rosa I, Treton X, Abitbol V, Amiot A, Bouguen G, Dib N, Fumery M, Pariente B, Carbonnel F, Peyrin-Biroulet L, Simon M, Viennot S, Bouhnik Y
Dig Liver Dis. 2019 Nov 12;:
Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis.
Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J
Gastroenterology. 2019 Nov 8;:
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®) for active, mild-to-moderate ulcerative colitis.
Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L
United European Gastroenterol J. 2019 Nov;7(9):1171-1182
Inflammatory bowel disease: estimates from the global burden of disease 2017 study.
Piovani D, Danese S, Peyrin-Biroulet L, Bonovas S
Aliment. Pharmacol. Ther.. 2019 Oct 29;:
Impact of a medical interview on the decision to switch from originator infliximab to its biosimilar in patients with inflammatory bowel disease.
Haghnejad V, Le Berre C, Dominique Y, Zallot C, Guillemin F, Peyrin-Biroulet L
Dig Liver Dis. 2019 Oct 21;:
Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn's disease.
Chateau T, Angioi K, Peyrin-Biroulet L
J Crohns Colitis. 2019 Oct 14;:
Application of Artificial Intelligence to Gastroenterology and Hepatology.
Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L
Gastroenterology. 2019 Oct 5;:
Will the Placebo Effect Disappear With New Targets For Treatment of Inflammatory Bowel Diseases?
Chateau T, Le Berre C, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2019 Oct 4;:
Gut microbiome in chronic rheumatic and inflammatory bowel diseases: Similarities and differences.
Salem F, Kindt N, Marchesi JR, Netter P, Lopez A, Kokten T, Danese S, Jouzeau JY, Peyrin-Biroulet L, Moulin D
United European Gastroenterol J. 2019 Oct;7(8):1008-1032
Young GI Angle: My best career decision.
Löhr M, Malfertheiner P, Peyrin-Biroulet L, Zabana Y
United European Gastroenterol J. 2019 Oct;7(8):1136-1138
[Thiopurines in inflammatory bowel disease: what's new ?]
Chaâteau T, Peyrin-Biroulet L
Rev Prat. 2019 Oct;69(8):819-825
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C,
N. Engl. J. Med.. 2019 09 26;381(13):1201-1214
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S,
N. Engl. J. Med.. 2019 09 26;381(13):1215-1226
Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review.
Estevinho MM, Rocha C, Correia L, Lago P, Ministro P, Portela F, Trindade E, Afonso J, Peyrin-Biroulet L, Magro F,
Clin. Gastroenterol. Hepatol.. 2019 Sep 14;:
Evolving therapeutic goals in ulcerative colitis: towards disease clearance.
Danese S, Roda G, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2019 Sep 13;:
Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
Le Berre C, Roda G, Nedeljkovic M, Danese S, Peyrin-Biroulet L
Expert Opin Biol Ther. 2019 Sep 9;:
Environmental, Nutritional and Socio-Economic Determinants of IBD Incidence: A Global Ecological Study.
Piovani D, Danese S, Peyrin-Biroulet L, Bonovas S
J Crohns Colitis. 2019 Aug 29;:
Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.
Bommelaer G, Laharie D, Nancey S, Hebuterne X, Roblin X, Nachury M, Peyrin-Biroulet L, Fumery M, Richard D, Pereira B, Goutte M, Buisson A,
Clin. Gastroenterol. Hepatol.. 2019 Aug 27;:
mTOR-Dependent Stimulation of Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease.
Ungaro F, Garlatti V, Massimino L, Spinelli A, Carvello M, Sacchi M, Spanò S, Colasante G, Valassina N, Vetrano S, Malesci A, Peyrin-Biroulet L, Danese S, D'Alessio S
Cells. 2019 Aug 18;8(8):
Comparison of the EMA and FDA Guidelines on Ulcerative Colitis Drug Development.
Reinisch W, Gottlieb K, Colombel JF, Danese S, Panaccione R, Panes J, Peyrin-Biroulet L, Rubin D, Sands BE, Schreiber S, Vermeire S, Mulberg A, Sandborn B
Clin. Gastroenterol. Hepatol.. 2019 Aug;17(9):1673-1679.e1
Cost-of-illness of inflammatory bowel disease patients treated with anti-tumour necrosis factor: A French large single-centre experience.
Lawton J, Achit H, Pouillon L, Boschetti E, Demore B, Matton T, Tournier C, Prodel M, Peyrin-Biroulet L, Guillemin F
United European Gastroenterol J. 2019 Aug;7(7):908-913
Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.
Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T
Expert Rev Gastroenterol Hepatol. 2019 Jul 26;:1-8
Ulcerative Colitis and Crohn's Disease Have the Same Burden and Goals for Treatment.
Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2019 Jul 10;:
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: a systematic review and network meta-analysis.
Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S
Br J Clin Pharmacol. 2019 Jul 3;:
Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial.
Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK
Gut. 2019 Jul;68(7):1162-1168
Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Bouguen G, Abitbol V, Fumery M, Gagniere C, Bouhnik Y,
Aliment. Pharmacol. Ther.. 2019 Jul;50(1):40-53
Challenges in the Pathophysiology, Diagnosis and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.
D'Haens G, Rieder F, Feagan BG, Higgins PDR, Panes J, Maaser C, Rogler G, Löwenberg M, van der Voort R, Pinzani M, Peyrin-Biroulet L, Danese S,
Gastroenterology. 2019 Jun 26;:
Activation of the VEGFC/VEGFR3 pathway induces tumor immune escape in colorectal cancer.
Tacconi C, Ungaro F, Correale C, Arena V, Massimino L, Detmar M, Spinelli A, Carvello M, Mazzone M, Oliveira AI, Rubbino F, Garlatti V, Spanò S, Lugli E, Colombo FS, Malesci A, Peyrin-Biroulet L, Vetrano S, Danese S, D'Alessio S
Cancer Res.. 2019 Jun 25;:
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter?
Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L
Gut. 2019 Jun 21;:
Approaches to Integrating Biomarkers into Clinical Trials and Care Pathways as Targets for Treatment of Inflammatory Bowel Diseases.
Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ
Gastroenterology. 2019 Jun 19;:
Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis.
Pineton de Chambrun G, Amiot A, Bouguen G, Viennot S, Altwegg R, Louis E, Collins M, Fumery M, Poullenot F, Armengol L, Buisson A, Abitbol V, Laharie D, Seksik P, Nancey S, Blanc P, Bouhnik Y, Pariente B, Peyrin-Biroulet L,
Clin. Gastroenterol. Hepatol.. 2019 Jun 13;:
Comorbidities in inflammatory bowel disease: a call for action.
Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot JF, Peyrin-Biroulet L, Danese S
Lancet Gastroenterol Hepatol. 2019 Jun 3;:
A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.
Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L
Am. J. Gastroenterol.. 2019 Jun;114(6):874-883
Detection and management of early stage inflammatory bowel disease: an update for clinicians.
Loy L, Roda G, Fiorino G, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S
Expert Rev Gastroenterol Hepatol. 2019 Jun;13(6):547-555
Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen.
Fiorino G, Peyrin-Biroulet L, Danese S
Gastroenterology. 2019 06;156(8):2349-2351
The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis.
Al-Shamma H, Lehmann-Bruinsma K, Carroll C, Solomon M, Komori HK, Peyrin-Biroulet L, Adams J
J. Pharmacol. Exp. Ther.. 2019 Jun;369(3):311-317
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L
J Crohns Colitis. 2019 May 10;:
Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study.
Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A,
J Crohns Colitis. 2019 May 6;:
Big data in IBD: a look into the future.
Olivera P, Danese S, Jay N, Natoli G, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):312-321
Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.
Pouillon L, Danese S, Hart A, Fiorino G, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, González-Lorenzo M, Bonovas S, Magro F, Peyrin-Biroulet L
Aliment Pharmacol Ther. 2019 05;49(9):1181-1187
Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing.
D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S
Immunotherapy. 2019 May;11(7):565-575
Psychological Functioning of Patients With Inflammatory Bowel Disease.
Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Allocca M, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G
Inflamm. Bowel Dis.. 2019 Apr 30;:
Environmental Risk Factors for Inflammatory Bowel Diseases: an Umbrella Review of Meta-analyses.
Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S
Gastroenterology. 2019 Apr 20;:
Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease.
Allocca M, Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S
Clin. Gastroenterol. Hepatol.. 2019 Apr 14;:
Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis.
Peyrin-Biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-Lorenzo M, Lytras T, Bonovas S
Clin. Gastroenterol. Hepatol.. 2019 Apr;17(5):838-846.e2
Lymphatic endothelium contributes to colorectal cancer growth via the soluble matrisome component GDF11.
Ungaro F, Colombo P, Massimino L, Ugolini GS, Correale C, Rasponi M, Garlatti V, Rubbino F, Tacconi C, Spaggiari P, Spinelli A, Carvello M, Sacchi M, Spanò S, Vetrano S, Malesci A, Peyrin-Biroulet L, Danese S, D'Alessio S
Int. J. Cancer. 2019 Mar 19;:
Combination Therapy With Vedolizumab and Tofacitinib in a Patient With Ulcerative Colitis and Spondyloarthropathy.
Le Berre C, Loeuille D, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2019 Mar;17(4):794-796
Effectiveness of golimumab in ulcerative colitis: A review of the real world evidence.
Olivera P, Danese S, Pouillon L, Bonovas S, Peyrin-Biroulet L
Dig Liver Dis. 2019 03;51(3):327-334
Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study.
Briot C, Faure P, Parmentier AL, Nachury M, Trang C, Viennot S, Altwegg R, Bulois P, Thomassin L, Serrero M, Ah-Soune P, Gilletta C, Plastaras L, Simon M, Dray X, Caillo L, Del Tedesco E, Abitbol V, Zallot C, Degand T, Rossi V, Bonnaud G, Colin D, Morel B, Winkfield B, Danset JB, Filippi J, Amiot A, Attar A, Levy J, Peyrin-Biroulet L, Vuitton L,
J Crohns Colitis. 2019 Feb 13;:
Impact of inflammatory bowel diseases on working life: A French nationwide survey.
Le Berre C, Peyrin-Biroulet L, Buisson A, Olympie A, Ravel MH, Bienenfeld C, Gonzalez F
Dig Liver Dis. 2019 Feb 11;:
Timely Use of Biologics in Early Crohn's Disease: The Return of "Hit Hard and Early"?
Le Berre C, Danese S, Peyrin-Biroulet L
Dig. Dis. Sci.. 2019 Feb 6;:
A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials.
Li K, Strauss R, Marano C, Greenbaum LE, Friedman JR, Peyrin-Biroulet L, Brodmerkel C, De Hertogh G
J Crohns Colitis. 2019 Feb 4;:
Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies.
Peyrin-Biroulet L, Demarest S, Nirula A
Autoimmun Rev. 2019 Feb;18(2):123-128
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
Pellet G, Stefanescu C, Carbonnel F, Peyrin-Biroulet L, Roblin X, Allimant C, Nachury M, Nancey S, Filippi J, Altwegg R, Brixi H, Fotsing G, de Rosamel L, Shili S, Laharie D,
Clin. Gastroenterol. Hepatol.. 2019 Feb;17(3):494-501
Integrating Patient-Reported Outcomes Into Treat-to-Target Monitoring Algorithms.
Dulai PS, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2019 Feb;17(3):395-396
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients.
Leone D, Gilardi D, Corrò BE, Menichetti J, Vegni E, Correale C, Mariangela A, Furfaro F, Bonovas S, Peyrin-Biroulet L, Danese S, Fiorino G
Inflamm. Bowel Dis.. 2019 Jan 28;:
Adalimumab for patients with Crohn's disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study.
Pineton de Chambrun G, Pariente B, Seksik P, Altwegg R, Vuitton L, Stefasnescu C, Nancey S, Aubourg A, Serrero M, Peyrin-Biroulet L, Filippi J, Viennot S, Abitbol V, Boualit M, Boureille A, Moreau J, Buisson A, Roblin X, Nachury M, Zappa M, Lambert J, Bouhnik Y,
J Crohns Colitis. 2019 Jan 25;13(Supplement_1):S616
Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials.
Ben-Horin S, Zhao Y, Guo J, Mao R, Novack L, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Colombel JF, Peyrin-Biroulet L, Kaplan G, Chen MH
BMJ Open. 2019 Jan 25;9(1):e024222
Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study.
Duricova D, Sarter H, Savoye G, Leroyer A, Pariente B, Armengol-Debeir L, Bouguen G, Ley D, Turck D, Templier C, Buche S, Peyrin-Biroulet L, Gower-Rousseau C, Fumery M,
Inflamm. Bowel Dis.. 2019 Jan 10;25(2):394-402
Biosimilars of adalimumab: the upcoming challenge in IBD.
Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S
Expert Opin Biol Ther. 2019 Jan 2;:
Anti-adhesion Molecules in IBD: Does Gut Selectivity Really Make the Difference?
D'Amico F, Roda G, Peyrin-Biroulet L, Danese S
Curr. Pharm. Des.. 2019 ;25(1):19-24
Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?
Argollo M, Gilardi D, Roda G, Fiorino G, Peyrin-Biroulet L, Danese S
Curr. Pharm. Des.. 2019 ;25(1):47-56
Biosimilars for the Management of Inflammatory Bowel Diseases: Economic Considerations.
Gulacsi L, Pentek M, Rencz F, Brodszky V, Baji P, Vegh Z, Gecse KB, Danese S, Peyrin-Biroulet L, Lakatos PL
Curr. Med. Chem.. 2019 ;26(2):259-269
Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, Danese S
Curr. Pharm. Des.. 2019 ;25(1):7-12
Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study.
Attar A, Duru G, Roblin X, Savarieau B, Brunel P, Lamure M, Peyrin-Biroulet L
Dig Liver Dis. 2019 01;51(1):112-119
Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation.
Gouynou C, Pouillon L, Rousseau H, Zallot C, Baumann C, Peyrin-Biroulet L
Gut. 2019 01;68(1):178-179
Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Martelli L, Peyrin-Biroulet L
Curr. Med. Chem.. 2019 ;26(2):270-279
Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
Argollo MC, Allocca M, Furfaro F, Peyrin-Biroulet L, Danese S
Curr. Pharm. Des.. 2019 ;25(1):25-31
Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases.
Kotze PG, Peyrin-Biroulet L, Danese S
Curr Drug Targets. 2019 ;20(13):1315-1316
Metagenomic analysis of intestinal mucosa revealed a specific eukaryotic gut virome signature in early-diagnosed inflammatory bowel disease.
Ungaro F, Massimino L, Furfaro F, Rimoldi V, Peyrin-Biroulet L, D'Alessio S, Danese S
Gut Microbes. 2019 ;10(2):149-158
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience.
D'Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S
Therap Adv Gastroenterol. 2019 ;12:1756284819848631
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus.
Danese S, Allez M, van Bodegraven AA, Dotan I, Gisbert JP, Hart A, Lakatos PL, Magro F, Peyrin-Biroulet L, Schreiber S, Tarabar D, Vavricka S, Halfvarson J, Vermeire S
Dig Dis. 2019 ;37(4):266-283
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study.
Allocca M, Fiorino G, Bonovas S, Furfaro F, Gilardi D, Argollo M, Magnoni P, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2018 Nov 28;12(12):1385-1391
Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage.
Sitte J, Frentiu E, Baumann C, Rousseau H, May T, Bronowicki JP, Peyrin-Biroulet L, Lopez A
Aliment. Pharmacol. Ther.. 2018 Nov 28;:
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making.
Allocca M, Fiorino G, Bonifacio C, Furfaro F, Gilardi D, Argollo M, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2018 Nov 15;12(11):1280-1287
Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease.
Thierry ML, Rousseau H, Pouillon L, Girard-Gavanier M, Baumann C, Lopez A, Danese S, Laurent V, Peyrin-Biroulet L
J Crohns Colitis. 2018 11 9;12(10):1180-1190
Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations.
Bonovas S, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2018 Nov 9;12(10):1257-1258
Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.
Pouillon L, Baumann C, Rousseau H, Choukour M, Andrianjafy C, Danese S, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2018 Oct 16;:
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
Kopylov U, Verstockt B, Biedermann L, Sebastian S, Pugliese D, Sonnenberg E, Steinhagen P, Arebi N, Ron Y, Kucharzik T, Roblin X, Ungar B, Shitrit AB, Ardizzone S, Molander P, Coletta M, Peyrin-Biroulet L, Bossuyt P, Avni-Biron I, Tsoukali E, Allocca M, Katsanos K, Raine T, Sipponen T, Fiorino G, Ben-Horin S, Eliakim R, Armuzzi A, Siegmund B, Baumgart DC, Kamperidis N, Maharshak N, Maaser C, Mantzaris G, Yanai H, Christodoulou DK, Dotan I, Ferrante M
Inflamm. Bowel Dis.. 2018 10 12;24(11):2442-2451
Anti-TNF therapy for genital fistulas in female patients with Crohn's disease: a nationwide study from the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID).
Le Baut G, Peyrin-Biroulet L, Bouguen G, Gornet JM, Stefanescu C, Amiot A, Laharie D, Altwegg R, Fumery M, Trang C, Vuitton L, Simon M, Gilletta de Saint Joseph C, Nahon S, Caillo L, Del Tedesco E, Plastaras L, Aubourg A, Pineton de Chambrun G, Seksik P, Viennot S
Aliment. Pharmacol. Ther.. 2018 Oct;48(8):831-838
Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis.
Atreya R, Reinisch W, Peyrin-Biroulet L, Scaldaferri F, Admyre C, Knittel T, Kowalski J, Neurath MF, Hawkey C
Dig Liver Dis. 2018 10;50(10):1019-1029
Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach.
Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK
Intest Res. 2018 Oct;16(4):522-528
Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.
Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2018 09 15;24(10):2106-2112
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars.
Pouillon L, Allocca M, Peyrin-Biroulet L
Aliment. Pharmacol. Ther.. 2018 Sep;48(5):574-575
Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review.
Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V
Clin. Gastroenterol. Hepatol.. 2018 Sep;16(9):1407-1419.e22
Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: A French population-based study.
Duricova D, Pariente B, Sarter H, Fumery M, Leroyer A, Charpentier C, Armengol-Debeir L, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C,
Dig Liver Dis. 2018 Sep;50(9):903-909
Review article: treating-to-target for inflammatory bowel disease-associated anaemia.
Peyrin-Biroulet L, Lopez A, Cummings JRF, Dignass A, Detlie TE, Danese S
Aliment. Pharmacol. Ther.. 2018 Sep;48(6):610-617
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV
J. Gastroenterol.. 2018 Sep;53(9):1048-1064
Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.
Altwegg R, Combes R, Laharie D, De Ledinghen V, Radenne S, Conti F, Chazouilleres O, Duvoux C, Dumortier J, Leroy V, Treton X, Durand F, Dharancy S, Nachury M, Goutorbe F, Lamblin G, Boivineau L, Peyrin-Biroulet L, Pageaux GP
Dig Liver Dis. 2018 07;50(7):668-674
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease.
Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L
Gastroenterology. 2018 07;155(1):76-87
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis.
Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S
Expert Opin Investig Drugs. 2018 Jul;27(7):623-629
Diffusion-weighted MRI in inflammatory bowel disease.
Pouillon L, Laurent V, Pouillon M, Bossuyt P, Bonifacio C, Danese S, Deepak P, Loftus EV, Bruining DH, Peyrin-Biroulet L
Lancet Gastroenterol Hepatol. 2018 06;3(6):433-443
High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease.
Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabaté JM, Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M,
Clin. Gastroenterol. Hepatol.. 2018 Jun;16(6):892-899.e2
Infliximab biosimilar CT-P13 for inflammatory bowel disease.
Bonovas S, Peyrin-Biroulet L, Danese S
Lancet Gastroenterol Hepatol. 2018 06;3(6):373-375
Pneumococcal and influenza vaccine uptake in adults with inflammatory bowel disease in France: Results from a web-based study.
Loubet P, Verger P, Abitbol V, Peyrin-Biroulet L, Launay O
Dig Liver Dis. 2018 Jun;50(6):563-567
Post-operative complications in elderly onset inflammatory bowel disease: a population-based study.
Sacleux SC, Sarter H, Fumery M, Charpentier C, Guillon-Dellac N, Coevoet H, Pariente B, Peyrin-Biroulet L, Gower-Rousseau C, Savoye G,
Aliment. Pharmacol. Ther.. 2018 Jun;47(12):1652-1660
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set.
Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V
Clin. Gastroenterol. Hepatol.. 2018 May;16(5):637-647.e13
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.
de Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel JF, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF
J Crohns Colitis. 2018 Apr 27;12(5):610-620
Is the Pharmacokinetic Profile of a First Anti-TNF Predictive of the Clinical Outcome and Pharmacokinetics of a Second Anti-TNF?
Roblin X, Vérot C, Paul S, Duru G, Williet N, Boschetti G, Del Tedesco E, Peyrin-Biroulet L, Marc Phelip J, Nancey S, Flourie B
Inflamm. Bowel Dis.. 2018 Apr 26;:
Zinc-Alpha-2-Glycoprotein in Inflammatory Bowel Disease.
Rolli V, Macquin C, Kokten T, Hablot J, Ndiaye NC, Netter P, Bahram S, Jouzeau JY, Peyrin-Biroulet L, Georgel P, Moulin D
Inflamm. Bowel Dis.. 2018 Apr 23;24(5):e10
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D,
Gastroenterology. 2018 04;154(5):1343-1351.e1
It is Time to Revise the STRIDE Guidelines Determining Therapeutic Goals for Treat-to-Target in Inflammatory Bowel Disease.
Pouillon L, Peyrin-Biroulet L
J Crohns Colitis. 2018 Mar 28;12(4):509
Independent Validation of a Self-Report Version of the IBD Disability Index (IBDDI) in a Population-Based Cohort of IBD Patients.
Shafer LA, Walker JR, Chhibba T, Ivekovic M, Singh H, Targownik LE, Peyrin-Biroulet L, Gower-Rousseau C, Sarter H, Bernstein CN
Inflamm. Bowel Dis.. 2018 03 19;24(4):766-774
Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.
Baji P, Gulácsi L, Brodszky V, Végh Z, Danese S, Irving PM, Peyrin-Biroulet L, Schreiber S, Rencz F, Lakatos PL, Péntek M
United European Gastroenterol J. 2018 Mar;6(2):310-321
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B,
Aliment. Pharmacol. Ther.. 2018 Mar;47(5):588-595
Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review.
Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ
Clin. Gastroenterol. Hepatol.. 2018 Mar;16(3):343-356.e3
Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L
Aliment. Pharmacol. Ther.. 2018 Mar;47(6):773-783
Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease.
Qiu Y, Chen BL, Feng R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Peyrin-Biroulet L, Mao R, Chen MH
J. Gastroenterol. Hepatol.. 2018 Mar;33(3):664-670
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men.
Allocca M, Gilardi D, Fiorino G, Furfaro F, Peyrin-Biroulet L, Danese S
Eur J Gastroenterol Hepatol. 2018 Mar;30(3):316-322
Telehealth in Inflammatory Bowel Disease: Every Patient May Need a Coach!
Jaboli F, Pouillon L, Bossuyt P, Danese S, Peyrin-Biroulet L
Gastroenterology. 2018 Mar;154(4):1196-1198
Vedolizumab for the treatment of Crohn's disease.
Argollo M, Fiorino G, Peyrin-Biroulet L, Danese S
Expert Rev Clin Immunol. 2018 03;14(3):179-189
Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis.
Bonovas S, Nikolopoulos GK, Lytras T, Fiorino G, Peyrin-Biroulet L, Danese S
Br J Clin Pharmacol. 2018 02;84(2):239-251
Development of an index to define overall disease severity in IBD.
Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L
Gut. 2018 02;67(2):244-254
Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988-2011): A Population-Based Study of French Adolescents.
Ghione S, Sarter H, Fumery M, Armengol-Debeir L, Savoye G, Ley D, Spyckerelle C, Pariente B, Peyrin-Biroulet L, Turck D, Gower-Rousseau C, Andre JM, Antonietti M, Aouakli A, Armand A, Aroichane I, Assi F, Aubet JP, Auxenfants E, Ayafi-Ramelot F, Bankovski D, Barbry B, Bardoux N, Baron P, Baudet A, Bazin B, Bebahani A, Becqwort JP, Benet V, Benali H, Benguigui C, Soussan BE, Bental A, Berkelmans I, Bernet J, Bernou K, Bernou-Dron C, Bertot P, Bertiaux-Vandaële N, Bertrand V, Billoud E, Biron N, Bismuth B, Bleuet M, Blondel F, Blondin V, Bohon P, Boniface E, Bonnière P, Bonvarlet E, Bonvarlet P, Boruchowicz A, Bostvironnois R, Boualit M, Bouche B, Boudaillez C, Bourgeaux C, Bourgeois M, Bourguet A, Bourienne A, Branche J, Bray G, Brazier F, Breban P, Brihier H, Brung-Lefebvre V, Bulois P, Burgiere P, Butel J, Canva JY, Canva-Delcambre V, Capron JP, Cardot F, Carpentier P, Cartier E, Cassar JF, Cassagnou M, Castex JF, Catala P, Cattan S, Catteau S, Caujolle B, Cayron G, Chandelier C, Chantre M, Charles J, Charneau T, Chavance-Thelu M, Chirita D, Choteau A, Claerbout JF, Clergue PY, Coevoet H, Cohen G, Collet R, Colombel JF, Coopman S, Corvisart J, Cortot A, Couttenier F, Crinquette JF, Crombe V, Dadamessi I, Dapvril V, Davion T, Dautreme S, Debas J, Degrave N, Dehont F, Delatre C, Delcenserie R, Delette O, Delgrange T, Delhoustal L, Delmotte JS, Demmane S, Deregnaucourt G, Descombes P, Desechalliers JP, Desmet P, Desreumaux P, Desseaux G, Desurmont P, Devienne A, Devouge E, Devred M, Devroux A, Dewailly A, Dharancy S, Di Fiore A, Djeddi D, Djedir R, Dreher-Duwat ML, Dubois R, Dubuque C, Ducatillon P, Duclay J, Ducrocq B, Ducrot F, Ducrotte P, Dufilho A, Duhamel C, Dujardin D, Dumant-Forest C, Dupas JL, Dupont F, Duranton Y, Duriez A, El Achkar K, El Farisi M, Elie C, Elie-Legrand MC, Elkhaki A, Eoche M, Evrard D, Evrard JP, Fatome A, Filoche B, Finet L, Flahaut M, Flamme C, Foissey D, Fournier P, Foutrein-Comes MC, Foutrein P, Fremond D, Frere T, Fumery M, Gallet P, Gamblin C, Ganga-Zandzou PS, Gérard R, Geslin G, Gheyssens Y, Ghossini N, Ghrib S, Gilbert T, Gillet B, Godard D, Godard P, Godchaux JM, Godchaux R, Goegebeur G, Goria O, Gottrand F, Gower P, Grandmaison B, Groux M, Guedon C, Guillard JF, Guillem L, Guillemot F, Guimber D, Haddouche B, Hakim S, Hanon D, Hautefeuille V, Heckestweiller P, Hecquet G, Hedde JP, Hellal H, Henneresse PE, Heyman B, Heraud M, Herve S, Hochain P, Houssin-Bailly L, Houcke P, Huguenin B, Iobagiu S, Ivanovic A, Iwanicki-Caron I, Janicki E, Jarry M, Jeu J, Joly JP, Jonas C, Katherin F, Kerleveo A, Khachfe A, Kiriakos A, Kiriakos J, Klein O, Kohut M, Kornhauser R, Koutsomanis D, Laberenne JE, Laffineur G, Lagarde M, Lannoy P, Lapchin J, Lapprand M, Laude D, Leblanc R, Lecieux P, Leclerc N, Le Couteulx C, Ledent J, Lefebvre J, Lefiliatre P, Legrand C, Le Grix A, Lelong P, Leluyer B, Lenaerts C, Lepileur L, Leplat A, Lepoutre-Dujardin E, Leroi H, Leroy MY, Lesage JP, Lesage X, Lesage J, Lescanne-Darchis I, Lescut J, Lescut D, Leurent B, Levy P, Lhermie M, Lion A, Lisambert B, Loire F, Louf S, Louvet A, Luciani M, Lucidarme D, Lugand J, Macaigne O, Maetz D, Maillard D, Mancheron H, Manolache O, Marks-Brunel AB, Marti R, Martin F, Martin G, Marzloff E, Mathurin P, Mauillon J, Maunoury V, Maupas JL, Mesnard B, Metayer P, Methari L, Meurisse B, Meurisse F, Michaud L, Mirmaran X, Modaine P, Monthe A, Morel L, Mortier PE, Moulin E, Mouterde O, Mudry J, Nachury M, Khac NE, Notteghem B, Ollevier V, Ostyn A, Ouraghi A, Ouvry D, Paillot B, Panien-Claudot N, Paoletti C, Papazian A, Parent B, Pariente B, Paris JC, Patrier P, Paupart L, Pauwels B, Pauwels M, Petit R, Piat M, Piotte S, Plane C, Plouvier B, Pollet E, Pommelet P, Pop D, Pordes C, Pouchain G, Prades P, Prevost A, Prevost JC, Quesnel B, Queuniet AM, Quinton JF, Rabache A, Rabelle P, Raclot G, Ratajczyk S, Rault D, Razemon V, Reix N, Revillon M, Richez C, Robinson P, Rodriguez J, Roger J, Roux JM, Rudelli A, Saber A, Savoye G, Schlosseberg P, Segrestin M, Seguy D, Serin M, Seryer A, Sevenet F, Shekh N, Silvie J, Simon V, Spyckerelle C, Talbodec N, Techy A, Thelu JL, Thevenin A, Thiebault H, Thomas J, Thorel JM, Tielman G, Tode M, Toisin J, Tonnel J, Touchais JY, Touze Y, Tranvouez JL, Triplet C, Turck D, Uhlen S, Vaillant E, Valmage C, Vanco D, Vandamme H, Vanderbecq E, Eecken VE, Vandermolen P, Vandevenne P, Vandeville L, Vandewalle A, Vandewalle C, Vaneslander P, Vanhoove JP, Vanrenterghem A, Varlet P, Vasies I, Verbiese G, Vernier-Massouille G, Vermelle P, Verne C, Vezilier-Cocq P, Vigneron B, Vincendet M, Viot J, Voiment YM, Wacrenier A, Waeghemaecker L, Wallez JY, Wantiez M, Wartel F, Weber J, Willocquet JL, Wizla N, Wolschies E, Zalar A, Zaouri B, Zellweger A, Ziade C,
Am. J. Gastroenterol.. 2018 02;113(2):265-272
Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort.
Tadbiri S, Peyrin-Biroulet L, Serrero M, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Gilletta C, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Fumery M, Claudepierre P, Bouhnik Y, Amiot A,
Aliment. Pharmacol. Ther.. 2018 02;47(4):485-493
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S
Aliment. Pharmacol. Ther.. 2018 02;47(4):454-465
Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?
Allocca M, Fiorino G, Gilardi D, Preatoni P, Papa A, Peyrin-Biroulet L, Danese S
Curr Drug Targets. 2018 ;19(7):748-756
Editorial: Personalized Medicine in Inflammatory Bowel Diseases: Myth or Reality?
Peyrin-Biroulet L, Danese S
Curr Drug Targets. 2018 ;19(7):721
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
Bouhnik Y, Carbonnel F, Laharie D, Stefanescu C, Hébuterne X, Abitbol V, Nachury M, Brixi H, Bourreille A, Picon L, Bourrier A, Allez M, Peyrin-Biroulet L, Moreau J, Savoye G, Fumery M, Nancey S, Roblin X, Altwegg R, Bouguen G, Bommelaer G, Danese S, Louis E, Zappa M, Mary JY,
Gut. 2018 01;67(1):53-60
Evolving Treatment Algorithms in Crohn's Disease.
Wisniewski A, Danese S, Peyrin-Biroulet L
Curr Drug Targets. 2018 ;19(7):782-790
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H
Aliment. Pharmacol. Ther.. 2018 01;47(2):219-228
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach.
Peyrin-Biroulet L, Baumgart DC, Armuzzi A, Gionchetti P, Sebastian S, Danese S, Magro F, Higgins S, Yaworksy A, Banderas B, Kachroo S
Dig Dis. 2018 ;36(5):346-353
Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.
Lo B, Prosberg MV, Gluud LL, Chan W, Leong RW, van der List E, van der Have M, Sarter H, Gower-Rousseau C, Peyrin-Biroulet L, Vind I, Burisch J
Aliment. Pharmacol. Ther.. 2018 Jan;47(1):6-15
Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe.
Rencz F, Gulácsi L, Péntek M, Gecse KB, Dignass A, Halfvarson J, Gomollón F, Baji P, Peyrin-Biroulet L, Lakatos PL, Brodszky V
Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):597-606
E-health in inflammatory bowel diseases: More challenges than opportunities?
Bossuyt P, Pouillon L, Bonnaud G, Danese S, Peyrin-Biroulet L
Dig Liver Dis. 2017 Dec;49(12):1320-1326
Early intervention in Crohn's disease: towards disease modification trials.
Danese S, Fiorino G, Peyrin-Biroulet L
Gut. 2017 12;66(12):2179-2187
Keeping the (S)toolbox Alive Outside of the Body for Drugs Discovery.
Poulin LF, Peyrin-Biroulet L, Collard D, Chamaillard M
Gastroenterology. 2017 Dec;153(6):1689-1691
Novel therapeutic targets for inflammatory bowel disease.
Argollo M, Fiorino G, Hindryckx P, Peyrin-Biroulet L, Danese S
J. Autoimmun.. 2017 Dec;85:103-116
Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S
Inflamm. Bowel Dis.. 2017 11;23(11):2048-2053
Letter: addition of methotrexate neither restores clinical response nor improves the pharmacokinetic profile of vedolizumab-treated patients.
Gouynou C, Peyrin-Biroulet L
Aliment. Pharmacol. Ther.. 2017 11;46(10):1019-1020
MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice.
Ungaro F, Tacconi C, Massimino L, Corsetto PA, Correale C, Fonteyne P, Piontini A, Garzarelli V, Calcaterra F, Della Bella S, Spinelli A, Carvello M, Rizzo AM, Vetrano S, Petti L, Fiorino G, Furfaro F, Mavilio D, Maddipati KR, Malesci A, Peyrin-Biroulet L, D'Alessio S, Danese S
Gastroenterology. 2017 11;153(5):1363-1377.e6
Preventing disability in inflammatory bowel disease.
Allen PB, Gower-Rousseau C, Danese S, Peyrin-Biroulet L
Therap Adv Gastroenterol. 2017 Nov;10(11):865-876
Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study.
Hochart A, Gower-Rousseau C, Sarter H, Fumery M, Ley D, Spyckerelle C, Peyrin-Biroulet L, Laberenne JE, Vasseur F, Savoye G, Turck D,
Gut. 2017 11;66(11):1912-1917
Effect of Adalimumab on Clinical Outcomes and Health-related Quality of Life Among Patients With Ulcerative Colitis in a Clinical Practice Setting: Results From InspirADA.
Travis S, Feagan BG, Peyrin-Biroulet L, Panaccione R, Danese S, Lazar A, Robinson AM, Petersson J, Pappalardo BL, Bereswill M, Chen N, Wang S, Skup M, Thakkar RB, Chao J
J Crohns Colitis. 2017 Oct 27;11(11):1317-1325
Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study.
Duricova D, Leroyer A, Savoye G, Sarter H, Pariente B, Aoucheta D, Armengol-Debeir L, Ley D, Turck D, Peyrin-Biroulet L, Gower-Rousseau C, Fumery M,
J Crohns Colitis. 2017 Oct 27;11(11):1326-1334
Frequency of and Factors Associated With Sexual Dysfunction in Patients With Inflammatory Bowel Disease.
Rivière P, Zallot C, Desobry P, Sabaté JM, Vergniol J, Zerbib F, Peyrin-Biroulet L, Laharie D, Poullenot F
J Crohns Colitis. 2017 Oct 27;11(11):1347-1352
Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting.
Martelli L, Lopez A, Strobel S, Danese S, Roblin X, Baumann C, Peyrin-Biroulet L
J Dig Dis. 2017 10;18(10):566-573
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO, Armuzzi A, Gisbert JP, Bokemeyer B, Peyrin-Biroulet L, Nguyen GC, Smyth M, Patel H
Dig Liver Dis. 2017 Oct;49(10):1086-1091
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease.
Hindryckx P, Novak G, Bonovas S, Peyrin-Biroulet L, Danese S
Clin. Pharmacol. Ther.. 2017 Oct;102(4):633-641
Positioning Ustekinumab in Crohn's Disease: From Clinical Evidence to Clinical Practice.
Danese S, Bonovas S, Peyrin-Biroulet L
J Crohns Colitis. 2017 Oct 1;11(10):1258-1266
IBD: To switch or not to switch: that is the biosimilar question.
Danese S, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):508-509
Tofacitinib Is the Right OCTAVE for Ulcerative Colitis.
Pouillon L, Bossuyt P, Peyrin-Biroulet L
Gastroenterology. 2017 Sep;153(3):862-864
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease.
Buisson A, Gonzalez F, Poullenot F, Nancey S, Sollellis E, Fumery M, Pariente B, Flamant M, Trang-Poisson C, Bonnaud G, Mathieu S, Thevenin A, Duruy M, Filippi J, Lʼhopital F, Luneau F, Michalet V, Genès J, Achim A, Cruzille E, Bommelaer G, Laharie D, Peyrin-Biroulet L, Pereira B, Nachury M, Bouguen G,
Inflamm. Bowel Dis.. 2017 08;23(8):1425-1433
Filgotinib in Crohn's Disease: JAK Is Back.
Danese S, Fiorino G, Peyrin-Biroulet L
Gastroenterology. 2017 Aug;153(2):603-605
Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice.
Yadav P, Ellinghaus D, Rémy G, Freitag-Wolf S, Cesaro A, Degenhardt F, Boucher G, Delacre M, ,Peyrin-Biroulet L, Pichavant M, Rioux JD, Gosset P, Franke A, Schumm LP, Krawczak M, Chamaillard M, Dempfle A, Andersen V
Gastroenterology. 2017 08;153(2):550-565
Implementing the Concept of Continuous Clinical Response Into Clinical Practice for Ulcerative Colitis.
Peyrin-Biroulet L, Van Assche G, Armuzzi A, Garcia-Alvarez L, Lara N, Black CM, Khalifa A, Cornillie F, Kachroo S
Clin. Gastroenterol. Hepatol.. 2017 Aug;15(8):1154-1161.e1
One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study.
Amiot A, Serrero M, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Gagniere C, Bouhnik Y,
Aliment. Pharmacol. Ther.. 2017 08;46(3):310-321
Value of cross-sectional imaging in assessing active Crohn's disease before stoma reversal.
Dirrenberger B, Clerc-Urmès I, Germain A, Bresler L, Olivera P, Martelli L, Danese S, Baumann C, Laurent V, Peyrin-Biroulet L
Dig Liver Dis. 2017 Aug;49(8):864-871
Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open-label, prospective and randomised clinical trial.
Roblin X, Boschetti G, Williet N, Nancey S, Marotte H, Berger A, Phelip JM, Peyrin-Biroulet L, Colombel JF, Del Tedesco E, Paul S, Flourie B
Aliment. Pharmacol. Ther.. 2017 07;46(2):142-149
Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
Danese S, Bonovas S, Peyrin-Biroulet L
J Crohns Colitis. 2017 Jul 1;11(7):767-768
JAK inhibition in inflammatory bowel disease.
Olivera P, Danese S, Peyrin-Biroulet L
Expert Rev Clin Immunol. 2017 07;13(7):693-703
Surgical rates in the era of biological therapy: up, down or unchanged?
Olivera P, Spinelli A, Gower-Rousseau C, Danese S, Peyrin-Biroulet L
Curr. Opin. Gastroenterol.. 2017 Jul;33(4):246-253
PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
Spadaccini M, D'Alessio S, Peyrin-Biroulet L, Danese S
Int J Mol Sci. 2017 Jun 15;18(6):
Clinical development of biologicals and biosimilars - safety concerns.
Bonovas S, Peyrin-Biroulet L, Danese S
Expert Rev Clin Pharmacol. 2017 06;10(6):567-569
Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2017 06;23(6):976-985
Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011].
Bequet E, Sarter H, Fumery M, Vasseur F, Armengol-Debeir L, Pariente B, Ley D, Spyckerelle C, Coevoet H, Laberenne JE, Peyrin-Biroulet L, Savoye G, Turck D, Gower-Rousseau C,
J Crohns Colitis. 2017 May 1;11(5):519-526
Is Mesalamine Effective for the Induction of Remission in Crohn's Disease?
Bonovas S, Peyrin-Biroulet L, Danese S
Inflamm. Bowel Dis.. 2017 05;23(5):E22-E23
Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Peyrin-Biroulet L, Christopher R, Behan D, Lassen C
Autoimmun Rev. 2017 May;16(5):495-503
Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials.
Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN
Aliment. Pharmacol. Ther.. 2017 May;45(10):1291-1302
Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
Bonovas S, Fiorino G, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S
Aliment. Pharmacol. Ther.. 2017 05;45(9):1179-1192
Crohn's disease.
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L
Lancet. 2017 04 29;389(10080):1741-1755
Ulcerative colitis.
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF
Lancet. 2017 04 29;389(10080):1756-1770
French national consensus clinical guidelines for the management of Crohn's disease.
Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X,
Dig Liver Dis. 2017 Apr;49(4):368-377
IBD immunopathogenesis: A comprehensive review of inflammatory molecules.
Park JH, Peyrin-Biroulet L, Eisenhut M, Shin JI
Autoimmun Rev. 2017 Apr;16(4):416-426
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort.
Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L, ,
Gut. 2017 04;66(4):588-596
Azathioprine for refractory ulcerative proctitis: A retrospective multicenter study.
Mallet AL, Bouguen G, Conroy G, Roblin X, Delobel JB, Bretagne JF, Siproudhis L, Peyrin-Biroulet L
Dig Liver Dis. 2017 Mar;49(3):280-285
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus.
Vuitton L, Peyrin-Biroulet L, Colombel JF, Pariente B, Pineton de Chambrun G, Walsh AJ, Panes J, Travis SP, Mary JY, Marteau P
Aliment. Pharmacol. Ther.. 2017 Mar;45(6):801-813
Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases.
Ghosh S, Louis E, Beaugerie L, Bossuyt P, Bouguen G, Bourreille A, Ferrante M, Franchimont D, Frost K, Hebuterne X, Marshall JK, OʼShea C, Rosenfeld G, Williams C, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2017 03;23(3):333-340
Head-to-head Comparative Studies: Challenges and Opportunities?
Peyrin-Biroulet L, Lopez A, Sandborn W
J Crohns Colitis. 2017 Mar 1;11(suppl_2):S567-S575
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome.
Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, Laurent V, Zallot C, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2017 Mar 1;11(3):274-280
Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence.
Collins M, Sarter H, Gower-Rousseau C, Koriche D, Libier L, Nachury M, Cortot A, Zerbib P, Blanc P, Desreumaux P, Colombel JF, Peyrin-Biroulet L, Pineton de Chambrun G
J Crohns Colitis. 2017 Mar 1;11(3):281-288
Primetime for e-health in IBD?
Bossuyt P, Pouillon L, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2017 03;14(3):133-134
25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.
Belle A, Gizard E, Conroy G, Lopez A, Bouvier-Alias M, Rouanet S, Peyrin-Biroulet L, Pawlotsky JM, Bronowicki JP
United European Gastroenterol J. 2017 Feb;5(1):69-75
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases.
Colombel JF, Narula N, Peyrin-Biroulet L
Gastroenterology. 2017 02;152(2):351-361.e5
Next generation of small molecules in inflammatory bowel disease.
Olivera P, Danese S, Peyrin-Biroulet L
Gut. 2017 02;66(2):199-209
Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients.
Williet N, Sarter H, Gower-Rousseau C, Adrianjafy C, Olympie A, Buisson A, Beaugerie L, Peyrin-Biroulet L
J Crohns Colitis. 2017 Feb;11(2):165-174
The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.
Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L,
Aliment. Pharmacol. Ther.. 2017 Feb;45(4):533-541
The natural history of Crohn's disease in children: a review of population-based studies.
Duricova D, Fumery M, Annese V, Lakatos PL, Peyrin-Biroulet L, Gower-Rousseau C
Eur J Gastroenterol Hepatol. 2017 Feb;29(2):125-134
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P,
J Crohns Colitis. 2017 Jan;11(1):3-25
Biosimilars in IBD: from theory to practice.
Danese S, Bonovas S, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):22-31
Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review.
Martelli L, Olivera P, Roblin X, Attar A, Peyrin-Biroulet L
J. Gastroenterol.. 2017 Jan;52(1):19-25
Development and Internal Validation of a Model Using Fecal Calprotectin in Combination with Infliximab Trough Levels to Predict Clinical Relapse in Crohn's Disease.
Roblin X, Duru G, Williet N, Del Tedesco E, Cuilleron M, Jarlot C, Phelip JM, Boschetti G, Flourié B, Nancey S, Peyrin-Biroulet L, Paul S
Inflamm. Bowel Dis.. 2017 01;23(1):126-132
ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
Danese S, Fiorino G, Raine T, Ferrante M, Kemp K, Kierkus J, Lakatos PL, Mantzaris G, van der Woude J, Panes J, Peyrin-Biroulet L
J Crohns Colitis. 2017 Jan;11(1):26-34
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting.
Allocca M, Landi R, Bonovas S, Fiorino G, Papa A, Spinelli A, Furfaro F, Peyrin-Biroulet L, Armuzzi A, Danese S
Digestion. 2017 ;96(3):166-172
Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy.
Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB
Aliment. Pharmacol. Ther.. 2017 01;45(1):50-62
Effects of enteral polymeric diet on gut microbiota in children with Crohn's disease.
Guinet-Charpentier C, Lepage P, Morali A, Chamaillard M, Peyrin-Biroulet L
Gut. 2017 01;66(1):194-195
Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice.
Hablot J, Peyrin-Biroulet L, Kokten T, El Omar R, Netter P, Bastien C, Jouzeau JY, Sokol H, Moulin D
PLoS ONE. 2017 ;12(9):e0184624
Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study.
Michetti P, Weinman J, Mrowietz U, Smolen J, Peyrin-Biroulet L, Louis E, Schremmer D, Tundia N, Nurwakagari P, Selenko-Gebauer N
Adv Ther. 2017 01;34(1):91-108
Insight into the role of TSLP in inflammatory bowel diseases.
Park JH, Jeong DY, Peyrin-Biroulet L, Eisenhut M, Shin JI
Autoimmun Rev. 2017 Jan;16(1):55-63
No Excess Cancer Recurrence After Immunosuppressive Drugs in a Meta-analysis of Cohorts of Patients With Immune-mediated Diseases: A Mirage Related to Propensity Bias?
Beaugerie L, Peyrin-Biroulet L
Gastroenterology. 2017 01;152(1):304-306
Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations.
Peyrin-Biroulet L, Lönnfors S, Roblin X, Danese S, Avedano L
J Crohns Colitis. 2017 Jan;11(1):128-133
Systematic Review of Tumor Necrosis Factor Antagonists in Extraintestinal Manifestations in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, García-Álvarez L, Lara N, Black CM, Kachroo S
Clin. Gastroenterol. Hepatol.. 2017 01;15(1):25-36.e27
Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN
Aliment. Pharmacol. Ther.. 2017 01;45(1):3-13
Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.
Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD
Am. J. Gastroenterol.. 2016 12;111(12):1806-1815
Implementation of the French national consensus for the management of ulcerative colitis into clinical practice.
Bonnaud G, Haennig A, Levy J, Sigur N, Ledit A, Cabarrot P, Faure P, Auzimour C, El Atmani A, Hebuterne X, Peyrin-Biroulet L
Dig Liver Dis. 2016 Dec;48(12):1405-1409
The IBD Disability Index should become a Major Secondary Endpoint in Clinical Practice and in Clinical Trials.
Peyrin-Biroulet L, Gower-Rousseau C
J Crohns Colitis. 2016 Dec;10(12):1375-1377
A practical guide to assess the Nancy histological index for UC.
Marchal-Bressenot A, Scherl A, Salleron J, Peyrin-Biroulet L
Gut. 2016 11;65(11):1919-1920
Diagnostic Delay Is Associated with a Greater Risk of Early Surgery in a French Cohort of Crohn's Disease Patients.
Nahon S, Lahmek P, Paupard T, Lesgourgues B, Chaussade S, Peyrin-Biroulet L, Abitbol V
Dig. Dis. Sci.. 2016 11;61(11):3278-3284
Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease.
Amiot A, Grimaud JC, Peyrin-Biroulet L, Filippi J, Pariente B, Roblin X, Buisson A, Stefanescu C, Trang-Poisson C, Altwegg R, Marteau P, Vaysse T, Bourrier A, Nancey S, Laharie D, Allez M, Savoye G, Moreau J, Gagniere C, Vuitton L, Viennot S, Aubourg A, Pelletier AL, Bouguen G, Abitbol V, Bouhnik Y, ,
Clin. Gastroenterol. Hepatol.. 2016 11;14(11):1593-1601.e2
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases.
Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B
Inflamm. Bowel Dis.. 2016 11;22(11):2711-2723
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S
Clin. Gastroenterol. Hepatol.. 2016 10;14(10):1385-1397.e10
Cancer and inflammatory bowel disease in the elderly.
Taleban S, Elquza E, Gower-Rousseau C, Peyrin-Biroulet L
Dig Liver Dis. 2016 Oct;48(10):1105-11
Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H, Dauchet L, Fumery M, Charpentier C, Marie Bouvier A, Dupas JL, Pariente B, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C
Am. J. Gastroenterol.. 2016 Oct;111(10):1428-1436
Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease.
Pouillon L, Bossuyt P, Peyrin-Biroulet L
Expert Opin Biol Ther. 2016 10;16(10):1277-90
Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease.
Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV
Clin. Gastroenterol. Hepatol.. 2016 10;14(10):1439-44
Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis.
Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO
Aliment. Pharmacol. Ther.. 2016 10;44(8):807-16
Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge.
Salleron J, Danese S, D'Agay L, Peyrin-Biroulet L
J Crohns Colitis. 2016 Sep;10(9):1096-102
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials.
Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L
Gut. 2016 09;65(9):1447-55
Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K, Rivals-Lerebours O, Billiet T, Vande Casteele N, Gils A, Ferrante M, Van Assche G, Rutgeerts PJ, Mantzaris GJ, Peyrin-Biroulet L, Vermeire S
J Crohns Colitis. 2016 Sep;10(9):1015-23
The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice.
Sandborn W, Colombel JF, D'Haens G, Ghosh S, Panaccione R, Panés J, Travis S, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2016 09;14(9):e121-2
Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease.
Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L
Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):915-27
French national consensus clinical guidelines for the management of ulcerative colitis.
Peyrin-Biroulet L, Bouhnik Y, Roblin X, Bonnaud G, Hagège H, Hébuterne X,
Dig Liver Dis. 2016 Jul;48(7):726-33
Immunomodulators for the treatment of Crohn's disease in adults: optimal use and prospects for future drug treatments.
Allen PB, Peyrin-Biroulet L
Expert Rev Clin Immunol. 2016 Jul;12(7):741-9
Natural History of Crohn's Disease in Elderly Patients Diagnosed Over the Age of 70 Years: A Population-Based Study.
Fumery M, Pariente B, Sarter H, Charpentier C, Armengol Debeir L, Dupas JL, Coevoet H, Peyrin-Biroulet L, dʼAgay L, Gower-Rousseau C, Savoye G,
Inflamm. Bowel Dis.. 2016 07;22(7):1698-707
NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn's disease: A genetic association study.
Germain A, Guéant RM, Chamaillard M, Allen PB, Bresler L, Guéant JL, Peyrin-Biroulet L
Surgery. 2016 Jul;160(1):74-80
What Proportion of Patients With Inflammatory Bowel Disease Want to Stop Infliximab Therapy?
Conroy G, Clerc-Urmès I, Allen PB, Baumann C, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2016 07;22(7):E25-6
Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study.
Van Assche G, Peyrin-Biroulet L, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S
Dig Liver Dis. 2016 Jun;48(6):592-600
Conditions of prescription of anti-TNF agents in newly treated patients with inflammatory bowel disease in France (2011-2013).
Blotière PO, Rudant J, Barré A, Racine A, Weill A, Peyrin-Biroulet L, Carbonnel F, Alla F
Dig Liver Dis. 2016 Jun;48(6):620-5
Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
Lopez A, Collet-Fenetrier B, Belle A, Peyrin-Biroulet L
J Dig Dis. 2016 Jun;17(6):383-91
Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent Malignancy.
Poullenot F, Seksik P, Beaugerie L, Amiot A, Nachury M, Abitbol V, Stefanescu C, Reenaers C, Fumery M, Pelletier AL, Nancey S, Peyrin-Biroulet L, Bourreille A, Hébuterne X, Brixi H, Savoye G, Lourenço N, Altwegg R, Buisson A, Cazelles-Boudier C, Racine A, Vergniol J, Laharie D,
Inflamm. Bowel Dis.. 2016 06;22(6):1362-9
Thiopurine Metabolism in the Era of Combotherapy.
Roblin X, Williet N, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2016 06;22(6):1496-501
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study.
Peyrin-Biroulet L, Van Assche G, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S
Dig Liver Dis. 2016 Jun;48(6):601-7
Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
Peyrin-Biroulet L, Salleron J, Filippi J, Reenaers C, Antunes O, Filipe V, Louis E, Hébuterne X, Roblin X
J Crohns Colitis. 2016 May;10(5):516-24
Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F
J Crohns Colitis. 2016 Apr;10(4):395-401
Early Combined Immunosuppression in Crohn's Disease: Acting Rather Than REACTing.
Peyrin-Biroulet L, Danese S
Gastroenterology. 2016 Apr;150(4):1040-1
Pharmacokinetics of Infliximab and Reduction of Treatment for Inflammatory Bowel Diseases.
Williet N, Paul S, Peyrin-Biroulet L, Roblin X
Dig. Dis. Sci.. 2016 Apr;61(4):990-5
Preventing Collateral Damage in Crohn's Disease: The Lémann Index.
Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2016 Apr;10(4):495-500
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions.
Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B
Clin. Gastroenterol. Hepatol.. 2016 Mar;14(3):348-354.e17
Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases.
Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH
Pharmacol. Ther.. 2016 Mar;159:110-9
Iron deficiency anaemia.
Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L
Lancet. 2016 Feb 27;387(10021):907-16
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, Nachury M, Novacek G, Danese S, Abitbol V, Bossa F, Moreau J, Bommelaer G, Bourreille A, Fumery M, Roblin X, Reinisch W, Bouhnik Y, Brixi H, Seksik P, Malamut G, Färkkilä M, Coulibaly B, Dewit O, Louis E, Deplanque D, Michetti P, Sarter H, Laharie D, ,
Gastroenterology. 2016 Feb;150(2):380-8.e4
Review article: the natural history of paediatric-onset ulcerative colitis in population-based studies.
Fumery M, Duricova D, Gower-Rousseau C, Annese V, Peyrin-Biroulet L, Lakatos PL
Aliment. Pharmacol. Ther.. 2016 Feb;43(3):346-55
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Grimaud JC, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-Biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B,
Clin. Gastroenterol. Hepatol.. 2016 Feb;14(2):242-50.e1-2
A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.
Papamichael K, Mantzaris GJ, Peyrin-Biroulet L
Expert Opin Drug Saf. 2016 ;15(4):493-501
Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study.
Danese S, Hart A, Dignass A, Louis E, D'Haens G, Dotan I, Rogler G, D'Agay L, Iannacone C, Peyrin-Biroulet L
BMJ Open Gastroenterol. 2016 ;3(1):e000092
Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Bonovas S, Fiorino G, Allocca M, Lytras T, Tsantes A, Peyrin-Biroulet L, Danese S
Medicine (Baltimore). 2016 Jan;95(2):e2308
Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation.
Coimbra AJ, Rimola J, O'Byrne S, Lu TT, Bengtsson T, de Crespigny A, Luca D, Rutgeerts P, Bruining DH, Fidler JL, Sandborn WJ, Santillan CS, Higgins PD, Al-Hawary MM, Vermeire S, Vanbeckevoort D, Vanslembrouck R, Peyrin-Biroulet L, Laurent V, Herrmann KA, Panes J
Aliment. Pharmacol. Ther.. 2016 Jan;43(1):61-72
Postoperative Complications in Pediatric Inflammatory Bowel Disease: A Population-based Study.
Penninck E, Fumery M, Armengol-Debeir L, Sarter H, Savoye G, Turck D, Pineton de Chambrun G, Vasseur F, Dupas JL, Lerebours E, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C,
Inflamm. Bowel Dis.. 2016 Jan;22(1):127-33
Self-medication with steroids in inflammatory bowel disease.
Filipe V, Allen PB, Peyrin-Biroulet L
Dig Liver Dis. 2016 Jan;48(1):23-6
The association of autoimmune diseases with pediatric ulcerative colitis does not influence its disease course.
Guinet-Charpentier C, Champigneulle J, Williet N, Peyrin-Biroulet L, Morali A
Scand. J. Gastroenterol.. 2016 Jan;51(1):33-40
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
Jones JL, Kaplan GG, Peyrin-Biroulet L, Baidoo L, Devlin S, Melmed GY, Tanyingoh D, Raffals L, Irving P, Kozuch P, Sparrow M, Velayos F, Bressler B, Cheifetz A, Colombel JF, Siegel CA
Clin. Gastroenterol. Hepatol.. 2015 Dec;13(13):2233-40.e1-2; quiz e177-8
Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review.
Peyrin-Biroulet L, Williet N, Cacoub P
Am. J. Clin. Nutr.. 2015 Dec;102(6):1585-94
Keratoconus in Inflammatory Bowel Disease Patients: A Cross-sectional Study.
Tréchot F, Angioi K, Latarche C, Conroy G, Beaujeux P, Andrianjafy C, Portier M, Batta B, Conart JB, Cloché V, Peyrin-Biroulet L
J Crohns Colitis. 2015 Dec;9(12):1108-12
A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases.
Vangeli E, Bakhshi S, Baker A, Fisher A, Bucknor D, Mrowietz U, Östör AJ, Peyrin-Biroulet L, Lacerda AP, Weinman J
Adv Ther. 2015 Nov;32(11):983-1028
Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
Nuij V, Fuhler GM, Edel AJ, Ouwendijk RJ, Rijk MC, Beukers R, Quispel R, van Tilburg AJ, Tang TJ, Smalbraak H, Bruin KF, Lindenburg F, Peyrin-Biroulet L, van der Woude CJ,
J Crohns Colitis. 2015 Nov;9(11):997-1003
Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.
Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L
Aliment Pharmacol Ther. 2015 Nov 9
Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures.
Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L, Amiot A, Altwegg R, Savoye G, Abitbol V, Bouguen G, Simon M, Duffas JP, Hébuterne X, Nancey S, Roblin X, Leteurtre E, Bommelaer G, Lefevre JH, Brunetti F, Guillon F, Bouhnik Y, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2015 Oct;13(10):1770-5
Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease.
Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-Biroulet L, Straumann A, Rogler G, Schoepfer AM,
Aliment. Pharmacol. Ther.. 2015 Oct;42(8):977-89
Is Diffusion-weighted Magnetic Resonance Imaging for Assessing Crohn's Disease Ready for Prime Time? Experience with the Nancy Score.
Peyrin-Biroulet L, Laurent V
Inflamm. Bowel Dis.. 2015 Oct;21(10):E25
Review article: the histological assessment of disease activity in ulcerative colitis.
Marchal Bressenot A, Riddell RH, Boulagnon-Rombi C, Reinisch W, Danese S, Schreiber S, Peyrin-Biroulet L
Aliment. Pharmacol. Ther.. 2015 Oct;42(8):957-67
Targeting SMAD7 in Crohn's Disease by Mongersen: Therapeutic Revolution Under Way?
Danese S, Fiorino G, Peyrin-Biroulet L
Gastroenterology. 2015 Oct;149(4):1121-3
Biologic agents for IBD: practical insights.
Danese S, Vuitton L, Peyrin-Biroulet L
Nat Rev Gastroenterol Hepatol. 2015 Sep;12(9):537-45
Comparing histological activity indexes in UC.
Bressenot A, Salleron J, Bastien C, Danese S, Boulagnon-Rombi C, Peyrin-Biroulet L
Gut. 2015 Sep;64(9):1412-8
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF
Am. J. Gastroenterol.. 2015 Sep;110(9):1324-38
Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease.
Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S
J Crohns Colitis. 2015 Aug;9(8):633-9
Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.
Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM
Inflamm. Bowel Dis.. 2015 Aug;21(8):1794-800
Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
Fréling E, Baumann C, Cuny JF, Bigard MA, Schmutz JL, Barbaud A, Peyrin-Biroulet L
Am. J. Gastroenterol.. 2015 Aug;110(8):1186-96
Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative.
Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF
J Crohns Colitis. 2015 Aug;9(8):601-6
Vaccination and Risk for Developing Inflammatory Bowel Disease: A Meta-Analysis of Case-Control and Cohort Studies.
Pineton de Chambrun G, Dauchet L, Gower-Rousseau C, Cortot A, Colombel JF, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2015 Aug;13(8):1405-15.e1; quiz e130
An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis.
Manginot C, Baumann C, Peyrin-Biroulet L
Gut. 2015 Jul;64(7):1181-2
CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease.
Germain A, Gueant RM, Chamaillard M, Bresler L, Gueant JL, Peyrin-Biroulet L
Dig Liver Dis. 2015 Jul 29. pii: S1590-8658(15)00419-3
Clinical trials in ulcerative colitis: a historical perspective.
Hindryckx P, Baert F, Hart A, Magro F, Armuzzi A, Peyrin-Biroulet L,
J Crohns Colitis. 2015 Jul;9(7):580-8
Defining Severity in Inflammatory Bowel Disease.
Peyrin-Biroulet L
Gastroenterol Hepatol (N Y). 2015 Jul;11(7):474-6
Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
Chandar AK, Singh S, Murad MH, Peyrin-Biroulet L, Loftus EV
Inflamm. Bowel Dis.. 2015 Jul;21(7):1695-708
IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
Freling E, Peyrin-Biroulet L, Poreaux C, Morali A, Waton J, Schmutz JL, Gueant JL, Barbaud A
Eur J Gastroenterol Hepatol. 2015 Jul 15.
Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
Fumery M, Jacob A, Sarter H, Michaud L, Spyckerelle C, Mouterde O, Savoye G, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C, Turck D,
J. Pediatr. Gastroenterol. Nutr.. 2015 Jun;60(6):744-8
Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.
Luthra P, Peyrin-Biroulet L, Ford AC
Aliment. Pharmacol. Ther.. 2015 Jun;41(12):1227-36
Systematic review: the financial burden of surgical complications in patients with ulcerative colitis.
Lindsay JO, Bergman A, Patel AS, Alesso SM, Peyrin-Biroulet L
Aliment. Pharmacol. Ther.. 2015 Jun;41(11):1066-78
The POCER Trial: Bet on Active Care.
Vuitton L, Peyrin-Biroulet L
Gastroenterology. 2015 Jun;148(7):1474-5
Treat to target: a proposed new paradigm for the management of Crohn's disease.
Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ
Clin. Gastroenterol. Hepatol.. 2015 Jun;13(6):1042-50.e2
Efficacy and safety of adalimumab 80 mg weekly in luminal Crohn's disease.
Bouguen G, Laharie D, Nancey S, Hebuterne X, Flourie B, Filippi J, Roblin X, Trang C, Bourreille A, Babouri A, Bretagne JF, Siproudhis L, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2015 May;21(5):1047-53
Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L
Dig Liver Dis. 2015 May;47(5):356-64
Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions.
Reinhard A, Sandborn WJ, Melhem H, Bolotine L, Chamaillard M, Peyrin-Biroulet L
Expert Rev Clin Immunol. 2015 May;11(5):637-57
Photodynamic therapy relieves colitis and prevents colitis-associated carcinogenesis in mice.
Reinhard A, Bressenot A, Dassonneville R, Loywick A, Hot D, Audebert C, Marchal S, Guillemin F, Chamaillard M, Peyrin-Biroulet L, Bezdetnaya L
Inflamm. Bowel Dis.. 2015 May;21(5):985-95
Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
Kotlyar DS, Lewis JD, Beaugerie L, Tierney A, Brensinger CM, Gisbert JP, Loftus EV, Peyrin-Biroulet L, Blonski WC, Van Domselaar M, Chaparro M, Sandilya S, Bewtra M, Beigel F, Biancone L, Lichtenstein GR
Clin. Gastroenterol. Hepatol.. 2015 May;13(5):847-58.e4; quiz e48-50
Beliefs and behaviour about smoking among inflammatory bowel disease patients.
Saadoune N, Peyrin-Biroulet L, Baumann C, Bigard MA, Wirth N, Martinet Y, Peyrin-Biroulet C
Eur J Gastroenterol Hepatol. 2015 Apr 27.
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
Amiot A, Peyrin-Biroulet L
Therap Adv Gastroenterol. 2015 Mar;8(2):66-82
Ileal ulcers not responding to infliximab therapy: think about intestinal ganglioneuromatosis.
Gizard E, Kalouche I, Merlin P, Peyrin-Biroulet L
Dig Liver Dis. 2015 Mar;47(3):257-8
Prevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials.
Carla-Moreau A, Paul S, Roblin X, Genin C, Peyrin-Biroulet L
Dig Liver Dis. 2015 Mar;47(3):191-6
Histologic features predicting postoperative Crohn's disease recurrence.
Bressenot A, Peyrin-Biroulet L
Inflamm. Bowel Dis.. 2015 Feb;21(2):468-75
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study.
Danese S, Rudziński J, Brandt W, Dupas JL, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S
Gut. 2015 Feb;64(2):243-9
Cost savings of anti-TNF therapy using a test-based strategy versus an empirical dose escalation in Crohn's disease patients who lose response to infliximab.
Roblin X, Attar A, Lamure M, Savarieau B, Brunel P, Duru G, Peyrin-Biroulet L
J Mark Access Health Policy. 2015 ;3:
Interventions to Improve Adherence in Patients with Immune-Mediated Inflammatory Disorders: A Systematic Review.
Depont F, Berenbaum F, Filippi J, Le Maitre M, Nataf H, Paul C, Peyrin-Biroulet L, Thibout E
PLoS ONE. 2015 ;10(12):e0145076
Unusual association of myasthenia gravis and ulcerative colitis in a 14-year-old boy.
Guinet-Charpentier C, Bilbault C, Kennel A, Perrier P, Peyrin-Biroulet L, Morali A
Arch Pediatr. 2015 Jan;22(1):81-3
Addressing current treatment challenges in Crohn's disease in real life: a physician's survey.
Vavricka SR, Radivojevic S, Manser CN, Frei P, Burri E, Fried M, Schoepfer A, Peyrin-Biroulet L, Michetti P, Rogler G, Biedermann L
Dig Liver Dis. 2014 Dec;46(12):1066-71
Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.
Dulai PS, Siegel CA, Colombel JF, Sandborn WJ, Peyrin-Biroulet L
Gut. 2014 Dec;63(12):1843-53
Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?
Lopez A, Beaugerie L, Peyrin-Biroulet L
Expert Rev Clin Immunol. 2014 Dec;10(12):1563-5
Clinical trials in luminal Crohn's disease: a historical perspective.
Hindryckx P, Baert F, Hart A, Armuzzi A, Panès J, Peyrin-Biroulet L,
J Crohns Colitis. 2014 Nov;8(11):1339-50
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab.
Bodini G, Savarino V, Peyrin-Biroulet L, de Cassan C, Dulbecco P, Baldissarro I, Fazio V, Giambruno E, Savarino E
Dig Liver Dis. 2014 Nov;46(11):1043-6
Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis.
Jess T, Lopez A, Andersson M, Beaugerie L, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2014 Nov;12(11):1793-1800.e1
[Disability in inflammatory bowel disease: an underestimated problem].
Vuitton L, Peyrin-Biroulet L
Rev Prat. 2014 Nov;64(9):1237-41
[Managing inflammatory bowel disease in the biologics era: treating beyond symptoms is not sufficient].
Peyrin-Biroulet L
Rev Prat. 2014 Nov;64(9):1207-9
[New therapeutic goals in inflammatory bowel diseases].
Vuitton L, Peyrin-Biroulet L
Rev Prat. 2014 Nov;64(9):1232-6
Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.
Dulai PS, Siegel CA, Peyrin-Biroulet L
Gastroenterol. Clin. North Am.. 2014 Sep;43(3):441-56
Diagnostic delay in a French cohort of Crohn's disease patients.
Nahon S, Lahmek P, Lesgourgues B, Poupardin C, Chaussade S, Peyrin-Biroulet L, Abitbol V
J Crohns Colitis. 2014 Sep;8(9):964-9
Improving quality of care in inflammatory bowel disease: what changes can be made today?
Panés J, O'Connor M, Peyrin-Biroulet L, Irving P, Petersson J, Colombel JF
J Crohns Colitis. 2014 Sep;8(9):919-26
Self-insertion of a nasogastric tube for home enteral nutrition: a pilot study.
Quilliot D, Zallot C, Malgras A, Germain A, Bresler L, Ayav A, Bigard MA, Peyrin-Biroulet L, Ziegler O
JPEN J Parenter Enteral Nutr. 2014 Sep;38(7):895-900
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease.
D'Alessio S, Correale C, Tacconi C, Gandelli A, Pietrogrande G, Vetrano S, Genua M, Arena V, Spinelli A, Peyrin-Biroulet L, Fiocchi C, Danese S
J. Clin. Invest.. 2014 Sep;124(9):3863-78
Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Roblin X, Rinaudo M, Del Tedesco E, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S
Am. J. Gastroenterol.. 2014 Aug;109(8):1250-6
Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease.
Seirafi M, de Vroey B, Amiot A, Seksik P, Roblin X, Allez M, Peyrin-Biroulet L, Marteau P, Cadiot G, Laharie D, Boureille A, De Vos M, Savoye G, Rahier JF, Carbonnel F, Bonaz B, Colombel JF, Bouhnik Y
Aliment Pharmacol Ther. 2014 Aug;40(4):363-73
Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists.
Duchesne C, Faure P, Kohler F, Pingannaud MP, Bonnaud G, Devulder F, Abramowitz L, Boustière C, Peyrin-Biroulet L,
Dig Liver Dis. 2014 Aug;46(8):675-81
Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease.
Williet N, Sandborn WJ, Peyrin-Biroulet L
Clin. Gastroenterol. Hepatol.. 2014 Aug;12(8):1246-56.e6
Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.
Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X
Inflamm. Bowel Dis.. 2014 Jul;20(7):1288-95
The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients.
Leclerc-Jacob S, Lux G, Rat AC, Laurent V, Blum A, Chary-Valckenaere I, Peyrin-Biroulet L, Loeuille D
Aliment. Pharmacol. Ther.. 2014 May;39(9):957-62
The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease.
Delvincourt M, Lopez A, Pillet S, Bourrier A, Seksik P, Cosnes J, Carrat F, Gozlan J, Beaugerie L, Roblin X, Peyrin-Biroulet L, Sokol H
Aliment. Pharmacol. Ther.. 2014 Apr;39(7):712-20
Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
Magro F, Peyrin-Biroulet L, Sokol H, Aldeger X, Costa A, Higgins PD, Joyce JC, Katsanos KH, Lopez A, de Xaxars TM, Toader E, Beaugerie L
J Crohns Colitis. 2014 Jan;8(1):31-44
Hypertrigyceridemia during infliximab therapy.
Javot L, Pere P, Got I, Petitpain N, Peyrin-Biroulet L, Gillet P
Joint Bone Spine. 2014 Jan;81(1):94-6
Endoscopy in inflammatory bowel disease: recommendations from the IBD Committee of the French Society of Digestive Endoscopy (SFED).
Peyrin-Biroulet L, Bonnaud G, Bourreille A, Chevaux JB, Faure P, Filippi J, Laharie D, Vuitton L, Bulois P, Gonzalez F, Trang C, Koch S, Bernardini D, Cellier C,
Endoscopy. 2013 Nov;45(11):936-43
Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease.
Beaugerie L, Svrcek M, Seksik P, Bouvier AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Flejou JF, Carrat F
Gastroenterology. 2013 Jul;145(1):166-175.e8
Submucosal plexitis as a predictor of postoperative surgical recurrence in Crohn's disease.
Bressenot A, Chevaux JB, Williet N, Oussalah A, Germain A, Gauchotte G, Wissler MP, Vignaud JM, Bresler L, Bigard MA, Plenat F, Gueant JL, Peyrin-Biroulet L
Inflamm Bowel Dis. 2013 Jul;19(8):1654-61
The effect of immune therapy on surgical site infection following Crohn's Disease resection.
Serradori T, Germain A, Scherrer ML, Ayav C, Perez M, Romain B, Palot JP, Rohr S, Peyrin-Biroulet L, Bresler L
Br J Surg. 2013 Jul;100(8):1089-93
Gastric intrinsic factor deficiency with combined GIF heterozygous mutations and FUT2 secretor variant.
Chery C, Hehn A, Mrabet N, Oussalah A, Jeannesson E, Besseau C, Alberto JM, Gross I, Josse T, Gerard P, Gueant-Rodriguez RM, Freund JN, Devignes J, Bourgaud F, Peyrin-Biroulet L, Feillet F, Gueant JL
Biochimie. 2013 May;95(5):995-1001
Ocular symptoms are not predictive of ophthalmologic inflammation in inflammatory bowel disease.
Cloche V, Buisson A, Trechot F, Batta B, Locatelli A, Favel C, Premy S, Collet-Fenetrier B, Freling E, Lopez A, Massoure MP, Humbert AL, Hansmannel F, Gueant JL, Bigard MA, Peyrin-Biroulet L, Angioi K
Dig Liver Dis. 2013 Mar;45(3):195-9
Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008).
Peyrin-Biroulet L, Lepage C, Jooste V, Gueant JL, Faivre J, Bouvier AM
Inflamm Bowel Dis. 2012 Dec;18(12):2247-51
Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.
Sokol H, Beaugerie L, Maynadie M, Laharie D, Dupas JL, Flourie B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N
Inflamm Bowel Dis. 2012 Nov;18(11):2063-71
Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased.
Peyrin-Biroulet L, Chevaux JB, Bouvier AM, Carrat F, Beaugerie L
Am J Gastroenterol. 2012 Sep;107(9):1443-4
Methyl donor deficiency impairs fatty acid oxidation through PGC-1α hypomethylation and decreased ER-α, ERR-α, and HNF-4α in the rat liver.
Pooya S, Blaise S, Moreno Garcia M, Giudicelli J, Alberto JM, Guéant-Rodriguez RM, Jeannesson E, Gueguen N, Bressenot A, Nicolas B, Malthiery Y, Daval JL, Peyrin-Biroulet L, Bronowicki JP, Guéant JL
J. Hepatol.. 2012 Aug;57(2):344-51
Urinary tract infections in hospitalized inflammatory bowel disease patients: a 10-year experience.
Peyrin-Biroulet L, Pillot C, Oussalah A, Billioud V, Aissa N, Balde M, Williet N, Germain A, Lozniewski A, Bresler L, Gueant JL, Bigard MA
Inflamm Bowel Dis. 2012 Apr;18(4):697-702
Helicobacter pylori serologic status has no influence on the association between fucosyltransferase 2 polymorphism (FUT2 461 G->A) and vitamin B-12 in Europe and West Africa.
Oussalah A, Besseau C, Chery C, Jeannesson E, Gueant-Rodriguez RM, Anello G, Bosco P, Elia M, Romano A, Bronowicki JP, Gerard P, Paoli J, Avogbe PH, Chabi N, Sanni A, Amouzou E, Peyrin-Biroulet L, Gueant JL
Am J Clin Nutr. 2012 Feb;95(2):514-21
Cytomegalovirus load in inflamed intestinal tissue is predictive of resistance to immunosuppressive therapy in ulcerative colitis.
Roblin X, Pillet S, Oussalah A, Berthelot P, Del Tedesco E, Phelip JM, Chambonnière ML, Garraud O, Peyrin-Biroulet L, Pozzetto B
Am. J. Gastroenterol.. 2011 Nov;106(11):2001-8
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, Hugot JP, Lemann M, Nahon S, Sabate JM, Tucat G, Beaugerie L
Gastroenterology. 2011 Nov;141(5):1621-28.e1-5
Methyl deficient diet aggravates experimental colitis in rats.
Chen M, Peyrin-Biroulet L, George A, Coste F, Bressenot A, Bossenmeyer-Pourie C, Alberto JM, Xia B, Namour B, Gueant JL
J Cell Mol Med. 2011 Nov;15(11):2486-97
Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease.
Peyrin-Biroulet L, Oussalah A, Williet N, Pillot C, Bresler L, Bigard MA
Gut. 2011 Jul;60(7):930-6
Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis.
Leblanc S, Allez M, Seksik P, Flourie B, Peeters H, Dupas JL, Bouguen G, Peyrin-Biroulet L, Duclos B, Bourreille A, Dewit O, Bouhnik Y, Michetti P, Chaussade S, Saussure P, Mary JY, Colombel JF, Lemann M
Am J Gastroenterol. 2011 Apr;106(4):771-7
The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts.
Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP
Aliment. Pharmacol. Ther.. 2011 Mar;33(6):707-13
Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy.
Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, Papay P, Allez M, Cosnes J, Cortot A, Laharie D, Reimund JM, Lemann M, Delaporte E, Colombel JF
Clin Gastroenterol Hepatol. 2010 Dec;8(12):1048-55
Crohn's disease: the hot hypothesis.
Peyrin-Biroulet L, Oussalah A, Bigard MA
Med. Hypotheses. 2009 Jul;73(1):94-6
TNF antagonists in the treatment of inflammatory bowel disease: results of a survey of gastroenterologists in the French region of Lorraine.
Peyrin-Biroulet L, Oussalah A, Boucekkine T, Bigard MA
Gastroenterol. Clin. Biol.. 2009 Jan;33(1 Pt 1):23-30
Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression.
Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, Oussalah A, Seddik M, Canva V, Cortot A, Sogni P, Gueant JL, Bigard MA, Roblin X, Bronowicki JP
Aliment Pharmacol Ther. 2008 Oct 15;28(8):984-93
Methylenetetrahydrofolate reductase 677 T allele protects against persistent HBV infection in West Africa
Bronowicki JP, Abdelmouttalebl D, Peyrin-Biroulet L, Venard V, Khiri H, Chabi N, Amouzou EK, Barraud H, Halfon P, Sanni A, Bigard MA, Le Faou A, Gueant JL
J Hepatol. 2008 Apr;48(4):532-9
Association of MTRR 66A>G polymorphism with superoxide dismutase and disease activity in patients with Crohn's disease.
Peyrin-Biroulet L, Guéant-Rodriguez RM, Chen M, Bronowicki JP, Bigard MA, Guéant JL
Am. J. Gastroenterol.. 2008 Feb;103(2):399-406
Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China.
Chen M, Peyrin-Biroulet L, Xia B, Gueant-Rodriguez RM, Bronowicki JP, Bigard MA, Gueant JL
BMC Med Genet. 2008 Aug 13;9:78.
Does hyperhomocysteinaemia contribute to gastric carcinogenesis in Helicobacter pylori infected patients?
Peyrin-Biroulet L, Gueant JL
Gut. 2007 Oct;56(10):1480; author reply 1480-1.
Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine.
Peyrin-Biroulet L, Rodriguez-Gueant RM, Chamaillard M, Desreumaux P, Xia B, Bronowicki JP, Bigard MA, Gueant JL
Am J Gastroenterol. 2007 May;102(5):1108-15
Coffee and diabetes: is homocysteine the missing link?
Peyrin-Biroulet L, Gueant JL, Roblin X
Arch Intern Med. 2007 Jan 22;167(2):204; author reply 205.
[Epigenetic changes and liver carcinogenesis].
Peyrin-Biroulet L, Barraud H, Darfeuil F, Lefebvre M, Bigard MA, Gueant JL, Bronowicki JP
Gastroenterol Clin Biol. 2006 Dec;30(12):1354-9.
Colon cancer after infliximab therapy for Crohn's disease in a young patient transplanted for primary sclerosing cholangitis.
Peyrin-Biroulet L, Bressenot A, Chone L, Denjean P, Boissel P, Bigard MA, Bronowicki JP
Am J Gastroenterol. 2006 Nov;101(11):2664-5.
Contribution of computed tomography with oral media contrast to the diagnosis of esophago-pericardial fistula.
Peyrin-Biroulet L, Bronowicki JP, Bigard MA, Regent D, Walter S, Platini C
Clin Imaging. 2006 Sep-Oct;30(5):347-9.
[Hepatitis A acquired from an asymptomatic adopted child].
Peyrin-Biroulet L, Donnais A, Barraud H, Darfeuil F, Watelet J, Hudziak H, Bronowicki JP, Bigard MA, Chone L
Gastroenterol Clin Biol. 2006 Apr;30(4):609-10.
[Intestinal permeability and cirrhosis].
Ancel D, Barraud H, Peyrin-Biroulet L, Bronowicki JP
Gastroenterol Clin Biol. 2006 Mar;30(3):460-8.
[Mediastinal lymph node and vertebral metastases 3 years after liver transplantation for cholangiocarcinoma: 2 unusual localizations].
Peyrin-Biroulet L, Bronowicki JP, Cinqualbre J, Gendrault P, Graff-Cailleaud P, Marchal C
Gastroenterol Clin Biol. 2005 Apr;29(4):469-71.
[Probable hepatoxicity from epigallocatecol gallate used for phytotherapy].
Peyrin-Biroulet L, Petitpain N, Kalt P, Ancel D, Petit-Laurent F, Trechot P, Barraud H, Bronowicki JP
Gastroenterol. Clin. Biol.. 2004 Apr;28(4):404-6
[Folate metabolism and colorectal carcinogenesis].
Peyrin-Biroulet L, Barraud H, Ancel D, Petit-Laurent F, Bigard MA, Gueant JL, Bronowicki JP
Gastroenterol. Clin. Biol.. ;28(6-7 Pt 1):582-92
[Hepatotoxicity associated with herbal remedies: clinical, biological, histological data and the mechanisms involved in some typical examples].
Peyrin-Biroulet L, Barraud H, Petit-Laurent F, Ancel D, Watelet J, Chone L, Hudziak H, Bigard MA, Bronowicki JP
Gastroenterol. Clin. Biol.. ;28(6-7 Pt 1):540-50
